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therapist Sheena Cadoo with screening patients in general practice.  
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Introduction: Differentiating mild cognitive impairment (MCI) from subjective memory 
complaints (SMC) and normal controls (NC) is challenging. Few short instruments have 
sufficient sensitivity and specificity for use in busy clinic settings. This thesis explores 
the development, psychometric evaluation and validation of a new short (3–5 min) 
cognitive screening instrument, designed to screen for MCI and early dementia, called the 
Quick Mild Cognitive Impairment (Qmci) screen. Derived from the ABCS 135, the Qmci 
is composed of six subtests: orientation, registration, clock drawing, delayed recall, verbal 
fluency and logical memory (LM). Specific aims included assessing 1) content validity 
(Qmci subtests), 2) concurrent validity against other short screens: ABCS 135, 
Standardised Mini-Mental State Examination (SMMSE), Montreal Cognitive Assessment 
(MoCA), 6-item Cognitive Impairment Test (6CIT) and General Practitioner Assessment 
of Cognition (GPCOG), 3) construct validity against detailed global and 
neuropsychological tests (ADAS-cog and Clinical Dementia Rating-CDR scale) and 4) 
refining the Qmci into a ‘home’-carer administered “Quick Memory Check-QMC”, with 
a view to showing the characteristics of an ideal short cognitive screen. 
 
Methods: Data from three Canadian databases were analysed to validate the Qmci, 
explore its subtests, assess its accuracy in different types of cognitive impairment, 
develop cut-off scores and compare its responsiveness, reliability and internal 
consistency. Once “ready”, the Qmci was externally validated in different settings 
(memory clinic, movement disorder clinic, general practice, rehabilitation unit) in Ireland 
in a prospective data collection. Translation and external validation in other languages 
was also begun. 
 
Results: The Qmci was more accurate than the ABCS 135, 6CIT, GPCOG, SMMSE and 
had similar sensitivity but greater specificity than the MoCA in differentiating MCI from 
SMC or NC. Using maximal accuracy, a cut-off of <60/100 yielded a sensitivity of 89% 
and specificity of 86% (AUC 0.95), using Youden’s Index a cut-off of <62/100 gave a 
sensitivity of 87% and specificity of 88%. LM was the most accurate subtest for detecting 
MCI across settings. Cut-off scores adjusted for age and education were produced. The 
Qmci correlated with global functional measures (Lawton-Brody ADL scale and CDR) 
and the gold standard cognitive measure used in clinical trials, the Standardised ADAS-
cog. The Qmci had excellent inter-rater and test-retest reliability in clinic and general 
practice. A shortened Qmci, administered by caregivers (QMC), was both acceptable to 
carers and had comparable accuracy to a battery of short cognitive screens. 
 
Discussion: This thesis presents an exploration of a new and arguably much needed 
short, yet highly sensitive and specific, cognitive screening instrument for use in clinics 
and general practice.  It also demonstrates the potential of shortening the instrument to 
allow caregivers score patients at home in an attempt to reduce performance anxiety. This 
project suggests that the Qmci could be substituted for more detailed and longer 
instruments in a wide variety of settings, as a rapid screening test for cognitive 
impairment, particularly where the suspicion favours the presence of MCI. Further 
research will focus on 1) increasing the sample size to confirm superiority over highly 
sensitive instruments such as the MoCA, 2) validation in other settings with lower 
prevalence of cognitive impairment, 3) the development of normative data and 4) external 
validation in other cultures and languages. The Qmci may be close to an ideal short 
cognitive screening instrument though further research is warranted. 
 
Word Count (including all tables): 48,137.  
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This thesis documents the work of a three year PhD commenced in 2012 and 
describes research conducted in the Centre for Gerontology and Rehabilitation 
(University College Cork), St Finbarr’s Hospital and selected general medical 
practices (Mallow Primary Healthcare Centre, Mallow and Elmwood Medical Centre, 
Douglas) in Cork City and County, Ireland.  
1.1 Overall Objective 
The overall objective is to develop, validate, refine and externally validate a new short 
cognitive screening instrument to differentiate normal cognition from mild cognitive 
impairment (MCI) and early dementia. The new screen is developed from an existing 
instrument called the AB Cognitive Screen 135 (ABCS 135) designed by Professor 
William Molloy; first validated and published in 2005. This new instrument, initially 
called the ABCS 100 after its predecessor and re-weighted scoring to accommodate a 
new subtest called logical memory (LM), was re-christened the Quick Mild Cognitive 
Impairment (Qmci) screen consistent with its intended use as a brief cognitive screen 
to identify MCI.  
1.2 Specific Aims 
This project aims:  
1) To validate the Qmci screen by analysing the original derivation data set, collected 
by Professor William Molloy in Canada between 2004 and 2010. This database, 
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containing Standardised Mini-Mental State Examination (SMMSE), ABCS 135 and 
LM scores, allows the Qmci to be reconstituted and validated against the SMMSE and 
ABCS 135.  
2) To explore the instruments psychometric properties (reliability, administration 
times, concurrent validity) and that of its individual cognitive domains (subtests). 
3) To analyse data from the original derivation sample and additional reconstituted 
Qmci data from two other data sets, collected by Professor William Molloy, to create 
usable Qmci cut-off scores for normal cognition, mild cognitive impairment, and 
dementia. To adjust these according to age and level of educational attainment. 
4) To examine the concurrent validity of the Qmci by correlating it with detailed 
neuropsychological tests in an clinical trial database. 
5) To investigate the diagnostic accuracy of the Qmci and its subtests in different 
dementia subtypes. 
6) To externally validate the Qmci in an older Irish population in four settings: a) a 
memory clinic, b) a movement disorder clinic, c) general practice and d) a hospital 
rehabilitation unit, against a battery of other short cognitive screening instruments 
including the Montreal Cognitive Assessment (MoCA), the 6-item Cognitive 
Impairment Test (6CIT) and the General Practitioner Assessment of Cognition 
(GPCOG). An important step in this involves the training of general practitioners 
(GP) in the use of the Qmci and measuring inter-rater reliability (IRR). 
7) To develop a modified, (shorter and reduced) version of the Qmci, with reweighted 
subtests, to increase the tools sensitivity and specificity in differentiating MCI from 
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normal cognition and dementia. To investigate if this shortened version could be used 
by caregivers to provide “home” cognitive screening in advance of clinic 
appointments. 
8) To translate and begin the external validation of the Qmci with colleagues in other 
countries. These include Dutch, Italian, German, Turkish, Chinese and Portugese 
translations and a further English language external validation in Australia. 
1.3 Overview of the structure of the thesis 
 
This thesis is divided into 5 sections comprising 15 chapters. This first section 
explores the objectives of the project and sets out the background behind and rationale 
for developing a new short screening instrument for MCI and early dementia. The 
second places emphasis upon the classification of neurocognitive disorders, principles 
of cognitive screening, characteristics of existing cognitive screening instruments and 
on the structure and scoring of the Qmci. The third section describes the psychometric 
properties of the Qmci and its subtests using data collected by Professor William 
Molloy in Canada in order to validate and produce a usable instrument. The third 
section describes the external validation of the Qmci in different clinical settings in 
Ireland including the development of a shortened version of the Qmci called the 
Quick Memory Check (QMC), validated for use by caregivers as a “home” 
administered “pre-screen”. The fourth section describes additional work conducted 
during this PhD using the Qmci including its use in monitoring change in an Irish 
sample of patients with MCI and its external validation in other countries. The fifth 







2.1 Neurocognitive disorders 
 
Neurocognitive disorders are a broad class of impairments in cognition, usually 
associated with ageing, that result in a decline from a previously attained level of 
cognitive functioning [Sachdev et al., 2014],[Foley et al., 2014]. Neurocognitive 
disorders include mild cognitive impairment (MCI) and dementia. Under the new 
American Psychiatric Associations’ Diagnostic and Statistical Manual of Mental 
Disorders, 5th edition (DSM-5) published in 2014, neurocognitive disorders are 
divided into two types: major incorporating dementia and minor including MCI. The 
incidence and prevalence of neurocognitive disorders including MCI [Plassman et al., 
2008],[Nie et al., 2011] and dementia [Plassman et al., 2007],[Hebert et al., 
2013],[Dong et al., 2007],[Prince et al., 2013] has increased in the face of societal 
ageing. Many challenges are associated with this, particularly in relation to their 
prompt diagnosis and management. Recent studies have however suggested that 
cohort effects are evident in dementia prevalence rates, with later-born generations 
having a lower risk of prevalent dementia [Matthews et al., 2013]. 
 
Prevalence of neurocognitive disorders 
In the United States, the prevalence of dementia in those aged over 70 years 
approaches 15%; approximately 5.0% in those aged 71–79 years, increasing to over 
35% in those aged 90 and older [Plassman et al., 2007]. This trend is repeated around 
the world with similar, albeit accelerated, patterns seen in China, India and South East 
Asia, such that the numbers of people with dementia will double every 20 years to 
over 80 million by 2040 [Ferri et al., 2006]. In Ireland, it is estimated that there are 
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approximately 48,000 people with dementia [Department of Health 2014]. This is 
expected to rise to 152,000 cases by 2046 [Department of Health 2014]. Though 
sometimes thought of as part of the ageing process, age is not exponentially or 
inevitably linked to the risk of developing neurocognitive disorders but instead fits an 
age-related flattened S shaped curve that falls between 80 and 84 years and then 
plateaus after 95 years at a prevalence rate of 40% [Fjell et al., 2014]. Prevalence 
rates of MCI are influenced by the definition of MCI used [Ward et al., 2012], 
ranging from 0.8% to 4.3% (65 years+) for amnestic type MCI (aMCI) in developing 
countries [Sosa et al., 2012] to 11.1% for aMCI and 16% for any subtype (70+) in 
developed countries [Petersen et al., 2010]. 
 
Diagnostic criteria for neurocognitive disorders 
Major neurocognitive disorder describes terms traditionally referred to as dementia, a 
heterogeneous group of disorders of cognition; minor includes MCI and subjective 
memory complaints (SMC) or subjective cognitive disorders (SCD). DSM-5 defines 
six key domains of cognitive function; executive function, perceptual motor function, 
language, learning and memory, complex attention and social cognition. These 
neurocognitive domains, each with their own subdomains, can be used to classify and 
diagnose patients. DSM-5 includes several subtypes of major neurocognitive 
disorders including Alzheimer’s dementia (AD), vascular dementia (VaD), lewy body 
dementia (LBD), frontotemporal dementia (FTD), Parkinson’s disease dementia 
(PDD), and those associated with HIV infection, Huntington’s disease, prion disease, 
traumatic brain injury and substance/medication-use. It also includes non-specific 
disorders including mixed dementia subtypes. DSM-5 rates the severity of major 
neurocognitive disorders as mild, moderate or severe. This classification is commonly 
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used in clinical practice and is similar to more detailed classifications such as the 
Functional Assessment Staging (FAST) or the Clinical Dementia Rating (CDR) 
scales. Minor neurocognitive disorders include the term MCI and like the major 
neurocognitive disorders these also have subtypes associated with specific cognitive 
disorders such as Alzheimer’s and cerebrovascular disease. Minor neurocognitive 
disorders are described as either probable or possible and may be accompanied by 
behavioral disturbance [Foley et al., 2014]. DSM-5 was published in 2014 and DSM-
4-R, its predecessor, was used to define dementia in this thesis. While DSM-4 
described dementia, it was limited to AD, VaD and mixed dementia subtypes and did 




Major neurocognitive disorders such as dementia are frequently under-diagnosed, 
particularly in older adults. Even in hospital, where at least 40% of patients aged over 
70 years have dementia, only half are diagnosed pre-admission [Sampson et al., 
2009]. Similarly low detection rates have been found in the community [Valcour et 
al., 2000]. Diagnostic rates of minor neurocognitive disorders are affected by 
fluctuations in the conversion rates with many patients reverting to normal or 
converting to dementia [Sachdev et al., 2013]. Reversion is less likely in participants 
with more marked cognitive deficits and multiple-domain MCI [Sachdev et al., 2013]. 





2.1.1 Major neurocognitive disorders 
 
Dementia  
Dementia is traditionally defined by the presence of memory impairment and 
difficulty with at least one of the following: language, coordinating, planning, 
recognising or personality, and is accompanied by loss of function (social or 
occupational) usually manifest as impairment in activities of daily living (ADL) [APA 
1994]. DSM-5 criteria do not specifiy the need for memory impairment, instead 
requiring the presence of significant cognitive deficits defined by two or more 
standard deviations from the mean based on normative data [APA 2013]. Dementia is 
gradual and persistent, and is diagnosed only when transient or reversible causes 
including delirium have been excluded. It is associated with increased mortality 
[Eaker et al., 2002],[Sampson et al., 2009] and other adverse outcomes including 
institutionalisation [Gaugler et al., 2007] and hospitalisation [Severson et al., 1994].  
 
Major neurocognitive disorder subtypes 
 
Alzheimer`s disease  
Alzheimer`s disease is the most prevalent form of dementia [Brunnström et al., 2009]. 
AD, like all dementia subtypes is associated with age. Early onset AD, before the age 
of 65 years, represents approximately 5% of cases and is associated with the 
apolipoprotein E4 allele and genetic mutations in either amyloid precursor protein or 
the Presenilin (1 or 2) genes [Huang et al., 2012]. Histologically, AD is characterized 
by the extracellular accumulation of the peptide amyloid-beta that is thought to arise 
from abnormalities in the cleavage and clearance of amyloid-beta. This process is also 
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described for those without clinically evident pathology, with approximately 30% of 
older adults considered cognitively normal, having evidence of amyloid-beta 
deposition [Savva et al., 2009]. Clinically, AD is classified as a cortical dementia and 
is associated with early impairment of episodic memory manifesting as an amnestic 
syndrome of the medial temporal type. It is also associated with language disorders, 
visuospatial deficits, executive dysfunction and neuropsychiatric disturbances such as 
apathy and psychotic symptoms [Huang et al., 2012].  
 
Vascular dementia 
Vascular dementia is associated with cerebrovascular disease including stroke and is 
characterised by a broad spectrum of cognitive deficits and focal neurological 
symptoms including bulbar signs, urinary symptoms and parkinsonism with gait 
dyspraxia, falls and psychomotor slowing [Korczyn et al., 2012]. Often insidious in 
onset, it usually follows a progressive “step-wise” deterioration. Personality and 
insight are relatively preserved in mild and moderate cases. Apart from DSM, the 
NINDS-AIREN Criteria are the most widely used [Roman et al., 1993]. 
 
Parkinson’s disease dementia  
Parkinson’s disease (PD) is a progressive neurodegenerative disease characterised by 
loss of the dopaminergic neurons of the substantia nigra in the presence of Lewy 
bodies; clumps of alpha-synuclein and ubiquitin protein in cerebral neurons. Like 
dementia, the prevalence of PD is projected to increase [Dorsey et al., 2007]. 
Cognitive impairment is common in PD [Aarsland et al., 2003],[Aarsland et al., 2007] 
and is the most frequent non-motor symptom [Sitek et al., 2014]. The prevalence of 
PD increases with age affecting between 0.5 to 5% of the population aged over 65 
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years [Kis et al]. Prevalence rates of cognitive impairment approach 80% [Aarsland et 
al., 2003] and PDD increases as persons with PD age. The lifetime incidence of PDD 
is more than 40% with many people having cognitive impairment from the initial 
diagnosis. PDD is subcortical such that it is characterised by relatively preserved 
recognition memory but marked executive dysfunction. It is associated with mood 
disturbance. 
 
Lewy Body Dementia  
LBD, also known as Dementia with Lewy Bodies, is also characterized anatomically 
by Lewy bodies. Although LBD has similarities to PDD [Weintraub et al 2007] it has 
its own unique clinical features that help distinguish it. These depend upon the 
pathway affected; nigrostriatal involvement results in motor features of parkinsonism, 
cortical involvement in cognitive impairment and neuropsychiatric symptoms and 
sympathetic nervous system in autonomic failure. LBD is classically described as 
“Fluctuating” and represents a clinical diagnosis characterised by at least one of the 
following: visual and/or auditory hallucinations, mild spontaneous parkinsonism, 
sensitivity to neuroleptics, and repeated unexplained falls and/or transient clouding or 
loss of consciousness [McKeith et al., 2005]. 
 
Frontotemporal dementia  
Frontotemporal dementia (FTD), previously called Picks disease, affects the frontal 
and temporal lobes, preferentially affecting spindle neurons [Seeley et al., 2006]. FTD 
can be predominantly frontal (frontal variant), characterised by prominent behavior 
disturbance, or temporal (primary progressive aphasia), characterised by difficulties 
with speech. Like AD it can occur sporadically but is more likely to have a genetic 
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predisposition [Ratnavalli et al., 2002]. Clinically it overlaps with motor neuron 
disease and PD. Core diagnostic features include insidious onset and gradual 
progression, early decline in social interpersonal conduct with difficulty regulating 
behavior, early emotional blunting, poor insight and apathy. Other supportive 
diagnostic features include behavioural disturbance, a decline in personal hygiene, 
mental rigidity and inflexibility, distractibility, hyperorality and dietary changes, and 
perseverative or stereotyped behavior (obsessions).! Before! DSM45,! the Lund-
Manchester Criteria were used [Brun et al., 1994]. 
 
2.1.2 Minor neurocognitive disorders 
Mild cognitive impairment 
Minor neurocognitive disorders include MCI and other mild age associated conditions 
such as SMC. Minor neurocognitive disorders and MCI in particular, represent a 
significant diagnostic challenge. The most commonly used diagnostic criteria for MCI 
are the Petersen criteria [Petersen et al.,1999] i.e. those with: 
(1) Subjective memory complaint (preferably corroborated by an informant such as 
carer or clinician), 
(2) Objectively abnormal memory function (i.e. assessed using appropriate cut-off 
scores and adjusting for age or level of education), 
(3) General cognition and functional performance (ADL) otherwise sufficiently 
preserved, 
(4) No dementia. 
 
Despite its inclusion in DSM, no “gold standard” criteria for the diagnosis of MCI are 
widely accepted [Morris 2012]. Several working groups have proposed different 
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criterion including the report of the International Working Group on Mild Cognitive 
Impairment [Winblad et al., 2004] which requires the presence of recent, subjective 
and or corroborated memory loss without obvious loss of social or occupational 
function with objective evidence of cognitive decline on cognitive testing. More 
recently, the MCI Working Group of the European Consortium on Alzheimer’s 
Disease [Portet et al., 2006] proposed similar guidelines, although these do not 
stipulate the requirement for deficits on cognitive testing. More recently, the National 
Institute on Aging-Alzheimer’s Association workgroup [Albert et al., 2011] approved 
diagnostic guidelines based on Petersens’ criteria [Petersen et al., 1999]. These are 
compared in Table 2.1. Prior to DSM-5, commonly used terms to describe MCI 
included dementia prodrome, incipient dementia, isolated memory impairment, and 
cognitive impairment not dementia. The absence of a precise definition has created 
heterogeneity in the literature with marked inconsistencies in the instruments, 
methodologies and diagnostic criteria used between clinical trials [Stephen et al., 
2013].  
 
Table 2.1.  Proposed working group criteria, including defining characteristics, for the 
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MCI is reported to be present in 11% of those over 75 years but varies according to its 
subtype and other demographic factors such as gender, being higher in those with the 
amnestic type MCI and in men [Petersen et al., 2010]. The annual conversion rate 
from MCI to dementia is estimated to be between 5-15% [Mitchell et al., 2009]. The 
reason for this is partly due to variability in the definitions used [Fisk et al., 2003], 
and may also be due to variations in the diagnostic methods employed. Conversion 
rates approach 100% at 8-10 years [Morris et al., 2001].  
 MCI is divided into subtypes, aMCI (amnestic), non-amnestic, mono-domain 
and multi-domain. This classification is presented in Figure 2.1. The subclassification 
of MCI into aMCI and non-amnestic subtypes is supported by the utility of different 
cognitive domains to predict progression to distinct dementia subtypes. For example, 
people with aMCI, characterized by poor short-term recall, are more likely to progress 
to Alzheimer’s disease pathology [Lyness et al., 2014], whereas those with non-
amnestic MCI are more likely to progress to PDD or LBD [Ferman et al., 2013]. 
DSM-5 criteria also define mild neurocognitive disorders associated with other major 
neurocognitive disorders including PD-MCI, LBD-MCI and FTD-MCI. 
 
PD-Mild Cognitive Impairment 
PD with mild cognitive impairment (PD-MCI) affects approximately 27% of patients 
with PD [Litvan] and is associated with an increased chance of developing dementia, 
particularly when already present at diagnosis [Pederson et al., 2013]. Single domain, 
non-amnestic is the most common subtype of PD-MCI [Litvan et al., 2011]. The 
diagnosis of PD-MCI is challenging, with uncertainty surrounding the duration of 
follow-up and the number of repeated cognitive tests required to make the diagnosis 
[Sitek et al., 2014], with some guidelines suggesting that up to a minimum of 10 
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repeat assessments are required for PD-MCI subtyping [Sitek et al., 2014]. It differs 
from MCI associated with Alzheimers disease [Caviness et al., 2007] and typically 
presents with exaggerated attention and executive function deficits [Petrova et al., 
2010].  




Subjective Memory Complaints 
The other class of minor neurocognitive disorders includes SMC. These are 
characterised by subjective difficulties with cognition, particularly short-term 
memory, but normal cognition on neuropsychological testing.  SMC are common, 
increase with age and are associated with cognitive decline and depression [Wang et 
al., 2004][Reisberg et al., 2010]. Prevalence across studies varies from 25-50% in 
persons aged >65 years [Jonker et al., 2000]. Recent evidence suggests that SMC are 
not benign and represent a significant independent predictor of progression to 
dementia. Age is also independently associated with progression from a minor to a 
major neurocognitive disorder [Waldorff et al., 2012]. As with MCI and dementia age 
and education affect the presentation of SMC and may affect the results of cognitive 
screening instruments [Fritsch et al., 2014].  
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2.2 Principles of cognitive screening 
2.2.1 Characteristics of an ideal short cognitive screen 
To diagnose neurocognitive disorders healthcare professionals must differentiate 
normal brain ageing from pathological processes associated with neurocognitive 
decline. Cognitive screening of symptomatic individuals followed by more detailed 
assessment with neuropsychological testing is the usual first step. It is important to 
distinguish between case-finding and screening. Case-finding aims to establish a 
diagnosis, to rule in or identify a target condition with minimal false negatives. 
Screening is not a diagnostic process but instead is intended to rule out of a target 
condition with minimal false positives. The utility of any diagnostic instrument is 
defined by two conditional probabilities, their sensitivity and specificity, and the 
utility of most cognitive screens is limited by these [Ritchie et al., 2001]. Sensitivity is 
the ability to rule in, specificity the ability to rule out disease [Griner et al., 
1981],[Gehlbach 1993]. In general, sensitivity and specificity are inversely related 
and vary with the threshold [Smit et al., 2010]. When an instrument is used as a 
screen it must be both sensitive and specific [Griner et al., 1981]. High sensitivity, 
rather than specificity, is preferential for short screens to reduce the rate of false 
negatives. Further assessment allows the exclusion of false positives. High specificity 
and the need to avoid false positives are more appropriate in secondary care and in 
specialised memory clinics. Ideally however, screening tests should strike a balance 
between both so they can confirm or exclude a disease. 
  Although sensitivity and specificity are both important, shorts cognitive 
screens require high sensitivity. Results are interpreted using established cut-off 
scores but these can be misleading, particularly in older adults, as normal ageing is 
associated with a decline in test scores that normalise only after correction for 
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baseline demographics such as age and education [Crum et al., 1993]. Delineating and 
testing appropriate cognitive domains is also important as their sensitivity and 
specificity may vary according to the underlying disease process or stage of 
progression. Several short cognitive screens are currently in use in clinical practice, 
each with their own advantages and disadvantages.  
 Apart from sensitivity and specificity, several factors determine the utility of 
short cognitive screening instruments including clinical and psychometric 
characteritics. In clinical practice, effective screening instruments must be short, easy 
to interpret, accurate and administered with only minimal supervision. Another 
important factor to consider is the setting. Different instruments may be more 
appropriate in different settings, depending on available time and resources. In busy 
clinical practice, particularly outpatients and general practice, short instruments are 
desirable. To use screening tests in clinical practice, cut-off scores, indicating 
transition points between different cognitive states, are useful. Since cognitive 
screening instruments provide a range of scores, the challenge is to select cut-off 
scores to maximise both sensitivity and specificity. Useful instruments should be 
responsive to change across the cognitive spectrum, from SMC to MCI and dementia. 
 Where no ‘gold standard’ exists for the diagnosis of neurocognitive disorders, 
for example dementia in those with existing intellectual disability and MCI, the 
traditional approach has been to compare findings with the judgment of clinicians. As 
clinicians make decisions based upon similar findings and principles as the 
instruments, it is likely that there will be a high level of agreement, irrespective of 
validity [Ball et al., 2004]. To overcome this, an important test of the validity of an 
instrument is concurrent validity, that is, where a test correlates well with a measure 
that has previously been validated. A further, arguably stronger measure is predictive 
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validity, when one measure, taken at a starting time, is meant to predict some later 
outcome. Predictive validity can be determined by examining the degree to which a 
diagnosis made at time point one predicts decline on cognitive tests and the diagnosis 
at a second time point, two [Ball et al., 2004]. Analysing large numbers of 
participants with and without the target condition is required to estimate the overall 
diagnostic accuracy of any test [Bachmann et al., 2006],[Flahalt et al., 2005]. When 
multiple tests are performed on the same individual to compare the accuracy of two or 
more tests, then the proportions (i.e., sensitivity and specificity) are considered 
dependent. The difference between the two is referred to as the effect size and this can 
be captured using Cohens σ. A small effect is 0.1-0.3, medium, 0.3-0.5 and 0.5-0.8 or 
greater is taken as big. Sample size increases if you are looking for a small effect, 
such that if you expect a big difference in e.g. sensitivity or specificity of a test a 
priori, you will need a smaller sample size [Fosgate 2009].   
 Other important psychometric properties include reliability, inter-rater and 
test-retest, and internal consistencey. Inter-rater reliability (IRR) is a measure of 
agreement between two or more raters. IRR is measured using Pearsons (best used for 
interval parametric data) or Spearman’s rank (best used for ordinal, non-parametric 
data) correlation coefficients. Pearsons correlation coefficient (r) measures the 
strength of linear dependence between two variables. Spearman’s Rank (rho ρ) 
measures monotonic relationships. Both can be measured for the same data to 
examine differences between the data, to confirm whether the assumptions of 
Pearsons (constant variance and linearity) were met. Correlations are scored between 
-1 and 1. A score of one or minus one represents perfect linear correlation with scores 
between suggesting weak to strong correlation. IRR can also be measured using either 
Cohens weighted Kappa [Cohen 1968], (measures agreement between two raters) or 
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Fleiss’s Kappa [Fleiss et al., 1969] (measures overall agreement between more than 
two raters). Kappa scores are interpreted as follows: a score of <0.2 is considered 
poor agreement, 0.21-0.4 fair, 0.41-0.6 moderate, 0.61-0.8 strong, and more than 0.8 
near complete agreement. Internal consistency measures correlations between an 
instruments subtests or between a test and itself over time. It can be measured using 
either Cronbach’s Alpha or an intraclass correlation coefficient or by measuring 
correlations between a test and itself over time. Cronbach’s Alpha scores above 0.7 
indicate a high degree of reliability. 
 Other useful characteristics include the positive predictive value (PPV) and 
negative predicitve value (NPV) of a screen, presented in Figure 2.1 The PPV defines 
the percentage of individuals with a positive test that have the condition, NPV defines 
the percentage of individuals with a negative that do not have the condition. The PPV 
and NPV of a test are dependent on the prevalence of the condition assessed [Altman 
1994], the higher the prevalence e.g. of cognitive impairment, the higher the PPV and 
lower the NPV. Provided prevalence is constant PPV and NPV can be compared 
between tests [Altman 1994]. A high PPV is important for a screening test. 
 
Figure 2.2. Calculation of positive predictive value (PPV) and negaitive predicitive 
value (NPV). 
 
PPV = sensitivity× prevalence
[sensitivity× prevalence]+[(1− specificity)× (1− prevalence)]
 
 
NPV = specificity× (1− prevalence)




Where there is a very high prevalence of a condition, particularly if greater than the 
true population prevalence such as the prevalence of cognitive impairment in patients 
attending a memory clinic, it is better to use liklihood ratios [Altman & Bland, 1994]. 
Positive likelihood ratios (PLR) describe how the probability of disease shifts when 
the finding is present. A score of between 2-5 suggests a small chance, 5-10 moderate 
and >10 a large chance of having the condition. Negative likelihood ratios (NLR) 
describe how the probability shifts when disease is absent [McGee 2002]. A score of 
0.2-0.5 suggests a small chance, 0.1-0.2 moderate and <0.1 a large chance. 
 Receiver operating characteristic (ROC) curve analysis is used to determine 
the overall diagnostic accuracy of a cognitive screening instrument. Accuracy is 
measured from the area under the curve (AUC) from ROC curves and these can be 
compared to determine if instruments differ statistically in accuracy [Hanley et al., 
1983],[Alberg et al., 2004]. The AUC is a function of the sensitivity and 1-specificity 
and is measured from 0 to 1.! ROC scores above 0.5 indicate that the component 
(instrument) has better predictive power than by chance alone. A score greater than 
0.8 suggests good accuracy, greater than 0.9 suggest excellent accuracy [Metz 1978]. 
The interpretation of ROC curves is presented in Table 2.2 and Figure 2.3. Accuracy, 
while an appealing construct to provide an “overall” marker of sensitivity and 
specificity, is not equivalent to both which remain the standard for the interpretation 
of the ability of screens to identify disease states [Alberg et al., 2004]. Finally, cut-off 
scores to required to allow screening instruments to be used quickly in clinical 
practice. While the use of cut-off scores is fraught with difficulty have Cut-off can be 
determined from the scores that offer the best balance between sensitivity and 
specificity, the “optimal” cut-off or can be calculated using Youden’s Index (J) 
[Larner 2015]. Youden’s Index is a method for establishing the maximum potential 
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effectiveness of a test [Youden 1950],[Ruopp et al., 2008]. It is determined from the 
ROC curve. The J can be defined mathematically as: 
 
    J = maxc {Se (c) + Sp (c) − 1}  
 
Where Se is the sensitivity, Sp is the specificity and c is the optimal cut-off point. The 
cut-point optimizes the tests ability to differentiate when equal weight is given to 
sensitivity and specificity [Youden 1950], or mathematically as:  J = Sensitivity + 
Specificity − 1. This is graphically presented in Figure 2.3 [Ruopp et al., 2008]. 
 
 
Figure 2.3. Receiver operating characteristic (ROC) curves showing the reference line 













Table 2.2. Table showing interpretation of area under the curve scores for receiver 
operating characteristics curves. 
 
 











Figure 2.4. Calculation of Youdens Index from receiver operating characteristics 







Understanding and targeting appropriate cognitive domains is also important for the 
correct use and interpretation of cognitive screening instruments. As described above, 
neurocognitive disorders present with different patterns of impairment necessitating 
the inclusion of the most common cognitive domains. Short instruments can only 
include a limited number of domains, longer and more comprehensive instruments 
can include more. Thus, there is a time-accuracy trade-off between different cognitive 
screening instruments [Larner, Progress in Neurology and Psychiatry 2015]. 
Instruments can be divided into comprehensive and non-comprehensive based on the 
! 38!
number of cognitive domains covered. Important cognitive domains, commonly 
incorporated in screens for MCI and early dementia, include orientation, memory, 
language, attention and calculation, reaction time and visuospatial function (assessed 
with drawing-copying tests) [Lonie et al., 2009]. A systematic review of short 
cognitive screens, exclusively in MCI, found that no instrument covers all domains 
[Lonie et al., 2009]. 
 A complete mental state examination shold target specific cognitive processes 
or domains [Woodford, 2007]. Domains of interest include attention, memory, 
language, visuospatial skills and frontal/executive function. Memory is divided into 
two major categories, declarative and procedural (implicit) memory. Procedural 
memory is usually preserved, surviving even into advanced dementia. Declarative 
memory comprises both episodic and semantic memory, which are the main types of 
memory including short-term memory. Normal ageing is different and although the 
evidence remains unclear, studies suggest differences in cognitive performance in 
healthy educated adults between the ages of 18 and 60 years. Longitudinal studies of 
ageing suggest that one type of memory, episodic memory, for individualized and 
unique personal experiences, usually declines from about the age of 50–60 years 
though this is not universal with approximately 20% maintaining their baseline 
episodic memory [Fjell!et!al.,!2014]. Physical fitness, female gender, and living with 
someone are protective while less education and not being employed increase the 
likelihood of memory loss with age. Other cognitive strengths do not appear to 





2.2.2 Challenges and potential benefits of cognitive screening 
Challenges for healthcare professionals 
There are many challenges associated with cognitive screening in older adults, 
particularly in asymptomatic but at risk groups, for example patients with PD.  These 
include physician specific and patient specific challenges. It is known that physicians 
are poor at predicting patients’ cognitive function, especially without the use of 
formal cognitive (neuropsychological) assessment [Harwood et al., 1997],[Burleigh et 
al., 2002]. Time is limited in clinical practice and for the majority of busy clinicians 
this necessiates the use of short cogntive screens [Burleigh et al., 2002],[Harwood et 
al., 1997]. Studies investigating physicians skills with cognitive screens are limited to 
examining their ability to predict the scores of common but often inaccurate 
instruments such as the Abbreviated Mental Test Score [Burleigh et al., 2002]. 
Studies exploring the views of doctors towards cognitive screening are also limited to 
those that characterise the perceived utility and popularly of instruments. These reveal 
that the MMSE is the most widely used instrument [Ismail et al., 2010]. Little is 
known as to whether physicians feel they have sufficent time or skill to adequately 
and competantly screen their patients. In Ireland, most GPs (90%) have no dementia 
specific training and most (83%) express a desire for same [Cahill et al., 2006].  
 There are other specific challenges for physicians. Cognitive impairment is a 
heterogeneous disorder and presents in a heterogeneous fashion. Patient populations 
(normative data) are likewise heterogeneous with different subgroups requiring 
different cut-off scores, adjusted for age and education [Crum et al 1993],[Rossetti et 
al., 2011],[Kenny et al., 2013]. The effect of developing and validating these among 
large populations of patients with different dementia subtypes is also required. People 
with memory loss most frequently present to their GP with SMC [Speechly et al., 
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2008], although little is known about what triggers patients to present in the 
community [Lin et al., 2013]. Although there is a paucity of evidence for screening in 
primary care, where cases are often undiagnosed [Bradford et al 2009],[Valcour et al., 
2000],[Connolly et al., 2011], research suggests that primary care offers superior post-
diagnostic management [Meeuwsen et al., 2012] over secondary care, suggesting that 
primary care may represent the ideal location to screen as well as manage patients 
with memory loss. Barriers in primary care include the lack of sufficiently sensitive 
and specific short screening instruments able to differentiate SMC from MCI and 
dementia. However, one single screening policy incorporating a single instrument is 
unlikely to be successful. 
 
Challenges for patients 
Similarly, there are challenges for patients. However, little is known about the views 
of patients themselves. Many report that cognitive screening, neuropsychological 
testing and the memory clinic experience is probing, demoralizing and in many cases 
confusing and frightening [Cahill et al., 2008]. Despite this, approximately half of 
new referrals in an Irish memory clinic found testing to be a positive experience, 
feeling they performed well [Cahill et al., 2008]. No data is available about the views 
of caregivers and/or their other family members and friends concerning the use of 
cognitive screening and their preceptions of whether they could screen others or 
indeed themselves. However, it is suggested that many patients and caregivers 
experience anxiety leading up to and while attending a memory clinic, suggesting that 
many patients may have performed better outside a clinical setting or at a home 
assessment [Cahill et al., 2008]. Whether shorter but more accurate instruments would 
be welcomed or beneficial is also unclear. 
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Evidence for and against screening 
It is estimated that only a small number of people meeting the criteria for a 
neurocognitive disorder are diagnosed [Thies et al., 2011]. Despite this, in 2013 the 
U.S. Preventive Services Task Force reviewed the evidence base for cognitive 
screening [Lin et al., 2013] among unselected community-dwelling older adults in 
primary care, concluding that there is insufficient evidence to recommend cognitive 
screening nor any single short cognitive screen. This is in part because of lack of 
sufficiently sensitive and specific screening tests to differentiate normal ageing from 
major and minor neurocognitive disorders [Winblad et al., 2004],[Boustani et al., 
2005]. Indeed, few short screening instruments have been widely validated in primary 
care and questions remain regarding the ethical [Boustani et al., 2005] and clinical 
benefits of unselected screening [Lin et al., 2013]. Screening for cognitive impairment 
doesn’t yet meet Wilson’s Criteria, recognised as the gold standard for the utility of 
any screening initiative.  
 
Potential benefits 
The potential benefits of screening for cognitive impairment are difficult to measure, 
which may explain the paucity of evidence to date, particularly with respect to 
unselected screening. There is however, growing opinion that cognitive screening 
among selected samples may benefit patients [Clionsky & Clionsky, 2014],[McCartan 
2013] particularly at risk populations including those with multiple co-morbidities. 
Potential advantages include allowing healthcare professionals and families to plan 
for the future, identify reversible causes and initiate treatment if appropriate. Early 
diagnosis allows prompt and appropriate initiation of care and treatment. In particular, 
it allows the physician to differentiate between normal ageing, MCI and early 
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dementia. Given that different treatments such as cholinesterase inhibitors are 
appropriate at different stages of disease progression [Tricco et al., 2013],[Cooper et 
al., 2013], clear staging of cognitive impairment through accurate screening and 
subsequent assessment is important. Prompt diagnosis allows for the identification 
and exclusion of reversible causes. These conditions, often misdiagnosed as dementia 
represent up to 20% of memory clinic referrals [Hejl et al., 2002] but in practice, less 
than 1.5% of cases of mild to moderate dementia are fully reversible [Boustani et al., 
2002]. There is growing recognition of the role cardiovascular (CV) risk factors, such 
as hypertension [Ligthart et al., 2010],[Tzourio et al., 2010],[Oveisgharan et al 2010], 
play in the conversion from MCI to dementia and dementia progression [Gao et al 
2013],[O’Caoimh, Gao et al., JAD 2014],[O’Caoimh, Kehoe et al., JAD 
2014],[O’Caoimh, Kehoe et al., 2013]. Lifestyle factors including obesity, lack of 
exercise and smoking are also associated with dementia and there is evidence that 
effectively managing these may prevent cognitive decline [Fillit et al., 2008]. Failure 
to recognise the presence of MCI, to screen for CV risks or to educate on lifestyle 
modifications can result in worse outcomes. Finally, prompt assessment gives time for 
acceptance for patients and families, allowing them to plan for eventualities and 
access information, resources and supports [Workman et al., 2010].   
2.3 Overview of existing cognitive screenings instruments for mild 
cognitive impairment and early dementia 
Systematic reviews [Lonie et al., 2009], have demonstrated that there are an 
increasing number and variety of short screening instruments available for the early 
identification and differentiation of MCI and early dementia. Lonie et al found 15 
different instruments, the majority of which covered a restrictive range of cognitive 
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domains. Instruments varied according to their administration time, reliability, 
sensitivity and specificity. Only one had adequate inter-rater and test-retest reliability. 
While most reported high levels of sensitivity, most reported low specificity. Further 
most instruments had small sample sizes. Administration times also differ 
considerably from as low as 1-2 minutes up to 45 minutes. Available short screening 
instruments for MCI do not adequately predict the course and eventual outcome of 
MCI [Lonie et al., 2009]. The authors concluded that none of the identified cognitive 
screening measures wholly fulfill all of the criteria identified as being important in 
MCI screening. This may in part relate to a lack of consensus on the definition of 
MCI and on differences in the characteristics of participants included in studies 
[Stephan et al., 2013],[Larner, Springer International Publishing 2015].  
 Multiple cognitive screening tests are available, each with different 
psychometric properties. Cognitive screening tests can be either direct 
neuropsychological or observer rated instruments. Observer rated tests are informant 
guided questionnaires or interviews. There is evidence to support that the addition of 
an observer rated test improves the diagnostic accuracy of directly administered 
neuropsychological screen [Roalf et al., 2012]. Observer-rated scales must however, 
be interpreted with caution as ageing caregivers may be developing cognitive 
difficulties themselves or may know the subject too well or insufficiently to be 
objective [Nieuwenhuis-Mark et al., 2009].The advantages and disadvantages of 
commonly used cognitive screening instruments is presented in Table 2.3. The 






Table 2.3. Comparison of the advantages and disadvantages of commonly used 
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Table 2.4. Psychometric properties of commonly used short cognitive screening 












5-10 <26 18% 100% Folstein et al., 1975; 
Molloy, 1991 
ADAS-Cog 45 6 (total 
score) 
73% 89% [Pyo et al., 2006] 
6CIT 2-3 >8/28 66% 70% Katzman et al., 1983; 
Abdel-Aziz & Larner, 
2015 
Mini-Cog 4-5 <3 58% NR Borson et al., 2005 
GPCOG 4-6 NA NA NA NA 
MoCA 10-12 <26 90% 87% Nasreddine et al., 2005 
ABCS 135 3-5 NR 80% 50% Molloy et al., 2005 
TYM 5-10 ≤42/50 NA NA Brown et al., 2009 
IQCODE = Informant Questionnaire on Cognitive Decline in the Elderly; ADAS-cog = Alzheimer's Disease Assessment Scale-
Cognitive section; MMSE = Mini-Mental State Examination; SMMSE Standardised MMSE; 6CIT = Six-Item Cognitive 
Impairment Test; GPCOG = General Practicioner Assessment of Cognition; MoCA = Montreal Cognitive Assessment; ABCS 
135 = AB Cognitive Screen; TYM = Test Your Memory 




Observer rated cognitive instruments 
The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) -
short form 
The Informant Questionnaire on Cognitive Decline in the Elderly -short form 
(IQCODE) [Jorm 1994] is a widely used observer rated instrument usually scored by 
families or close contacts. It is limited by its length, albeit shorter than the original 
version, and its awkward scoring. It not useful in detecting decline in cognition over 
time [Eramudugolla et al., 2012]. The IQCODE short from is widely validated in MCI 
and dementia [Perroco et al., 2008] but may be less accurate in MCI [Razavi et al., 





The AD8 Dementia Screening Interview 
The AD8 [Gavin et al., 2005] is another, more recently developed, observer-rated 
cognitive instrument (See Appendix 2.2).  An informant answers eight questions on 
whether there has been a recent change (over several years) directly attributable to 
memory loss in a variety of daily tasks. Informers can respond with ‘yes’ (a change), 
‘no’ (no change) or ‘don’t know’ answers. A score of one point is given for every 
score answered ‘yes’. A score of two or greater is suggestive of cognitive impairment 
(sensitivity of 84% and specificity of 80%). The test can also be administered to or 
self-administered by the patient directly, although an informant is preferable. The 
AD8 is validated in both MCI and dementia [Razavi et al., 2014]. 
!
Direct neuropsychological cognitive instruments 
The Mini-Mental State Examination (MMSE) and Standardised MMSE  
The Mini-Mental State Examination (MMSE) [Folstein et al., 1975] is the most 
widely used short cognitive screening instrument [Ismail et al., 2010]. The 
Standardised Mini-Mental State Examination (SMMSE) is a standardised form of the 
MMSE that improved inter-rater reliability and reduced administration time by using 
explicit administration and scoring guidelines [Molloy et al., 1991],[Molloy et al., 
1997]. Both screening tests are scored from 30 points. A score of 25 or more suggests 
that the individual may have normal cognition. Below this, scores can indicate mild 
(21-24 points), moderate (10-20 points) and severe cognitive impairment (≤9 points) 
though a cut-off of <24 optimises sensitivity [Molloy et al., 1991],[Molloy et al., 
1997]. The MMSE and SMMSE have a limited role in identifying MCI [Mitchell & 
Shiri-Feshki, 2009], with a ‘low’ ceiling and ‘floor’ effects such that a score of 30/30 
does not always mean normal cognition and a score of zero does not always support 
dementia. The MMSE has insufficient sensitivity to differentiate between normal 
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cognition and MCI particularly where individuals have higher levels of academic 
achievement [Crum et al 1993]. Despite these limitations, the MMSE remains the 
most validated short cognitive screening instrument in general practice (primary care) 
[Lin et al., 2013]. The SMMSE is presented in Table 2.5. 
Table 2.5. The Standardised Mini-Mental State Examination (SMMSE) scoring sheet. 
                                         Standardised Mini-Mental State Examination 
Maximum 
    Score Patient`s   Score 
Questions 
5  Orientation “What is the year? Season? Date? Day? Month?” 
5  “Where are we now? State? County? Town/city? Hospital? Floor?” 
3  Registration Ask the subject if you may test his/her memory. Then say "ball", "flag", "tree" clearly and 
slowly, about 1 second for each. After you have said all 3 words, ask him/her to repeat them - 
the first repetition determines the score (0-3): 
5  Concentration & Calculation Serial 7s 
Ask the subject to begin with 100 and count backwards by 7. ( 93,86,79,72,65....). Stop after 5 
subtractions. Score the correct subtractions. 
Or Spell WORLD backwards 
Ask the subject to spell the word "WORLD" backwards. The score is the number of letters in 
correct position. For example, "DLROW" is 5, "DLORW" is 3, "LROWD" is 0. 
3  Recall Ask the subject to recall the 3 words you previously asked him/her to remember.  
2  Naming Show the subject 2 objects, e.g. a wrist watch & pencil and ask him/her what it is.  
1  Repetition Ask the subject to repeat the following:"No ifs, ands, or buts" 
3  3 Stage Command following Give the subject a plain piece of paper and say, "Take the paper in your hand, fold it in half, 
and put it on the floor." 
1 point for each TAKES, FOLDS, PUTS 
1  Reading Hold up the card reading, "Close your eyes", so the subject can see it clearly. Ask him/her to 
read it and do what it says. Score correctly only if the subject closes eyes 
   CLOSE YOUR EYES 
1  Writing Ask him/her to write a sentence, It must be spontaneous and contain a subject and verb and be 
sensible. 
______________________________________________________________ 
1  Copying Give subject a piece of paper and ask him/he to copy a design of two intersecting shapes. One 
point is awarded for correctly copying it. All angles on both figures must be present, and the 
figures must have one overlapping angle.  
30  Total 
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Six-item Cognitive Impairment Test (6CIT) 
The 6CIT is a short (administration time between 2-3 minutes), cognitive screen 
including seven questions covering three domains (orientation, episodic memory and 
attention) [Katzman et al., 1983],[Brookes et al., 1999]. The 6CIT is scored out of 28 
points with high scores suggesting cognitive impairment. Initially designed to detect 
dementia using a cut-off of ≥8/28, it is also validated in MCI [Abdel-Aziz & Larner 
2015] though sensitivity (66%) and specificity (70%) are low. The 6CIT is presented 
in Table 2.6. 
 
Table 2.6. Six-item Cognitive Impairment Test (6CIT). 
 
Question Score Patient 
Score 
1. What year is it? Correct: 0 points, Incorrect: 4 points  
2. What month is it? Correct: 0 points, Incorrect: 3 points  
3. Give the patient an address phrase to remember with five components  
4. About what time is it 
(within one hour)? 
Correct: 0 points, Incorrect: 3 points  
5. Count backwards from 20-
1 
Correct: 0 points, One error: 2 points, 
More than one error: 4 points 
 
6. Say the months of the year 
backwards 
Correct: 0 points, One error: 2 points, 
More than one error: 4 points 
 
7. Repeat the address Correct: 0 points 
One error: 2 points 
Two errors: 4 points 
Three errors: 6 points 
Four errors: 8 points 
All wrong: 10 points 
 




The Mini-Cog is a brief (3-4 minute) measure including two subtests: three word 
registration, delayed recall (which serves as an attention test and distracter) and clock 
drawing [Borson et al., 2000]. The Mini-cog has little education or language bias and 
is particularly useful as a pre-screen. 
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The General Practitioner Assessment of Cognition (GPCOG) 
The General Practitioner Assessment of Cognition (GPCOG), designed specifically 
for use in general practice, is short (5-6 mins) and acceptable to patients and 
physicians alike [Brodaty et al., 2002]. It is criticised for having age and educational 
bias [Cullen et al., 2007],[Brodaty et al., 2004]. The GPCOG is presented in 
Appendix 2.3. 
 
The Montreal Cognitive Assessment (MoCA) 
The MoCA is a short cognitive screening test with high sensitivity for detecting 
cognitive impairment, over and above the MMSE [Nasreddine et al., 2005]. It has 
seven subtests covering five cognitive domains; memory, language, visuospatial, 
attention and cognitive control, scored out of 30 points [Nasreddine et al., 2005]. 
The MoCA is widely validated in multiple languages and different clinical settings 
[see http://www.mocatest.org/]. Its high sensitivity makes it useful as a cognitive 
screen. It low ceiling makes it particularly useful in those with subtle cognitive 
deficits such as in MCI. Although the MoCA is increasingly accepted as one of the 
short cognitive screens of choice, its use presents some challenges. It is long, taking at 
least 10 minutes to complete [Nasreddine et al., 2005] and is considered by some to 
be too difficult to use in those with significant cognitive impairment [O’Caoimh & 
Molloy, 2013]. No age or education specific cut-offs are available for those with 
cognitive impairment and the utility of its recommended cut-off score (<26/30) has 
been questioned [Luis et al., 2008]. The specificity of the MoCA at a cut-off score of 
<26 is low, with studies demonstrating specificities between 35% [Luis et al., 2008] 
and 50% [Smith et al., 2007]. Recently, it has been suggested that lowering its cut-off 
will improve its specificity without adversely affecting sensitivity [McLennan et al., 
2011], [Freitas et al., 2013].  However, uncertainty remains as to which cut-off is 
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most appropriate and in which setting. In addition, the MoCA subtest scores have also 
been criticised for having unacceptably poor levels of accuracy when predicting 
impairment in their respective cognitive domains [Moafmashhadi et al., 2013].  The 
MoCA is presented in Appendix 2.4. 
 
Alzheimer`s Disease Assessment Scale-Cognitive section (ADAS-cog)  
The existing accepted standard for measuring cognitive function in clinical trials in 
dementia, is the Alzheimer`s Disease Assessment Scale-Cognitive section (ADAS-
cog) [Rosen et al., 1984],[O'Halloran et al., 2011],[Weyer et al., 1997]. The ADAS-
cog has 11 domains, including: word recall, object naming, command following, 
construction, orientation, word recognition, language, speech comprehension, word 
finding and recall, and takes 30-40 minutes to complete [Rosen et al., 1984]. Total 
scores range from 0–70; higher scores (≥ 18) indicate greater cognitive impairment. 
The minimal important change has been determined to be approximately four points 
and many regulatory authorities, including the Food and Drug Authority, require 
evidence of such change at six months to confirm the benefit of any new medication 
[McKhann et al., 1984],[!Matthews et al., 2000],[Aisen et al., 2003]. The ADAS-cog, 
although comprehensive and useful at different stages of dementia, has limitations. 
The ADAS-cog is long, requires training and there is concern about the instruments` 
inter-rater reliability [Connor et al., 2008]. It also has a ceiling effect, limiting 
usefulness in the initial stages of dementia [Mohs et al., 1997]. To overcome these 
limitations, the Standardised Alzheimer`s Disease Assessment Scale-cognitive section 
(SADAS-cog) was developed, to improve inter-rater reliability using explicit 
administration and scoring guidelines [Standish et al., 1996]. The SADAS-cog, is 
equally lengthy, taking up to 45 minutes. The SADAS-cog is presented in Appendix 
2.5. 
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The AB Cognitive Screen 135 (ABCS 135) 
The ABCS 135 was developed to improve the accuracy of diagnosing MCI [Molloy et 
al., 2005]. The ABCS 135 has five domains: orientation, registration, clock drawing, 
delayed recall (DR) and verbal fluency (VF) [Molloy et al., 2005]. Administered in 
three to five minutes, it is more sensitive in differentiating MCI from normal controls 
and dementia compared with the SMMSE [Molloy et al., 2005], although floor effects 
were suggested in those with advanced dementia. Like other instruments, age and 
education affect ABCS135 median scores and accuracy [Molloy et al., 2005]. While 
its accuracy and sensitivity is high (80%), its specificity (50%) is low [Molloy et al., 
2005]. Its DR and VF subtests were best at distinguishing MCI from those with 
normal controls (NC) [Standish et al., 2007]. Analysis of the subtests suggests that 
although all of the domains are useful, orientation, registration and clock drawing did 
not enhance the ability of the test to differentiate normal from MCI. For this reason, 
the Quick Mild Cognitive Impairment (Qmci) screen was developed, to enhance the 
sensitivity of the ABCS 135, particularly for MCI. Thus, the ABCS 135 is the 
predecessor of the Qmci.  
 
Test Your Memory (TYM) 
The Test Your Memory (TYM) [Brown et al., 2009] scored by patients, under 
supervision of trained raters, the TYM is validated in memory clinics against the 
MMSE [Brown et al., 2009], Addenbrooke's Cognitive Examination-Revised 
[Hancock & Larner, 2011] and detailed neuropsychological testing [Koekkoek]. It is 
composed of 25 items scored out of 50 points and requires five to ten minutes to 
complete. It is validated in different languages [Hanyu et al., 2011],[Szczesniak er al., 
2013]. 
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2.4 The Quick Mild Cognitive Impairment (Qmci) Screen 
Development of the Qmci  
The Qmci, originally called the ABCS 100 after its predecessor, is a modified version 
of the ABCS 135. It is scored out of 100 points and places greater emphasis on verbal 
fluency and memory including recall compared to the 135 version. Although, the 
ABCS 135 is a sensitive and quick test to differentiate subtypes of cognitive 
impairment from normal cognition, much of the test is inadequate at detecting MCI. 
Given this, the scores of the ABCS 135 subtests were re-weighted to accomadate the 
introduction of an additional subtest logical memory (LM) and to reduce the total 
score to 100 points [O’Caoimh et al., 2013]. The scores of the ABCS 135 and Qmci 
are presented by way of comparison in Table 2.6 in sub-section 2.4.  
 Figure 2.5, which has been previously published by another research team 
[Standish et al., 2007], shows the mean subtest scores for the ABCS 135 expressed as 
a percentage for subjects with normal cognition, MCI and established dementia. The 
orientation, registration and clock drawing subtests did not enhance the discriminatory 
properties of the test. Further, while sensitivity was high, specificity was low, 
approximately 50%.  For this reason the Qmci was developed to enhance the 
sensitivity of the ABCS 135. To do this, the weightings of delayed recall and verbal 
fluency were increased, and a logical memory subset was added to the original score 
(see Table 2.7). Thus, on the basis of these results, orientation was reweighted from 
25 to 10 points, registration from 25 to 5 points, clock drawing from 30 to 15 and VF 
from 30 to 20. DR was increased in weighting to 20 and a test of LM was added at a 




Table 2.7: Comparison of the weightings of the AB Cognitive Screen 135 (ABCS 
135) and the Quick Mild Cognitive Impairment (Qmci) screen. 
 
ABCS 135 Score Qmci Score 
Orientation 25 Orientation 10 
Registration 25 Registration 5 
Clock drawing 30 Clock drawing 15 
Delayed recall 25 Delayed recall 20 
Verbal fluency 30 Verbal fluency 20 
  Logical memory 30 
 
 
Figure 2.5. Mean subset scores for the AB Cognitive Screen 135 (ABCS 135) 
expressed as a percentage for normal controls (NC), and patients with mild cognitive 




Qmci Scoring and administration guidelines 
The Qmci is then scored out of a total of 100 points. The Qmci has a short 
administration time, median time 4.24 minutes [O’Caoimh et al., 2013], which if 
scored according to the administration guidelines cannot take more than five minutes 
to complete. The Qmci screening instrument includes six subtests, covering five 
cognitive domains: orientation, working memory, sematic memory (verbal fluency for 
animals), visuo-spatial (clock drawing) and two tests of episodic memory, delayed 
recall and logical memory (immediate verbal recall of a short story).  














The first subtest, orientation, has five items (country, year, month, day and date). Two 
points for the correct answer, 1 point for wrong answers, and 0 points for no answer 
or a conceptually unrelated answer. Maximum of 10 seconds for each answer to a 
total time of 30 seconds. The maximum score is 10 points. 
 
Registration 
The second subtest is word registration. It is composed of five items to be repeated 
back immediately. Three alternative word sets are provided. One point is scored for 
each word recalled after the first reading. If subject recalls all five, the five items are 
repeated once before proceding to the next subtest. If a subject does not repeat all 5, 
the 5 items are repeated. This is done until the subject correctly recalls all 5 items or 
for a maximum of 3 trials. Trials 2 and 3 do not count. These trials are to help the 
person learn in preparation for the delayed recall (DR) subtest. Ten seconds are 
allowed for recall. The maximum score is 5 points. 
 
Clock Drawing Test 
The third subtest is a one minute clock drawing test.!The clock drawing subtest is a 
moderately sensitive and specific test, in its own right, to screen for executive 
dysfunction and visuospatial problems. Clock drawing is a popular short screening 
test for dementia, in both community [Sager et al., 2006] and hospital settings [Death 
et al., 1993], and can be scored reliably by both trained and untrained raters [Lessig et 
al., 2008]. There is excellent IRR for clock drawing between specialists in dementia 
[Nair et al., 2010]. It can be abnormal despite, a normal SMMSE [Juby et al., 2002]. It 
is also included in other short screening test batteries including the Mini-Cog [Borson 
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et al., 2000]. A blank circle “clock face” and scoring template are provided to the test 
subject. This transparent scoring template is placed over the circle of the patient’s 
completed clock. The template is rotated so that the “12”s align. One point is scored if 
the 1, 2, 4, 5, 7, 8, 10, and 11 numbers are drawn in the correct quadrants. One point 
is also scored if the 12, 3, 6, and 9 touch their quadrant lines. One point is subtracted 
for each number repeated or for numbers above 12. One point is given for each hand 
between the dashed lines (see Appendix 1.1.). One point is scored for hands 
connecting at the pivot. The maximum score is 15 points. 
 
Delayed Recall (DR) 
The fourth subtest, delayed recall (DR), relates to the five words in the registration 
subtest using the clock subtest as a distractor. The patient is asked to remember the 
five words from the registration task. DR is timed at 20 seconds and words may be 
recalled in any order. The maximum score is 20 points. 
 
Verbal Fluency (VF) 
The fifth subtest is a test of verbal fluency (VF). Subjects must name as many words 
as possible relating to a named category within 60 seconds. A half a point is given for 
each word named to a maximum of 40 words. The final score is rounded up. Words 
with different suffixes are not counted twice (e.g. fish / fishes, mouse / mice, etc.). 
Alternate species (e.g. blue jay, robin, sparrow, duck, etc.) are accepted. Alternate 
validated forms include fruits and vegetables, cities and towns [Cunje et al., 2007]. 




Logical Memory (LM) 
The sixth and final subtest is logical memory (LM). LM is a highly sensitive and 
specific test to differentiate normal cognition from MCI [Cunje et al., 2007]. LM is a 
linguistic memory test (for verbal stories) [Wechsler 1997] and tests immediate verbal 
recall. LM is unaffected by age or education [Lichtenberg & Christensen, 1992]. 
Two points are given for each correct word item recalled verbatim. All bolded words 
within each section of the short story must be recalled to score 2 points. Otherwise 
score 0. Recall may be in any order.  In total 30 seconds are allowed for 
administration and 30 seconds for response. Again alternative validated alternatves 
are available. The maximum score is 30 points. 
 
Thus, the Qmci can be performed and scored in less than five minutes. Alternative, 
validated forms of the Qmci are available: VF (plants and flowers or fruits and 
vegetables) and LM (different stories) [Cunje et al., 2007]. The Qmci scoring template 
is presented in Figure 2.6.  The doubled sided scoring sheet including alternative 
versions and the clock scoring template are presented in Appendix 1.1. Detailed 
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     Quick Mild Cognitive Impairment screen (Qmci) 
Name:                             DOB:                 Gender:                 Years in Education:                Date:                Time: 
1. Orientation 
To begin ask 5 questions.  
! One minute. 
!  Give 2 points for correct answer, 1 if 
attempted but incorrect, 0 if no attempt. 
What country is it?                                                                             ___  / 2 
What year is it?                                                                                   ___  / 2 
What month is it?                                                                               ___  / 2 
What is todays date?                                                                          ___  / 2 




__/ 10  
2. Word Registration 
To begin say… 
“I am going to say 5 words.  
After I have said these 5 words, 
repeat them back to me.  Are 
you ready?”  
! 30 seconds. 
!  Give 1 point per word repeated, in any 
order, no hints. 
 
Dog   Rain    Butter      Love       Door 
     
Alternate word groups include… 
Cat Dark Pepper Fear Bed 









3. Clock Drawing  
“Use the circle provided over 
page to draw a clock face, set the 
time to ‘ten past eleven’.” 
! One minute approximately.  
!  Give 1 mark for each number, 1 for each 
hand & 1 for the pivot correctly placed or close 
to their ideal location. Loose 1 mark for each 
number duplicated or greater than 12, e.g, 15 or 
45, i.e. errors.  
 
 
Score:                Numbers  Correct + ______/ 12 
  Errors - ______ 
                           Hands  + ______/ 2 
                           Pivot                          + ______/ 1 








4. Delayed Recall  
 “A few minutes ago I named 
five words.  Name as many of 
those words as you can 
remember.”  
! 30 seconds. 
!  Recall in any order, within 30 seconds, 
giving 4 points per word, no hints. 
 
Dog   Rain    Butter      Love        Door 
     
Alternate word groups include… 
Cat Dark Pepper Fear Bed 









5. Verbal Fluency  
“Name as many animals as you 
can in one minute.  Ready? Go.” 
! One minute. 
!  Give half a point per animal named; to a 
maximum of 40. Accept all ‘creatures’ 
including birds, fish, insects etc. Do NOT count 
suffixes twice, e.g. mouse/mice but allow points 
for similar names calf, cow, bull.  
Alternative forms include: fruit & veg or towns & cities. 
Score 0.5 x number of animals =  










6. Logical Memory  
“I am going to read you ONE 
short story. After I have finished 
reading it completely, I want you 
to tell me as much of the story as 
you can. OK?”   
! 30 seconds. 
Give 2 points per highlighted word, recalled 
exactly, immediately within 30 seconds, in any 
order, no hints. Two alternatives are provided. 








The red It was a hot The brown It was a cold The white It was a warm 
fox May dog October hen September 
ran across 
the 
morning. ran across day. walked 
across 
afternoon. 
ploughed Fragrant  the metal Ripe the concrete  Dry 













a brown the bushes. a white the trees. a black the wind. 
dog.  Rabbit.  cat.   
Qmci Total score                                                                                                                            *___/ 100  
*adjust score for age & education (see over).                                 Administered by:____________________  
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2.5 The Memory Clinic  
The main external validation of the Qmci in this PhD was conducted in the memory 
clinic in the Assessment and Treatment Centre in St Finbarrs Hospital, Cork City. An 
additional “out-reach” memory clinic was created in Mallow Primary Healthcare 
Centre, Mallow Co Cork, to facilitate diagnosis of patients in the community-general 
practice setting. Historically, the earliest memory clinic prototype emerged in 
America in the early 1980s. Clinics have since emerged across Europe, first reaching 
Ireland in 1991. The importance of memory clinics is well established [Philips & 
O’Brien, 2004],[Passmore & Craig, 2002].Memory clinics are specialised medical 
clinics focusing on identifying, investigating and managing memory disorders, 
including dementia [Jolley et al., 2006].  
 
Referral pathways   
Memory clinics see patients across the spectrum of memory problems from normal 
ageing to MCI and dementia. Acceptance criteria vary between clinics but early 
referral is desirable. Advanced dementia, presenting for the first time, although 
representing less of a diagnostic challenge, can be referred, especially if the diagnosis 
is uncertain. Patients with advanced dementia with behaviours that challenge are 
usually not accepted and are often redirected to the old age psychiatry team. Memory 
clinics usually accept referral directly from GPs or other physicians. Standardised 
referral letters have been developed but are not typical. A small number of 
appointments are usual, allowing time for comprehensive assessment. A waiting 
period of three months has been observed in Ireland [Cahill et al., 2011].. Referral 
should ideally be made after screening for depression and initial blood work, provided 
this doesn`t cause unnecessary delay (See Figure 2.7). 
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The role of the Memory clinic 
Memory clinics, co-ordinated by psychiatry or geriatrics usually accept referrals 
directly from GPs or other physicians, seeing patients with a spectrum of memory 
problems, including people with SMC. New presentations of advanced dementia 
should be referred if the diagnosis is uncertain. Acceptance criteria vary between 
clinics but as a rule early referral is desirable. Referral should ideally be made after 
screening for depression and initial blood work, provided this doesn`t cause 
unnecessary delay. When a diagnosis is made, depending upon the stage of 
progression and the extent to which a patient or their family accept the diagnosis, 
advice and literature can be provided regarding creating a will, an enduring power of 
attorney, advanced care directives or home supports. Memory clinic assessment is 
usually completed over a short period before patients are discharged back to their 
primary physician. Some patients are followed for longer where the diagnosis is 
uncertain or close monitoring is desirable particularly for MCI.   
 The exclusion of reversible causes of cognitive impairment, which can 
represent between 13% [Clarfield 1988] and 20% [Hejl et al., 2002] of referrals, is 
paramount. Fewer reversible cases are now presenting to memory clinics [Clarfield 
2003]. The most common, primary reversible causes are depression followed by 
hydrocephalus and alcohol dependency, all more likely in younger than older patients. 
Where patients have symptoms that meet the diagnostic criteria for dementia (marked 
cognitive and functional impairment), a reversible cause is found in less than 5% 
[Hejl et al., 2002]. Individuals with self-reported memory loss are the most likely to 
have reversible cognitive impairment. A major challenge for memory clinics lies is 
differentiating symptomatic patients with normal cognition from those with MCI. 
Prevalence of normal cognition varies considerably between clinics; 4% in Ireland 
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[Popoola et al., 2008] but up to 50% in the United States [Steenland].  Diagnosis is 
based on a multi-disciplinary assessment taking into account the results of 
investigations, using cognitive screening tools as an adjunct. Delirium and 
subsyndromal delirium, a common cause of new onset cognitive impairment 
particularly in hospitalised older adults [Ryan et al., 2013],[Meagher et al., 2015] are 
an infrequent cause of memory problems in memory clinics [Hejl et al., 2002].  Four 
cardinal features, history of recent onset, fluctuating confusion, inattention, 
disorganised thinking and altered consciousness [Inouye et al., 1990] combined with 
short tests of attention help distinguish delirium from dementia.   
Figure 2.7. Suggested referral algorithm to a memory clinic for patients with memory 











to medical or 
psychiatric team 
Possible  
MCI or Dementia 
Investigate 
Blood tests /ECG if 
available 
Consider referral 
to a memory clinic 
Exclude Depression 
 
Exclude other causes 
(assess risk factors, 
review drugs) 
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2.6 Rationale for the study 
From the review above, six key reasons for undertaking the project emerged: 
 
1) At present there is insufficient evidence for suitably accurate, sensitive and specific 
short cognitive screening instruments that can differentiate MCI from normal ageing 
but SMC and early dementia, for use in busy clinical practice (hospital clinics and 
general practice). 
 
2) While patients often present to general practice with SMC, GPs are poor at 
differentiating these from patients with MCI and early dementia. Few short screens 
are validated in general practice and it is not clear which instruments are most useful. 
In particular, little is known about the reliability (inter-rater) of short screens in 
primary care. 
 
3) It is not clear if a single, short cognitive screen are accurate across different 
neurocognitive disorders (across the cognitive spectrum), particularly in different 
dementia subtypes. Although the MMSE and MoCA are brief and widely validated 
instruments, their use presents challenges. In particular, the MoCA is rarely compared 
to tests designed specifically to detect MCI. 
 
4) While normative data is increasingly available for some short screens, little is 
known to what extent instruments need to be adjusted for demographic details in 
those presenting with symptomatic memory loss and what effects these have on cut-
offs for different tests. 
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5) At present it is not known whether a short cognitive screen can substitute for more 
detailed instruments and whether brief screens have similar responsiveness to change 
over time.  
 
6) Can short cognitive screening instruments be shortened further, based upon 
analysis of their subtests, to provide a “home” caregiver-administered screen, without 
loosing their diagnostic accuracy? 
 
In summary, this PhD sets out to investigate the characteristics of an ideal short 
cognitive screen and explores the psychometric properties of a new instrument, the 
Qmci and its subtests, in different clinical settings with a view to demonstrating its 
construct validity as an easy to use, short screen to differentiate normal ageing from 
MCI and early dementia. The rationale for each study undertaken as part of this PhD 





 Development of the Quick Mild Cognitive 




Validation of the Quick Mild Cognitive Impairment screen; 
Comparison to the AB Cognitive Screen 135 and 
Standardised Mini-Mental State Examination. 
 
3.1 Introduction 
As discussed in Chapter 2, MCI represents a heterogeneous group of disorders of 
memory impairment [Petersen et al., 2004]. Individuals with MCI have variable, 
subtle cognitive changes and although many go on to develop dementia, the rate of 
progression differs considerably. When people present with memory loss, it is 
important to differentiate between MCI and dementia as treatment choices differ. In 
particular, patients with dementia benefit from cholinesterase inhibitors while those 
with MCI do not have a sustained response [Petersen et al., 2005]. Clinical and 
functional assessment has been used to differentiate between these two groups. While 
those with MCI generally do not have functional impairment, evidence suggests that 
subtle functional changes are present in 31% [Artero et al., 2001]. Several cognitive 
screening tools have been used in an attempt to differentiate between normal controls, 
MCI and dementia [Lonie et al., 2009].  Not all of these are able to distinguish 
between MCI and dementia, and it has been suggested that no single screening tool 
will fit all situations [Cullen et al., 2007].  
 The MMSE and SMMSE, while widely used and validated have a limited role 
in identifying MCI [Mitchell 2009], lacking the sensitivity to differentiate between 
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those with normal cognition and MCI, in particular where individuals have higher 
levels of academic achievement [Crum et al., 1993].  To address this problem the 
ABCS 135 was developed [Molloy et al., 2005]. Despite its superior sensitivity, its 
specificity was low and a new subtest (LM) was added and the remaining subtest 
scores reweighted favouring the most accurate domains: delayed recall DR and VF, 
producing the Qmci. The rationale for and development of the Qmci is described in 
Chapter 2.  
 The primary objective of this study was to compare the accuracy of the Qmci 
with that of the SMMSE and its predecessor, the ABCS 135, in distinguishing 




The population is similar to that studied in the validation of the ABCS 135 and was 
sampled in the same fashion [Molloy et al., 2005]. Patients with MCI and dementia 
were recruited from patients attending four memory clinics across Ontario, Canada 
(Hamilton, Paris, Niagara Falls, and Grand Bend) for investigation of cognitive loss 
between 2004 and 2010. Caregivers and those attending with the patients were asked 
to participate as controls. A diagnosis of dementia was based upon NINCDS 
[McKhann et al., 1984] and DSM-IV criteria [APA 1994]. Dementia severity was 
correlated to the Reisberg Functional Assessment Staging (FAST) scale. A diagnosis 
of MCI was made by a consultant geriatrician if patients had subjective but 
corroborated memory loss without obvious loss of function. While in keeping with 
previous working group criteria this definition does not require the demonstration of 
cognitive deficits on objective cognitive testing [Winblad et al., 2004]. Patients were 
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excluded if they were aged under 55 years, if they were unable to communicate 
verbally in English or had depression as defined by a Geriatric Depression Scale 
(GDS) greater than seven [Yesavage 1988],[Marc et al., 2008].  
  
The Reisberg Functional Assessment Staging (FAST) scale  
The Reisberg FAST is a global measure designed to stage dementia severity. The 
Reisberg FAST scale presented in Table 3.1.  
 
Table 3.1. Reisberg Functional Assessment Staging (FAST) scale. 
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Functional Assessment Staging (FAST) 
scale stage 
Description 
Stage 1 - Normal adult 
 
No functional decline evident. 
Stage 2 - Normal older adult 
 
Insight and awareness into some 
functional decline. 
Stage 3 - Early Alzheimer's disease 
 
Some noticeable deficits with demanding 
tasks. 
Stage 4 - Mild Alzheimer's 
 
Requires assistance in complicated 
instrumental activities including handling 
medications & finances, etc. 
Stage 5 - Moderate Alzheimer's 
 
Requires assistance with dressing. 
Stage 6 - Moderately severe Alzheimer's 
 
Requires assistance with dressing, 
bathing, and toileting. Experiences 
urinary and fecal incontinence. 
Stage 7 - Severe Alzheimer's 
 
Decline in speech. Progressive loss of 
















The Geriatric Depression Scale (GDS) 
The GDS is a clinician-administered measure of depression. It has two accepted 
forms, the long form with 30 questions and a short form with 15. The GDS-30 was 
originally validated with standard research diagnostic criteria for depression. With a 
cut-off score of 11/30 it provides a sensitivity of 84% and specificity of 95% for 
depression. Test retest reliability is satisfactory with a correlation of 0.85. The 15 item 
GDS-Short Form has a cut-off 0 to 5 score of ≥5 for depression [Yesavage 
1988],[Marc et al., 2008]. While the performance of the GDS is compromised by 
severe cognitive impairment (approximately 14 or less out of 30 on the MMSE), it is 
suitable as a brief screen for depression in those with mild to moderate dementia. The 
GDS Short Form is presented in Table 3.2. 
 









Patient’s Name:         Date:      
 
Instructions: Choose the best answer for how you felt over the past week. Note: when asking the 
patient to complete the form, provide the self-rated form (included on the following page). 
 
No. Question Answer Score
1. Are you basically satisfied with your life? YES / NO  
2. Have you dropped many of your activities and interests? YES / NO  
3. Do you feel that your life is empty? YES / NO  
4. Do you often get bored? YES / NO  
5. Are you in good spirits most of the time? YES / NO  
6. Are you afraid that something bad is going to happen to you? YES / NO  
7. Do you feel happy most of the time? YES / NO  
8. Do you often feel helpless? YES / NO  
9. Do you prefer to stay at home, rather than going out and doing new things? YES / NO  
10. Do you feel you have more problems with memory than most people? YES / NO  
11. Do you think it is wonderful to be alive? YES / NO  
12. Do you feel pretty worthless the way you are now? YES / NO  
13. Do you feel full of energy? YES / NO  
14. Do you feel that your situation is hopeless? YES / NO  
15. Do you think that most people are better off than you are? YES / NO  
TOTAL  
(Sheikh & Yesavage, 1986) 
 
Scoring: 
Answers indicating depression are in bold and italicized; score one point for each one selected. A score of 0 to 5 
is normal. A score greater than 5 suggests depression. 
 
Sources:   
x Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter 
version. Clin Gerontol. 1986 June;5(1/2):165-173. 
x Yesavage JA. Geriatric Depression Scale. Psychopharmacol Bull. 1988;24(4):709-711. 
x Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: 
a preliminary report. J Psychiatr Res. 1982-83;17(1):37-49.
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Data collection 
Each patient had demographic data collected including age, gender and years of 
education. Each underwent a comprehensive evaluation including a physical 
examination and work-up for causes of cognitive impairment including a brain 
computerised tomogram (CT) scan, an electrocardiograph and blood tests. Caregivers 
were asked to score caregiver burden, ADL, behaviour, depression and safety scores. 
All patients had the SMMSE and the Qmci administered in random order by a trained 
rater, who was blind to the diagnosis.  
 
Statistical analysis 
Data were entered into SPSS version 16.0. Subjects were subdivided according to age, 
> or ≤ 75 years (to provide a balance in the numbers in each group – most patients 
were aged over 75) and educational level achieved, ≥ or < 12 years (approximating 
high school / secondary school level in North America). A subset labeled as having 
“everything else”, incorporating patients with normal and MCI, was used to compare 
the ability of the tools to select for dementia. A subset of patients called “cognitive 
impairment” was included to compare those with any cognitive deficits to normal 
controls. Data were analysed using ROC curves. Students t tests compared mean 
scores were data were parametric; Mann-Whitney U tests were used to compare non-
parametric data, between different conditions. 
 
3.3 Results 
A total of 965 participants were included in the study; 561 males (43 %) and 424 
females (57%). In all, 630 participants had normal cognition (65.3%), 154 had MCI 
(16%) and 181 (19%) had dementia. The mean age of the total population was 70.5 
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years; those with normal cognition had a mean age 67.4 years compared to 73.3 for 
the MCI group and 78.7 for dementia group. The dementia group was older than the 
normal cognition (p <0.001) and MCI (p <0.001) groups. They also had spent less 
time in education, 11 years (95% CI: 10.4-11.5) compared to the normal (13.8 years; 
95% confidence intervals (CI): 13.6-14.1, p <0.001) and MCI (12.2 years; CI 11.6-
12.8, p <0.005) groups. Dementia was divided into mild (n=141), moderate (n=33) 
and severe cognitive impairment (n=7). Table 3.3 summarises the demographics and 
Table 3.4 the median screen scores of the patients and controls.      
 
Table 3.3. Demographic characteristics of the normal controls, mild cognitive 







630 154 784 181 
Age 
 Mean 67.4 73.6 68.6 78.1 
95% CI 66.7 – 68.1 72.2 – 75.0 68.0 – 69.3 77.0 – 79.2 
Range 44 - 92 50 - 88 44 - 92 49 - 93 
Proportion female (57.0%) n=561 
 Mean age 67.0 73.3 68.1 78.7 
95% CI 66.1 – 68.0 71.1 – 75.4 67.2 – 69.0 77.1 – 80.3 
Range 50 - 92 50 - 87 50 - 92 49 - 93 
Proportion male (43.0%) n=424 
 Mean Age  68.0 73.9 69.4 77.6 
95% CI 66.9 – 69.1 71.9 – 75.9 68.4 – 70.4 76.1 – 79.1 
Range 44 - 85 51 - 88 44 - 88 53 - 92 
Education (years in education) 
 Mean 13.8 12.2 13.5 11.0 
95% CI 13.6 – 14.1 11.6 – 12.8 13.3 – 13.8 10.4 – 11.5 
Range 5 - 29 5 - 26 5 - 29 3 - 20 
 
Table 3.4. Median Quick Mild Cognitive Impairment (Qmci), AB Cognitive 135 
Screen (ABCS 135) and SMMSE scores with 95% Confidence Intervals (CI) for 
normal controls, mild cognitive impairment (MCI) and Dementia. 
 
Instrument Normal Controls MCI Dementia 
Qmci 
























Normal controls had a median SMMSE score of 29 and a median Qmci score of 76, 
the MCI group scored 28 and 62 and the dementia group scored 22 and 36 on the 
SMMSE and Qmci, respectively. All three cognitive tests (SMMSE, ABCS 
135 and the Qmci) were sensitive in differentiating MCI from controls. The Qmci was 
best able to do this in a clinically useful way. The median difference in scores 
between those with MCI or controls was one for the SMMSE compared with 14 for 
the Qmci. This represents a diffe ence of 3.33% of the total score of 30 with the 
SMMSE and a 14% difference for the Qmci (scored out of 100 points). All three tests 
distinguished dementia from MCI. Patients with MCI scored a median 26 points more 
on the Qmci than those with dementia (p <0.001), whereas there was a 40-point 
difference in the Qmci between controls and those with dementia (p <0.001). 
 Although the Qmci, ABCS 135 and the SMMSE were able to distinguish MCI 
from NC, the Qmci was more accurate with an AUC of 0.86 (95% CI: 0.83–0.89) 
compared with 0.83 (95% CI: 0.79–0.86) for the ABCS 135 and 0.67 (95% CI: 0.62–
0.72) for the SMMSE. The Qmci was statistically significantly more accurate than the 
SMMSE, z=7.1, p<0.001.The difference between the ABCS 135 and Qmci although 
small, was of borderline statistical significance, z=1.9, p=0.059. The Qmci had similar 
accuracy at differentiating MCI from dementia, AUC of 0.92 (95% CI: 0.89–0.95) 
versus 0.91 (95% CI: 0.88– 0.94) for the ABCS 135 and 0.91 (95% CI: 0.88–0.94) for 
the SMMSE. When moderate and severe dementia cases were removed from analysis, 
the AUC of the Qmci and SMMSE for differentiating MCI from mild dementia cases 
alone was unchanged at 0.92 (95% CI: 0.89–0.95) and 0.90 (95% CI: 0.85–0.93), 
respectively. Figure 3.1 and 3.2 present ROC curves demonstrating the accuracy of 
the Qmci, ABCS 135 and SMMSE in differentiating MCI from controls and MCI 
from dementia respectively.  
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Figure 3.1. Receiver Operating Characteristic curve demonstrating sensitivities and 
specificities of Quick Mild Cognitive Impairment (Qmci) screen, AB Cognitive 
Screen 135 (ABCS 135) and Standardised Mini-Mental State Examination (SMMSE) 








Figure 3.2. ROC curve demonstrating sensitivities and specificities of Quick Mild 
Cognitive Impairment (Qmci) screen, AB Cognitive Screen 135 (ABCS 135) and 
Standardised Mini-Mental State Examination (SMMSE) in differentiating mild 
cognitive impairment and dementia.!
!  
Instrument Area Under the Curve 
Qmci 0.86 
ABCS 135 0.82 
SMMSE 0.67 
Instrument Area Under the Curve 
Qmci 0.92 
ABCS 135 0.91 
SMMSE 0.91 
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Subanalysis for age (> or < 75 years of age) and education (> or <12 years) showed 
that the Qmci was more accurate with a larger AUC than the SMMSE. The Qmci was 
best for distinguishing MCI from controls in an older age group, ( >75 years), with 
more time, (>12 years), in education, with an AUC of 0.86 (95% CI: 0. 79–0.92) 
compared with 0.55 (95% CI: 0.44–0.66) for the SMMSE. The only participants 
where the difference in accuracy between the Qmci and SMMSE was less obvious 
was for younger individuals, (<75 years) with less than 12 years in education, AUC of 
0.72 (95% CI: 0.62–0.82) for the Qmci versus 0.65 (95% CI: 0.54–0.76) for the 
SMMSE. The SMMSE, ABCS 135 and Qmci were all able to differentiate MCI from 
dementia, irrespective of age or educational status (p <0.001). 
 
3.4 Discussion 
This study compares a new short cognitive screening instrument called the Qmci to its 
predecessor, the ABCS 135, and the established SMMSE in their ability to 
discriminate controls from MCI and dementia. The results presented here show that 
the Qmci is more accurate than the SMMSE in differentiating MCI from NC, while all 
three are able to distinguish NC from dementia. Although the Qmci had a higher AUC 
score this was modestly greater than the ABCS 135 and of only borderline statistical 
significance. Although, the SMMSE was useful in differentiating MCI and NC 
groups, from dementia subjects, it was not able to separate MCI from NC. The small 
percentage difference (3.33%) of the total score for the SMMSE between those with 
NC and MCI, shows that the SMMSE is not clinically useful in distinguishing MCI 
from normals. The Qmci had a wider and more clinically significant percentage 
difference in median scores to help discriminate MCI from dementia. Similarly, the 
median SMMSE score for MCI cases and controls, even taking the IQR into account, 
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at 28 out of 30 (IQR 29-27=2) lies within the accepted cut off interval for normal 
cognition , at greater than 25 out of 30 [Molloy et al., 1997],[Mungas 1991].This 
again suggests that the SMMSE is not adequately sensitive in detecting MCI. The 
Qmci was also more sensitive than the SMMSE in differentiating MCI from NC 
among older adults, over 75 years, especially those with more than 12 years in 
education. 
  Of note, age and educational level did not affect the ability of the Qmci or 
SMMSE to discriminate between MCI and dementia. The dementia group in this 
study was significantly older and had spent less time in formal education than either 
the MCI or NC group. The dementia group was weighted towards the mild spectrum 
of dementia. This is important, as differentiating MCI from mild dementia is more 
challenging than differentiating it from severe dementia. Removing moderate and 
severe dementia cases from analysis, showed that the Qmci retains and even improves 
its increased sensitivity, for differentiating MCI from mild dementia, confirming that 
this tool is useful across the whole range of the cognitive impairment spectrum. 
Our paper has several limitations. First we cannot be certain that all patients were 
classified appropriately as having normal or impaired cognition. This is difficult to 
do, especially where controls are drawn from a sample of convenience. Controls in 
this study did not have any complaints of memory loss. We acknowledge that one of 
the major clinical challenges is to separate symptomatic patients with NC from those 
with MCI, especially as approximating 50%, attending some memory clinics with 
subjective memory problems, have NC [Steenland et al., 2010]. However, within the 
confines of a sample of convenience, the subjects chosen as normal controls were 
tested rigorously, screened for cognitive impairment and depression and underwent 
the same detailed assessment as cases with MCI and dementia. Future validation of 
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the Qmci, will also investigate sensitivity and specificity in patients presenting with 
SMC. Another limitation is that we used NINCDS and DSM IV criteria to make a 
diagnosis of dementia, and while there is no defined gold standard, these criteria are 
broadly accepted and have been validated internationally [O’Connor et al., 1996]. 
Third, the diagnosis of dementia was based upon a single assessment which may have 
reduced accuracy, while one rater scored both cognitive tests which may have led to 
‘practice’ effects. However, the raters were blind to the eventual diagnosis made at 
the clinical assessment. Finally, we compared the Qmci to the SMMSE and ABCS 
135 which are not  gold standards for differentiating MCI from NC or dementia. This 
said, the SMMSE is the most widely used screen for dementia and no gold standard 
yet exists for the diagnosis of MCI and the objective of this study within the PhD was 
to validate the instrument. The strengths of this study are the large sample size, 
comprehensive assessment, and bigger number of controls than the original ABCS 
135 validation paper. The diagnosis of MCI and diagnosis and grading of dementia 
are based upon both functional and cognitive assessments.  This study was performed 
at multiple sites.  
 In summary, this study confirms that the Qmci, a short cognitive screen, is 
more sensitive in differentiating normal controls from those with MCI, than the 
widely used SMMSE. Compared to the ABCS135, the Qmci is slightly more accurate 
in differentiating MCI, takes a similar albeit longer (by 30 seconds to one minute) 
time to complete and is conveniently scored out of 100 making it easy to interpret  in 
clinical practice. However, based upon this initial analysis it remains unclear if the 
addition of LM to the ABCS 135 has improved the accuracy of the instrument. The 






Investigation of the Quick Mild Cognitive Impairment 
(Qmci) Screen subtests 
 
4.1 Introduction 
As time is limited in clinical practice, short screening instruments help improve 
diagnostic efficiency. One of the major challenges in cognitive testing has been the 
development of rapid screening tests that can differentiate MCI from normal 
cognition. As demonstrated in Chapter 3, instruments such as the SMMSE are useful 
in distinguishing normal cognition and MCI from dementia but take time to complete 
and are less able to distinguish MCI from normal than instruments such as the ABCS 
135 and the Qmci. Previous analysis of the Qmci’s predecessor, the ABCS 135, 
showed that its verbal fluency (VF) and delayed recall (DR) subsets best 
distinguished between MCI and normal controls [Standish et al., 2007]. It is not 
known which of the subtests of the Qmci is best at doing this or what is the impact of 
the reweighting of the subtests and addition of a logical memory (LM) component on 
the sensitivity and specificity of the instrument. 
 Given this, the primary objective of this study was to assess which of the 
individual subtests of the Qmci most affects its accuracy in differentiating between 
normal cognition, MCI and dementia, in order to help further refine the development 
of this rapid screening tool for detecting MCI in clinical practice. The secondary 
objectives were to assess whether age and educational attainment also affect the 






As this is a secondary analysis of the Qmci validation database, the recruitment of 
subjects is the same as that described in Chapter 3. In summary, subjects were 
recruited between 2004 and 2010 from patients attending four memory clinics in 
Ontario, Canada. Caregivers and those attending with the subjects were recruited as 
controls that is, those with normal cognition. In total 965 individuals were included. 
16% (n=154) had MCI, 19% (n=181) had dementia, the majority of which had mild 
dementia as defined by the SMMSE with 65% (n=630) having normal cognition. 
Ethical approval was obtained and subjects provided verbal consent. Assent was 
obtained in the case of individuals with cognitive impairment.  
 
Data analysis 
Data were analysed using SPSS 16.0. Subjects were classified as normal controls, 
MCI or dementia. Subgroup analysis was performed for age (greater and less than 75 
years) and for years in formal education (greater or less than 12 years). ROC curves 
were constructed to determine the accuracy of the subtests of the Qmci. Area Under 
the Curve (AUC) was calculated for each of the subsets and was analysed for age and 
for total years in education. Normality was tested using the Shapiro–Wilk test. The 
majority of the data were not normally distributed and were analysed using a Mann– 
Whitney U test. Normally distributed data were analysed using Student’s t-tests. 
Pearson Chi-squared tests were used to establish the difference between the 
distributions when it was impossible to analyse differences in medians. Test–retest 




Figure 4.1 shows box plot distributions for each Qmci subtest with the median and 
IQR scores for those with dementia, MCI and normal cognition. The VF and LM 
subtests of the Qmci clearly distinguish between dementia, MCI and controls. 
Orientation and registration did not show a median difference between MCI and NC. 
All individual subtests had statistically significant differences, p < 0.001, in 
distributions between NC, MCI and dementia. Figure 4.2 and Table 4.1 show the 
median Qmci subtest scores expressed as percentages. Table 4.2 shows the median 
scores and IQR’s for the Qmci subtests. Although there were statistically significant 
differences between Qmci subtests scores, they were not all able to differentiate MCI 
and NC in a clinically useful way; DR (four point difference), VF (four points) and 
LM (7.5 points) all had clinically useful median score differences between patients 
with MCI and controls. These differences, expressed as a percentage of the total score 
for each subtest, are 20% (four point difference out of a total score of 20) for DR, 
20% for VF and 25% for LM. There was a median one-point difference for clock 
drawing (6.66%), and no difference (0%) for orientation and registration, suggesting 
that these three subtests are clinically less useful. 
 The best performing SMMSE subtest was short-term memory (0.66), the 
worst registration (0.51). ROC curves with AUC values for the SMMSE subtests are 
presented in Tables 4.5 and 4.6, and in Figure 4.3 and 4.4. Table 4.2 also shows AUC 
values for the SMMSE compared with the best performing subtest, LM after adjusting 
for age and education. The AUC for the LM was superior to the SMMSE in 
differentiating MCI from NC, irrespective of the educational level or age (over or 
under 75 years) of subjects. The improved performance of LM over the SMMSE was 
more evident for the older age group (age over 75) who had more than 12 years 
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education, AUC of 0.79 (95% CI: 0.71– 0.88) versus 0.55 (95% CI: 0.44–0.66). There 
was a significant difference between the median scores for LM, for the MCI and NC 
groups, irrespective of age or educa- tional status. This difference was not significant 
for the SMMSE for older people, >75 years with >12 years in education (p =0.350).  
 Taken in isolation, the LM (AUC 0.80) component of the Qmci scored had 
similar accuracy to the ABCS 135 and greater accuracy then the SMMSE (AUC of 
0.80 and 0.67, respectively). Comparing the ability of the Qmci subtests to 
discriminate between MCI and NC showed that the most accurate subtest was LM 
(AUC of 0.80), followed by VF (0.77) and DR (0.73). Registration (0.56), orientation 
(0.57) and clock drawing (0.66) were the least accurate subtests. These AUC values, 
comparing the Qmci subtests in their ability to differentiate MCI from NC and MCI 
from dementia are summarised in Tables 4.5 and 4.6 and presented in Figures 4.5 and 
4.6 respectively. 
 Test–retest reliability was also obtained from the database by analysing the 
correlation between patients who had the Qmci scored on two separate occasions, a 
minimum of one week apart, (n=20). Pearson’s correlation coefficient showed good 
























































































NC 99% 98% 97% 81% 55% 64% 
MCI 97% 92% 89% 60% 39% 43% 
Dementia 66% 74% 58% 19% 21% 22% 
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Table 4.2. Qmci Subtests: Median scores and IQR,  (Q1 = 1st Quartile, Q3= 3rd 
Quartile) by diagnosis, and p value of the median difference between MCI and NC, 
dementia and MCI, along with AUC scores for SMMSE and the best performing 
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(MCI & NC, N=X) Test variables 




Diff MCI and NC 
(p value) 
 
Age <= 75 with education  
< 12 years  
N = 127 
SMMSE 0.65 (0.54 – 0.76) 29 (p = 0.011) 
LM 0.72 (0.62 – 0.82) 15.49 * (mean) (p < 0.001) 
 
Age <= 75 with education  
> = 12 years 
N = 449 
SMMSE 0.66 (0.57 – 0.75) 29 (p < 0.001) 
LM 0.79 (0.73 – 0.86) 20 (p < 0.001) 
 
Age > 75 with education  
< 12 years  
N = 71 
SMMSE 0.64 (0.51 – 0.77) 28 (p = 0.034) 
LM 0.74 (0.62 – 0.85) 14.35 * (mean) (p < 0.001) 
 
Age > 75 with education  
> = 12 years  
N = 127 
SMMSE 0.55 (0.44 – 0.66) 29 (p = 0.350) 
LM 0.79 (0.71 – 0.88) 16.91* (mean) (p < 0.001) 
Overall  
SMMSE 0.67 (0.62 – 0.72) 29 (p < 0.001) 
LM 0.80 (0.76 – 0.84) 18 (p < 0.001) 
 
*Normally distributed data. 
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Figure 4.3. Receiver operating characteristic curves showing the ability of the 
Standardised Mini-Mental State Examination to differentiate normal controls from 
mild cognitive impairment (MCI) compared with the Quick Mild Cognitive 






Table 4.3. Comparision of the subtests of the Standardised Mini-Mental State 
Examination (SMMSE) in their ability to differentiate normal controls from mild 
cognitive impairment, compared with the Quick Mild Cognitive Impairment (Qmci) 
screen total score and logical memory (LM) subtest. 













SMMSE Total 0.67 








Figure 4.4. Receiver operating characteristic curves showing the ability of the 
Standardised Mini-Mental State Examination to differentiate MCI from dementia, 
compared with the Quick Mild Cognitive Impairment (Qmci) screen total score and 






Table 4.4. Comparision of the subtests of the Standardised Mini-Mental State 
Examination (SMMSE) in their ability to differentiate mild cognitive impairment 
from dementia, compared with the Quick Mild Cognitive Impairment (Qmci) screen 
total score and logical memory (LM) subtest. 














SMMSE Total 0.91 
Qmci Total 0.92 
LM 0.82 
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Figure 4.5. Reciever Operating Characteristic curves for the Quick Mild Cognitive Impairment (Qmci) subtests for normal controls vs MCI. 










Table 4.5. Receiver operating characteristic curves illustrating the area under the 

















Table 4.6. Receiver operating characteristic illustrating the area under the curve 





























Qmci Orient 0.57 
Qmci Reg 0.56 
Qmci Clock 0.66 
Qmci DR 0.73 
Qmci VF 0.77 




Qmci Orient 0.88 
Qmci Reg 0.64 
Qmci Clock 0.76 
Qmci DR 0.84 
Qmci VF 0.83 




The analysis presented in this chapter shows the ability of each of the individual Qmci 
subtests to differentiate normal controls from MCI and patients with MCI from those 
with dementia. The Qmci includes a battery of subtests (n=6), but not all differentiate 
MCI from NC in a clinically useful way. This study found that subtests with the 
greatest median differences between MCI from normal controls, expressed as 
percentage of their total scores, were DR, VF and LM. The addition of LM, explored 
in Chapter 3 in the original validation study [O’Caoimh et al., 2012], added to the 
original ABCS 135, improving the accuracy of the test in differentiating MCI from 
NC and is the most useful subtest of the Qmci. Orientation, registration and clock 
drawing, as individual subtests, do not enhance the discriminating power of the tool to 
the same extent. These subtests have lower ceilings and are insensitive to early 
cognitive changes [Standish et al., 2007]. When age and education were taken into 
account, the best performing subtest, LM, was more accurate than the entire SMMSE 
in differentiating MCI from normal controls, suggesting that alone, it may be better at 
distinguishing MCI in the oldest and most educated subjects.   
 All Qmci subtests could differentiate dementia from MCI and normal. None of 
the SMMSE subtests performed better than the complete SMMSE or LM. 
From the results we conclude that tests targeting episodic memory (DR and LM) best 
discriminate MCI from NC whereas orientation is best for assessing dementia, 
allowing the Qmci accurately monitor disease progression. The remaining subtests, 
further enhance sensitivity, structure the test and may enhance its ability to identify 
MCI syndromes that convert to different dementia subtypes. 
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 The strength of this study is that it included large numbers of patients with 
MCI and dementia, and that the tool was validated in a clinical sample in a busy 
memory clinic, increasing the generalisability of these results. A weakness is that it 
compares the Qmci to the SMMSE and ABCS 135, which are not gold standards for 
diagnosing MCI or dementia. No objective cognitive testing was used in the diagnosis 
of MCI which may also have led to bias, although when data collection began MCI 
consensus guidelines did not stipulate the requirement for independent cognitive 
testing [Winblad et al., 2004]. Furthermore, the diagnosis was supported by patients 
clinical history, examination and the opinion of an independent, senior, consultant 
physician specialised in the diagnosis of cognitive impairment. Where doubt existed 
patients had an independent neuropsychological assessment providing MCI criteria 
not inconsistent with Petersen’s criteria (see section 2.1.2). The GDS Short Form, 
used to support a diagnosis of depression, is limited in advanced dementia [Burke et 
al., 1989], although the majority of subjects in this study were at an early stage. 
Subjects were only classified with MCI if there was no evidence of functional 
impairment. This may have created bias given that evidence suggests that up to 30% 
of subjects with MCI may have subtle impairment in instrumental ADL [Artero et al., 
2001]. Another limitation is that the reweighting of the subtests in favour of DR, VF 
and LM, may have overestimated their contribution to the sensitivity of the Qmci, 
minimising the role of the other subtests. However, the overall improved accuracy of 
the Qmci over the ABCS 135, in differentiating MCI from normal, suggests that the 
reweighting and addition of LM have enhanced the test as a whole. Only including 
caregivers attending with subjects as normal controls could also have led to bias as 
the challenge in diagnosing MCI lies in differentiating MCI from persons with 
subjective memory complaints (SMC) but who have normal cognition. This 
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population accounts for up to 50% of referrals in memory clinics [Steenland et al., 
2010], but  accounted for less than 10% of our clinic population.  
In summary, this chapter confirms that reweighting the Qmci subtests and the addition 
of LM, improved the ability of the original ABCS 135 to differentiate subjects with 
MCI and normal cognition. This secondary analysis of the original Qmci validation 
database presented in chapter 1, further highlights and describes some attributes of an 
ideal short cognitive screening test for MCI that can be used in everyday clinical 
practice. As presented in chapter 1, the Qmci was more accurate than its predecessor, 
the ABCS 135 and the SMMSE in distinguishing MCI from NC and dementia. The 
Qmci incorporates several important cognitive domains, across the spectrum of 
cognition and its subtests allow discrimination of MCI from both normal cognition 
and dementia, potentially allowing the Qmci to continue monitoring patients 
throughout the stages of cognitive impairment. The Qmci also has the advantage of 
being quick to administer and has excellent test-retest reliability and of having 
alternative forms. Other tools such as the SMMSE and the ABCS 135 are less 
sensitive and because of their scoring range, are less practical for use clinically. The 
development of cut-off scores for the Qmci, to increase its usability, and comparison 












Developing cut-off scores for the  
Quick Mild Cognitive Impairment (Qmci) Screen 
 
5.1 Introduction 
While screening for symptomatic cognitive impairment is advocated [Boustani et al., 
2003], [Cordell et al., 2013], there is limited evidence supporting routine screening in 
clinical practice [Boustani et al., 2005], [Lin et al., 2013]. This is in part because most 
cognitive screens lack sufficient sensitivity and specificity to differentiate 
symptomatic memory loss with normal cognition from MCI and dementia, [Winblad 
et al., 2004], [Boustani et al., 2005] particularly in those with low education [Cordell 
et al., 2013], but also because of the effects of age and education on scoring 
variability [Crum et al 1993], [Freitas et al., 2012]. Misclassifying may be harmful as 
treatments that are indicated at one stage may not benefit at another [Peterson et al., 
2005],[Tricco et al., 2013], [Cooper et al., 2013]. Cut-off scores, transitions points 
along the spectrum of cognitive impairment, are useful in busy clinical practice. 
Although age and educational cut-offs, based upon population-based norms are 
available for some widely used short cognitive screens, including the MMSE [Crum 
et al., 1993] and MoCA [Rosetti et al., 2011], [Kenny et al., 2013], few studies have 
published usable cut-off scores for patients presenting with symptomatic memory 
loss. Given this, we sought to define cut-off scores for symptomatic MCI and 
dementia in patients populating three clinical and research cohorts (derived in Canada 
by Prof William Molloy), including the original Qmci validation data set, and 






We pooled data from two outpatient databases: the GAT (Geriatric Assessment Tool) 
[Gao et al., 2013] and the Qmci validation databases [O’Caoimh et al., 2012], with the 
DARAD (Doxycycline And Rifampicin for Alzheimers Disease) [Molloy et al., 2012] 
clinical trial database. Participant characteristics and recruitment from all three studies 
have been published previously [O’Caoimh et al., 2012],[Gao et al., 2013],[Molloy et 
al 2012]. In summary, the GAT is a customised software application that automates 
clinicians’ outpatient reviews [Gao et al., 2013]. GAT data were collected in 
outpatient geriatric and memory clinics in two university hospitals in Ontario, Canada 
between 1999 and 2010. The GAT contains over 8000 individual assessments from 
1749 people aged 41–104 years including SMMSE and Qmci screen scores. The Qmci 
validation database, presented in Chapter 3 and 4, includes patients referred for 
assessment of cognition, aged ≥55 years and recruited from four memory clinics in 
Ontario Canada [O’Caoimh et al., 2012]. The DARAD was a multi-centre, blinded, 
randomised trial conducted between 2006 and 2010, comparing the effect of 
rifampicin and doxycycline to placebo on the progression of AD [Molloy et al., 
2012]. The DARAD database includes patients ≥50 years with mild to moderate AD 
recruited from 14 Canadian centres.  
 Participants were included in this analysis if both their SMMSE and Qmci 
scores were available. Participant selection is presented in Figure 5.1. All data were 
collected under the supervision of the same principle investigator (Prof William 
Molloy) and each participant underwent similar comprehensive work-up including 
laboratory investigations, neuropsychological assessment and neuroimaging where 
appropriate [Gao et al., 2013],[Molloy et al., 2012]. MCI was diagnosed in patients 
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presenting with subjective and objective memory loss, without loss of 
function. This was consistent with Petersen’s criteria, described in section 
2.1.2 (minor neurocognitive disorders), where patients present with subjective 
memory complaints, objective abnormal memory function but preservation of ADL 
and have no evidence of dementia [sen 1999]. Dementia was diagnosed using the 
Diagnostic and Statistical Manual of Mental Disorders (4th-edition) [APA 1994]. 
Those with active depression screened using the GDS-Short Form [Yesavage 1988] 
were excluded. Participants were English literate. Persons attending with patients 
(mainly caregivers) without memory loss were recruited by convenience sampling 
were available as controls.  
Figure 5.1. Flow chart demonstrating the recruitment of patients from the three 
databases: the Quick Mild Cognitive Impairment screen validation (Qmci), 
Doxycycline And Rifampicin for Alzheimers Disease (DARAD) study and Geriatric 
Assessment Tool (GAT), including the number of Qmci and Standardised Mini-
Mental State Examination (SMMSE) assessments available, for participants with 
normal cognition (NC), mild cognitive impairment (MCI) and dementia (Kindly 






The SMMSE and Qmci were common to all three databases. Alternative forms of its 
subtests were used to avoid learning effects [Cunje et al., 2007]. 
 
Analysis 
Pooled data were grouped according to age (≤75 or >75 years) and education (≤12 or 
>12 years), to create four subgroups. An age cut-off of 75 years provided the best 
balance in numbers between the four subgroups and represents the accepted age cut-
off for CI using the MMSE [Ylikoski et al., 1992], above which scores must be 
adjusted to account for age. The cut-off for education was 12 years, the average 
length of formal schooling in North America [http://hdr.undp.org/en/content/mean-
years-schooling-adults-years].  Accuracy was calculated from the area under the curve 
(AUC) of receiver operating characteristic curves. Optimal cut-off scores were 
estimated using Youden’s Index [Youden 1950]. Likelihood ratios for the probability 
of having MCI and dementia were determined. As described in Chapter 2, a PLR of 
between 2-5 suggests a small chance, 5-10 moderate and >10 a large chance of having 
cognitive impairment. A NLR of 0.2-0.5 suggests a small chance, 0.1-0.2 moderate 
and <0.1 a large chance of not having the condition. The Mann–Whitney U test 
compared non-parametric data and student's t-tests compared parametric data. The 









In all, 2,074 patients representing 3,387 assessments were included. The median age 
of all participants was 76 years, interquartile range (IQR) of +/-12. The median age of 
those with dementia was 78 (+/-8) years, older than those with normal cognition, 69 
(+/-14) (p<0.001) or MCI, 76 (+/-10) (p<0.001). Half (49%) were male. The median 
number of years education was 12 (+/-5) for those with dementia compared with 13 
(+/-4) (p<0.001) for controls and 12 (+/-4) (p=0.46) for those with MCI. The median 
SMMSE score for controls was 29 (+/-2) points, compared to 28 (+/-3) for MCI and 
23 (+/-7) for dementia. The scores were significantly different in the three groups, 
615 (p<0.001). The median Qmci scores were 74 (+/-15) points for controls, 
57 (+/-20) for MCI and 37 (+/-26) for dementia. Qmci scores were also significantly 
different in the three groups, 811 (p<0.001). The number and characteristics 
of those included in each database is presented in Table 5.1.  There was no 
statistically significant difference in age or gender between those with MCI or 
dementia. Median age, gender, education, SMMSE and Qmci screen scores, though 
similar, were significantly different between the three databases, irrespective of 
diagnosis. These comparisons are presented in Table 5.2. The characteristics of 
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Table 5.1. Baseline characteristics of participants included from the Quick Mild 
Cognitive Impairment (Qmci) screen validation, Doxycycline And Rifampicin for 
Alzheimers Disease (DARAD) study and Geriatric Assessment Tool (GAT) databases, 
divided according to their Standardised Mini-Mental State Examination (SMMSE) 
and Qmci screen scores, including numbers included with normal cognition (NC), 










































339 79 +/-9 
(82-73) 






GAT NC 252 73 +/-14 
(80-66) 






MCI 619 76 +/-9 
(80-71) 






Dementia 1242 78 +/-8 
(82-74) 






All 2113 77 +/-9 
(81-72) 








NC 623 67 +/-14 
(74-60) 






MCI 147 75 +/-13.5  
(80.5-67) 






Dementia 165 79 +/-8 
(83-75) 






All 935 71 +/-15 
(78-63) 






Total NC 875 69 +/-14 
(76-62) 






MCI 766 76 +/-10 
(80-70) 






Dementia 1,746 78 +/-8 
(82-74) 






All 3387 76 +/-12 
(81-69) 







Table 5.2.  Comparison of participant characteristics: age, education, gender and 
Standardised Mini-Mental State Examination (SMMSE) and Quick Mild Cognitive 
Impairment (Qmci) screen scores, according to diagnosis: normal controls, mild 
cognitive impairment (MCI) and dementia. (Non-parametric data compared using 










































































Table 5.3. Descriptive statistics for patients with Standardised Mini-Mental State Examination (SMMSE) and Quick Mild Cognitive Impairment 
(Qmci) scores available, comparing patients with normal controls (NC), mild cognitive impairment (MCI) and dementia, grouped according to 





























Overall NC 157 50.3% 68 (7) 10 (1) 29 (2) 853 43.0% 69 (14) 13 (4) 75 (15) 
 
MCI 135 57% 71 (6) 9 (2) 28 (2) 703 56.2% 78 (10) 12 (4) 57 (20) 
 
Dementia 476 58.4% 72 (5) 9 (2) 21 (9) 2975 50.3% 79 (9) 12 (5) 37 (23) 
 
Age ≤ 75 
Edu < 12 
 
NC 550 40% 65 (11) 15 (4) 30 (1) 133 51.9% 68 (7) 10 (1) 70 (15) 
 
MCI 188 51.1% 69 (10) 14 (4) 28.5 (3) 109 57.8% 71 (8) 9 (2) 57 (19) 
 
Dementia 571 53.9% 70 (9) 14 (4) 23 (8) 369 59.9% 72 (5) 9 (2) 32 (21) 
 
Age ≤ 75  
Edu ≥ 12 
 
NC 114 52.6% 81 (8) 9 (2) 29 (2) 487 37.8% 64 (11) 15 (4) 78 (13) 
 
MCI 200 45.0% 81 (7) 9 (2) 28 (3) 159 50.9% 69 (12) 14 (4) 63 (20) 
 
Dementia 1134 44.6% 82 (5) 9 (2) 22 (7) 530 58.6% 70 (8) 14 (4) 38 (24) 
 
Age > 75  
Edu < 12 
 
NC 218 48.2% 81 (8) 14 (4) 29 (2) 68 45.6% 79.5 (7) 9 (2) 67.5 (13) 
 
MCI 222 58.6% 81 (5) 14 (4) 29 (2) 197 58.4% 81 (7) 9 (2) 55 (21) 
 
Dementia 1043 49.5% 81 (6) 13 (4) 23 (6) 969 45.6% 82 (5) 9 (2) 37 (22) 
 
Age > 75 
Edu ≥ 12 
 
NC 1039 44.7% 70 (15) 13 (5) 29 (1) 165 50.3% 81 (6) 14 (5) 70 (15) 
 
MCI 745 52.8% 77 (11) 12 (5) 28 (2) 238 57.1% 81 (5) 14 (3) 56 (20) 
 
Dementia 3224 49.9% 79 (9) 12 (5) 22 (7) 1107 47.2% 81 (6) 13 (4) 38 (22) 
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Effects of age and education on median scores 
Table 5.4 presents the results of comparisons between median SMMSE and Qmci 
scores, where age was constant and education varied and vice versa, for controls, MCI 
and dementia. This table shows that median SMMSE scores were similar between 
these subgroups classified by age or education, although some statistical differences 
were seen. Age influenced median Qmci scores for patients with more compared to 
those with less education, for controls (78 versus 70 points, p <0.001) and MCI (63 
versus 56 points, p <0.001), but not dementia, (38 versus 38 points, p =0.884). !
!
Table 5.4. Comparisons between median and interquartile range (IQR) scores for the 
Standardised Mini-Mental State Examination (SMMSE) and Quick Mild Cognitive 
Impairment (Qmci) screen, where age (≤75, >75 years) was constant and education 
(<12, ≥12 years) varied and vice versa of patients with normal cognition (NC), mild 






Diagnosis SMMSE score 
Median (IQR) 
p-value Qmci score 
Median (IQR) 
p-value 
≤75 ≥12 vs <12 NC 29 (2) vs 30 (1) <0.001 78 (13) vs 70 (15) 0.001 
MCI 28 (2) vs 28.5 (3) 0.002 63 (20) vs 57 (19) 0.001 
 
Dementia 21 (9) vs 23 (8) <0.001 38 (24) vs 32 (21) 0.001 
 
>75 ≥12 vs <12 NC 29 (2) vs 29 (2) 0.004 70 (15) vs 67.5 (13) 0.11 
MCI 28 (3) vs 29 (2) <0.001 56 (20) vs 55 (21) 0.11 
 
Dementia 22 (7) vs 23 (6) <0.001 38 (22) vs 37 (22) 0.08 
 
≤75 vs >75 <12 NC 29 (2) vs 29 (2) <0.001 70 (15) vs 67.5 (13) 0.05 
MCI 28 (2) vs 28 (3) 0.621 57 (19) vs 55 (21) 0.30 
 
Dementia 21 (9) vs 22 (7) 0.312 32 (21) vs 37 (22) 0.002 
 
≤75 vs >75 ≥12 NC 30 (1) vs 29 (2) 0.405 78 (13) vs 70 (15) 0.001 
MCI 28.5 (3) vs 29 (2) 0.252 63 (20) vs 56 (20) 0.001 
 







For subjects with less education differences in median Qmci scores between older and 
younger patients were only significant for dementia, 32 (21) vs 37 (22) points, p 
=0.002. Contrasting this, for! those! with! more education, Qmci score differences 
between older and younger patients were only significant for controls and MCI, but 
not for dementia, 38 (24) vs 38 (22) points, p =0.884. Education affected median 
Qmci score for older patients but there were no significant differences in median 
Qmci scores between more and less educated individuals whereas scores were 
significantly different for younger patients irrespective of the diagnosis. There were 
statistically significant differences between median SMMSE scores for controls, MCI 
and dementia, irrespective of age.  
 
Cut-off scores for the SMMSE 
The cut-off scores that provided the best balance between sensitivity and specificity 
for the SMMSE are presented in Table 5.5. A cut-off of <28 for cognitive impairment 
(MCI or dementia) produced a sensitivity of 90% and specificity of 81%, and yielded 
an AUC of 0.91, (95% CI: 0.90-0.92). The optimal cut-off for MCI was higher at <29, 
with a lower sensitivity of 75% and specificity of 56%, AUC 0.69 (0.67-0.72). The 
optimal cut-off for dementia was <27, sensitivity 89%, specificity 86% with an AUC 
of 0.94 (0.93-0.94). The SMMSE more accurately identified cognitive impairment for 
older adults (>75 years) with less formal education (<12 years), sensitivity 90% and 
specificity of 81% (AUC 0.91, 95% CI: 0.89-0.93), than for younger patients (≤75) 
with more education (≥12), sensitivity 84%, specificity 83%, although this did not 
reach significance, p =0.43. This preferential accuracy for older and less educated 
patients was reversed for those with established dementia: sensitivity 82%, specificity 
82% (AUC of 0.89, 95% CI: 0.87-0.92) compared with a sensitivity of 90% and 
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specificity of 90%, AUC 0.95 95% CI: 0.93-0.95) for younger patients with more 
education, p<0.001. The SMMSE was also more accurate for younger patients with 
more education in differentiating MCI from normal cognition. These results are 
summarised in Table 5.5 and presented in Figure 5.2. Few clinically meaningful 
differences in SMMSE cut-offs were found. There was only a one-point difference 
between normal cognition and dementia SMMSE cut-offs for younger patients with 
more education (<29 to <28), and a one-point difference for older subjects with less 
education (<27 to <26).  
 
Cut-off scores for the Qmci 
The Qmci cut-off scores selected using the maximal approach (AUC of ROC) were 
<60 for cognitive impairment, <65 for MCI and <50 for dementia (see Table 5.5). At 
a cut-off of <60 the Qmci had a sensitivity of 89% and specificity of 86% for 
cognitive impairment and excellent accuracy in differentiating normal cognition from 
MCI and dementia, AUC 0.95 (0.94-0.95). This was selected using the AUC of the 
ROC curve. However, using Youden’s index the optimal cut-off was calculated at 
<62. This provided a sensitivity of 87% and specificity of 88% (AUC 0.94), see 
Figure 5.2. 
  At <65 the Qmci produced a sensitivity of 81% and specificity of 70% for 
distinguishing MCI from normal cognition, AUC 0.84 (0.82-0.86). A score <50 
yielded a sensitivity of 84% and specificity of 79% for dementia, AUC of 0.89 (0.88-
0.90). The cut-off for dementia using Youden’s index was also <50. For older adults 
with less education the optimal Qmci cut-off for cognitive impairment fell from <60 
(for the total population) to <54 points, providing a sensitivity of 81% and specificity 
of 85%. In contrast to the SMMSE, the Qmci’s sensitivity (86%) and specificity (89%) 
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for cognitive impairment was higher for younger patients with more education, AUC 
of 0.95 (0.94-0.96) at a cut-off of <67 and lower for older patients with less formal 
education, 81% and 85% respectively at a cut-off of <54, AUC of 0.89 (0.85-0.94), p 
<0.001. The accuracy of the Qmci for detecting MCI was lower for older adults with 
less education (AUC 0.76; 0.69-0.83) compared with younger patients with more 
education (AUC 0.85; 0.81-0.88), p <0.001. The Qmci also had lower accuracy for 
detecting dementia for older adults with less education, AUC of 0.81 (0.78-0.84) with 
a cut-off of <42, compared with younger more educated adults, AUC of 0.95 (0.94-
0.96) using a cut-off of <53, p <0.001. These results are summarised in Table 5.5 and 
presented in Figures 5.2 and 5.3. There were more clinically useful differences in cut-
offs between patients with normal cognition and dementia for the Qmci compared 
with the SMMSE. Overall, the range of cut-off scores were narrow for both 
instruments. This mirrors the results other screening cognitive instruments including 
the MoCA, which have a similarly narrow range between diagnostic categories and 
reflects the challenges of using cut-off scores in isolation from clinical evaluation. 
Cut-offs, were however wider for younger subjects with more education, (range from 
<67 to <53), a 14-point spread and narrower for older subjects with less education, 









Table 5.5. Cut-off scores* for the Standardised Mini-Mental State Examination (SMMSE) and Quick Mild Cognitive Impairment (Qmci) screen 
with sensitivity, specificity and area under the curve (AUC) values, grouped by age (≤75, >75 years) and education (<12, ≥12 years), comparing 
patients with normal controls (NC) to those with cognitive impairment (CI), those with dementia compared to the rest, those with NC versus 












Sensitivity Specificity AUC 
(95% 
 Confidence  
Interval) 
Qmci 




Sensitivity Specificity AUC 
(95% 
 Confidence  
Interval) 
Overall NC vs CI 
(1039 vs 3969) 
<28 90% 81% 0.91 (0.90-0.92) NC vs CI 
(853 vs 3678) 
<60 89% 86% 0.95 (0.94-0.95) 
MCI 
(1039 vs 745) 
<29 75% 56% 0.69 (0.67-0.72) MCI 
(853 vs 703) 
<65 81% 70% 0.84 (0.82-0.86) 
MCI vs 
Dementia 
(745 vs 3224) 
<27 81% 86% 0.90 (0.89-0.91) MCI vs 
Dementia 
(703 vs 2975) 
<44 80% 66% 0.80 (0.78-0.82) 
Dementia 
(3224vs 1784) 
<27 89% 86% 0.94 (0.93-0.94) Dementia 
(2975 vs 1556) 
<50 84% 79% 0.89 (0.88-0.90) 
Age ≤ 75 
Edu < 12 
NC vs CI 
(157 vs 611) 
<28 80% 81% 0.89 (0.86-0.91) NC vs CI 
(133 vs 478) 
<57 87% 82% 0.93 (0.91-0.95) 
MCI 
(157 vs 135) 
<29 65% 63% 0.66 (0.60-0.72) MCI 
(133 vs 109) 
<62 80% 62% 0.80 (0.74-0.85) 
MCI vs 
Dementia 
(135 vs 476) 
<26 89% 79% 0.91 (0.88-0.93) MCI vs 
Dementia 







(476 vs 292) 
<27 84% 87% 0.93 (0.91-0.95) Dementia 
(369 vs 242) 
<47 85% 80% 0.90 (0.88-0.93) 
Age ≤ 75 
Edu ≥ 12 
NC vs CI 
(550 vs 759) 
<29 84% 83% 0.90 (0.88-0.92) NC vs CI 
(487 vs 689) 
<67  86%  89% 0.95 (0.94-0.96) 
Dementia 
(571 vs 738) 
<28 90% 90% 0.95 (0.93-0.96) Dementia 
(530 vs 646) 
<53 93% 81% 0.95 (0.94-0.96) 
MCI 
(550 vs 188) 
<29 84% 50% 0.71 (0.66-0.75) MCI 
(487 vs 159) 
<69 83% 69% 0.85 (0.81-0.88) 
MCI vs 
Dementia 
(188 vs 571) 
<27 87% 83% 0.90 (0.88-0.93) MCI vs 
Dementia 




























Age > 75 
Edu < 12 
NC vs CI 
(114 vs 1334) 
<27 90% 81% 0.91 (0.89-0.93) NC vs CI 
(68 vs 1166) 
<54 81% 85% 0.89 (0.85-0.94) 
Dementia 
(1134 vs 314) 
<26 85% 82% 0.89 (0.87-0.92) Dementia 
(969 vs 265) 
<42 80% 62% 0.81 (0.78-0.84) 
MCI 
(114 vs 200) 
<28 79% 41% 0.67 (0.60-0.73) MCI 










(200 vs 1134) 
<25 84% 73% 0.86 (0.83-0.89) MCI vs 
Dementia 
(197 vs 969) 
<45 73% 70% 0.77 (0.73-0.81) 
Age > 75 
Edu ≥ 12 
NC vs CI 
(218 vs 1265) 
<28 87% 79% 0.89 (0.87-0.91) NC vs CI 
(165 vs 1345) 
<56 87% 81% 0.91 (0.89-0.93) 
Dementia 
(1043 vs 440) 
<27 91% 84% 0.94 (0.92-0.95) Dementia 
(1107 vs 403) 
<47 82% 71% 0.85 (0.83-0.88) 
MCI 
(218 vs 222) 
<29 70% 48% 0.62 (0.57-0.67) MCI 
(165 vs 238) 
<59 80% 55% 0.77 (0.73-0.82) 
MCI vs 
Dementia 
(222 vs 1043) 
<27 90% 84% 0.92 (0.91-0.94) MCI vs 
Dementia 
(238 vs 1107) 
<45 78% 66% 0.79 (0.76-0.82) 
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Figure 5.2. The distribution of a. the Quick Mild Cognitive Impairment screen (Qmci) 
and b. the Standardised Mini-Mental State Examination (SMMSE) cut-off scores 
(using Youden’s Index), together with sensitivity and specificity levels for controls 
versus cognitive impairment (CI) and dementia, for the total sample and four 
subgroups, stratified according to age (≤75 or >75 years) and education (≤12 or >12 
years).  
 







Figure 5.3. Age and educational cut-off scores for the Quick Mild Cognitive 





Likelihood ratios were calculated for several cut-off scores for the total population 
and according to age and education. At the optimal Qmci cut-off for CI (<60), patients 
had a moderate chance of having cognitive impairment (NLR 0.17). Above 60 points, 
there was a moderate chance of having normal cognition (PLR 7.88). Above 65 points 
there was a ‘large’ chance (PLR >10) of being normal whereas at or below 65 the 
chance of having normal cognition was small (NLR 0.23). Those scoring <50, the 
optimal Qmci cut-off score for dementia, had a moderate chance of having dementia 
(PLR 5.0) while at a score >50 there was a small chance of having dementia (NLR 
0.28). Liklihood ratios also confirmed the choice of cut-off scores for each subgroup. 
For example, the cut-off above which younger subjects (≤75) with more formal 
education (≥12) had a large chance of being normal was <70. Below 70, the chance of 
not being normal was also small, confirming that the optimal Qmci cut-off for these 
patients (≤67) lies below this. 
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5.4 Discussion 
This paper presents cut-off scores for two short cognitive screens, the SMMSE and 
Qmci, adjusted for age and education, based upon a large population of patients in 
three pooled databases. The results showed small albeit significant, differences in 
median SMMSE and large and significant differences in median Qmci scores, which 
clearly separated normal cognition, MCI and dementia. Twenty years after Crum et 
als’ [Crum et al., 2013] work exploring population-based norms for the MMSE by age 
and education, this paper presents adjusted cut-off scores for the SMMSE for a large 
sample of patients with symptomatic memory loss. It is also the first to compare the 
differential effects of age and education on two short cognitive screens, one designed 
specifically to screen for MCI (Qmci). 
  Using Youdens Index, a cut-off score for cognitive impairment (i.e. either 
MCI or dementia) of <28 for the SMMSE and <62 for the Qmci provided the best 
balance between sensitivity and specificity. At these cut-offs, the SMMSE had a 
sensitivity of 90% and specificity of 81%, while the Qmci had an 87% sensitivity and 
88% specificity. At a cut-off score of <27 the SMMSE had a sensitivity of 89% and 
specificity of 86% for dementia while at <50 the Qmci had a sensitivity of 84% and 
specificity of 80%. For MCI, a higher cut-off of <65 was found for the Qmci 
(sensitivity 81%, specificity 70%), but the SMMSE cut-off remained similar at <29 
but provided lower sensitivity (75%) and specificity (56%).  
 In this study, both age and education affected the cut-off scores for all 
cognitive categories. Differences were more marked between younger patients with 
more education and older patients with less education. For younger adults with more 
education, the best performing SMMSE cut-off for cognitive impairment was <29, 
compared to <67 for the Qmci. For older adults with the less education this dropped to 
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<27 for the SMMSE and <54 for the Qmci, a difference of two and 13 points 
respectively, suggesting that the Qmci cut-offs may be more clinically useful. The 
discriminating ability of the Qmci to detect cognitive impairment was lower in older 
adults with less time in formal education (AUC 0.89) and higher in younger adults 
with more education (AUC 0.95). There was no difference in accuracy for the 
SMMSE AUC 0.91 and 0.90 respectively) suggesting that it is less responsive to the 
effects of age and education than the Qmci. Cut-off scores for dementia were less 
affected by age and education.  
 For younger adults with more education, the best performing cut-offs for 
dementia were <28 for the SMMSE and <53 for the Qmci, compared to <26 and <42, 
respectively for those older with less education. Only median differences in Qmci 
scores for MCI, between younger adults with more education and older adults with 
less education, were sufficient to change diagnosis, (63 versus 55). No median 
differences in SMMSE scores were sufficient to change diagnosis irrespective of age 
or education. Individuals with more education required Qmci cut-off score adjustment 
for age when they presented with normal cognition and MCI, but not dementia. 
Participants with less education only required age-adjustment when they developed 
dementia. Therefore, age is an important factor to consider in people with more 
education and only becomes relevant for those with less education when they present 
with dementia, suggesting a “falling off the cliff” phenomenon. These results also 
suggest that only symptomatic younger adults should have their cut-off scores 
adjusted for education, irrespective of their stage at presentation. Although statistical 
differences between median SMMSE scores were seen, values were similar 
irrespective of age or education.   
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 Irrespective of age and education, all but one of the SMMSE cut-offs for 
patients with symptomatic memory loss presented here, were above the recommended 
cut-off of <25 [Molloy et al., 1997], suggesting that any failure to fully complete the 
test should prompt more detailed assessment. As expected, the Qmci was more 
accurate than the SMMSE in distinguishing MCI from normal cognition. This 
supports the results of the Qmci validation study presented in Chapter 3 [O’Caoimh et 
al., 2012]. The Qmci was more accurate for differentiating MCI, irrespective of age or 
education, supporting evidence that screening tests designed to identify MCI should 
be used in preference to the SMMSE when subtle cognitive changes are suspected. 
Based upon these results, the Qmci compares favourably with other short cognitive 
screens, including the MoCA, which has a similar sensitivity of 90% [Nasreddine et al 
2005] but similar or lower specificity of between 35% [Luis et al 2008] and 87% 
[Nasreddine et al., 2005] for CI, at its recommended cut-off of <26. Given that the 
Qmci is shorter (median 4.24 [O’Caoimh et al., 2013] compared to 10-12 minutes 
[Nasreddine et al., 2005]), it may be a more useful instrument in those presenting to 
memory clinics where time is at a premium. The results of this study suggest that the 
Qmci is particularly useful for differentiating MCI from normal cognition in older 
adults. The results also support evidence that while education may protect against the 
development of cognitive impairment [Mortimer & Graves, 1993],[Ott et al., 
1995],[Stern et al., 1994], once developed, it does not protect against a fall in 
cognitive scores towards the level of those with less education. Indeed, patients with 
more education may also experience a greater decline in cognitive scores, relative to 
those with less education, as they age. This supports previous research suggesting that 
some cognitive domains decline irrespective of baseline education [Leibovici et al., 
1996].  
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Strengths and weaknesses 
 Strengths of this study include the inclusion of a large sample of patients 
presenting with memory loss in a clinic setting, allowing analysis of subgroups 
according to age and education. Another strength is that cut-offs were confirmed as 
clinically meaningful using likelihood ratios. The study includes patients with 
different dementia subtypes, all of whom underwent comprehensive assessments 
using standardised diagnostic criteria, across multiple sites. This paper has a number 
of limitations. This study included pooled data from three sources, a clinical trial and 
two outpatient databases, potentially resulting in spectrum bias. The findings are 
drawn from a single country, potentiallt reducing the generalisability of results. 
However, Canada is an ethnically diverse country with similar demographics to many 
other industrialised nations and data were drawn from multiple clinics spread over a 
large geographic area. The age and educational level cut-offs chosen could also limit 
the external validity of these results. Although 12 years is the average number of 
years of education for older adults in North America, this figure is lower in other 
countries. Another potential limitation is that the SMMSE was used as an inclusion 
criteria for patients entering the DARAD trial.  
 
Conclusions 
 In summary, this study provides usable cut-off scores for the SMMSE and 
Qmci and illustrates the effects of age and education on cut-off scores for patients 
presenting with symptomatic memory loss. The results suggest that the SMMSE may 
be less sensitive to these effects than the Qmci, likely reflecting the poor 
discriminating power of the SMMSE. This study also suggests that educational levels 
are less important in older adults. Thus, this study suggests that while SMMSE 
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population norms, in unselected community dwellers, require adjustment for age and 
education [Crum et al., 1993], smaller adjustments are required for older adults who 
present with symptomatic memory loss. The type of test selected also determines the 
extent to which adjustments in age and education are required. Based upon this 
analysis, the authors recommend overall SMMSE cut-offs of <28 for cognitive 
impairment, <29 for MCI and <27 for dementia. The recommended Qmci cut-offs are 
<60, <65 and <50 respectively.  
 From the clinicians perspective this study shows the importance of selecting 
the appropriate instrument in the appropriate context. In busy clinics the instrument 
chosen should reflect the pre-test probability so as to avoid unnecessary delays and 
inconvenience to the patient. Where mild deficits such as MCI are expected e.g. in 
younger, functionally independent patients screens such as the Qmci should be used in 
preference to the SMMSE. Once the appropriate instrument is selected, age and 
education should be further considered to provide context. It must be remembered 
however, that although cut-offs are useful in clinical practice and the effects of age 
and education are important, they should act only as a guide and not replace clinical 
judgment [Cullen et al., 2007]. Further study is required to confirm these findings in 












Performance of the Qmci Screen and its Subtests in 




Although short cognitive screening instruments such as the MMSE are widely used in 
clinical practice and research studies, their accuracy and hence suitability for use in 
different dementia subtypes is poorly characterised [Woodford 2007]. Given that the 
MMSE and the Standardised MMSE contain a limited number of cognitive domains, 
their use in particular dementia subtypes, and in MCI is unclear. Both lack a subtest 
measuring executive function, something that screens such as the Qmci and MoCA 
include. The pentagon task may lack accuracy in post-stroke, frontotemporal and 
subcortical dementias [Bak et al.,2005]. Although evidence suggests that depression 
in MCI is associated with disease progression, the effects of depression on scoring 
cognitive screening is poorly characterised [Van der Mussle et al., 2014]. The extent 
to which depression affects the results of cognitive screening instruments is poorly 
understood and it is not known the extent to which different dementia subtype scores 
are influenced by the presence of comorbid depression.  
 The objective of this study is to explore the performance (accuracy) of the 
Qmci and SMMSE in different dementia subtypes, to reaffirm the superior accuracy 
of Qmci over the SMMSE in a large, pooled sample of patients and to examine the 
subtests of the Qmci and their accuracy in different dementia subtypes, MCI and 





This study compared the SMMSE and the Qmci screen in patients (n=3,020) pooled 
from three memory clinic databases in Canada including those with MCI 
(predominantly aMCI), AD, VaD, FTD, LBD and PDD, with and without a history of 
comorbid depression. Patients without cognitive impairment and with depression as 
the primary symptom were excluded. Caregivers (n=875), without cognitive 
symptoms, were included as normal controls. Data from the three data sets (original 
Qmci, GAT and DARAD) were pooled and analysed using simple descriptive 
statistics, ROC curve analysis and the Mann-Whitney U test. Only those with both a 
Qmci and SMMSE scores at the same visit were included. Comparisons between 
participant characteristics in each database are presented in Chapter 5. Available 


























Figure 6.1 Flow chart presenting the recruitment of participants pooled from three 
data sets: The Geriatric Assessment Tool (GAT), Quick Mild Cognitive Impairment 
(Qmci) screen and Doxycycline and Rifampicin for Alzheimer’s Disease (DARAD) 
trial databases; it includes the number of controls, those with mild cognitive 
impairment (MCI) and specific dementia subtypes: Alzheimer’s disease (AD), 
Vascular dementia (VaD), Mixed dementia, Frontotemporal dementia (FTD), 










































The median age of patients was 77 years (Interquartile = +/-9), controls 69 (+/14). 
Median SMMSE scores were 23/30 (+/-8) for dementia, 28/30 (+/-4) for MCI and 
29/30 (+/-2) for controls. Median Qmci scores were 38/100 (+/-26) for dementia, 
56/100 (+/-20) for MCI and 74/100 (+/-15) for controls. Differences in gender were 
seen between diagnosis with the percentage of males ranging from as high as 73% in 
those with VaD to as low as 41% in those with dementia and comorbid depression. 
Both instruments accurately differentiated cognitive impairment from normal. The 
SMMSE most accurately differentiated AD (AUC 0.94) and LBD (AUC 0.94) and 
least accurately identified MCI (AUC 0.73), VaD (AUC 0.74) and PDD (AUC 0.81). 
Characteristics of participants are presented in Table 6.1. The Qmci had statistically 
similar or greater accuracy in distinguishing all dementia subtypes but particularly 
MCI (AUC 0.85). ROC curves demonstrating the accuracy of both instruments in 
each type of dementia, in MCI and in those with and without depression are presented 
in Figure 6.2. Comorbid depression did not affect the accuracy of either instrument 
for dementia but improved accuracy in those with MCI. Comparison of median scores 
for MCI with and without depression showed that scores were significantly different 
for both the Qmci, 51.5 and 57 respectively (z=-2927, p=0.003) and SMMSE 26 and 
28 respectively, (z=-3302, p=0.001). There were no statistically significant 
differences in age, education or gender between MCI patients with and without a 
history of comorbid depression and in fact patients without depression were older 
(median 76 years compared to a median of 73 years of age for those with comorbid 
depression). Similarly, significant differences were found between median scores for 
dementia alone (excluding MCI), with (n=2,160) and without (n=1879) depression, 
for the Qmci (z=-4.771, p<0.001) and the SMMSE (z=-5.627, p<0.001).  
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Table 6.1. Characteristics of participants from the Quick Mild Cognitive Impairment 
(Qmci) screen validation, Doxycycline And Rifampicin for Alzheimer’s Disease 
study and Geriatric Assessment Tool databases, divided according to diagnosis: 
depression, controls, mild cognitive impairment (MCI) and dementia (AD= 
Alzheimer’s disease, VaD= Vascular dementia, FTD= Frontotemporal dementia, 
PDD= Parkinson’s dementia, LBD= Lewy Body dementia), including their 
Standardised Mini-Mental State Examination (SMMSE) and Qmci screen scores; 




NC = Normal Controls 
CI = Cognitive Impairment 
IQR = Interquartile Range 
AUC = Area Under the Curve 
NA = Not applicable 
*Missing data 
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Figure 6.2. Receiver operating characteristic curves (a-l) comparing the accuracy of 
the Quick Mild Cognitive Impairment (Qmci) screen and Standardised Mini-Mental 
State Examination in differentiating normal controls (n=875) from those with mild 
cognitive impairment (MCI), different dementia subtypes and comorbid depression 
for participants included within the Qmci screen validation, Doxycycline And 




a. All patients (n=3020)    b. All patients with dementia (n=2,160) 
 
   
   c. Dementia excluding    d. Alzheimer’s dementia (n=1,483) 
    depression (n=1,879)      
 
e. Vascular dementia    f. Mixed dementia (n=400) 








g. Alzheimer’s, vascular,    h. Frontotemporal dementia (n=41) 
    mixed dementia (n=2,013) 
 
 











The median subtest scores and AUC scores derived from ROC curves according to 
diagnosis are presented in Tables 6.2 and 6.3 respectively. ROC curves comparing the 
subtests of the Qmci are presented in Figure 6.3. The highest median score for the 
clock drawing subtest was found in those with VaD (14/15), the lowest was in LBD 
(7/15). All subtest scores were less accurate for MCI in those with comorbid 
depression. LM was again the most accurate for most dementia subtypes and MCI 
(AUC 0.80). Orientation was accurate for AD (AUC 0.88) but had particularly low 
accuracy in VaD (AUC 0.71), FTD (AUC 0.78), PDD (AUC 0.71) and MCI (AUC 
0.68). 
 
Table 6.2. Median scores for the Quick Mild Cognitive Impairment (Qmci) screen 
subtests divided according to diagnosis: depression, mild cognitive impairment (MCI) 
and dementia (AD= Alzheimer’s disease, VaD= Vascular dementia, FTD= 
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Table 6.3. Comparison of the accuracy of the Quick Mild Cognitive Impairment 
(Qmci) screen subtests in differentiating each diagnosis from normal controls (n=875): 
depression, mild cognitive impairment (MCI) and dementia (AD= Alzheimer’s 
disease, VaD= Vascular dementia, FTD= Frontotemporal dementia, PDD= 
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Figure 6.3. Receiver operating characteristic curves (a-l) comparing the accuracy of 
the Quick Mild Cognitive Impairment (Qmci) subtests in differentiating normal 
controls (n=875) from those with mild cognitive impairment (MCI), different 
dementia subtypes and comorbid depression for participants included within the Qmci 
screen validation, Doxycycline And Rifampicin for Alzheimer’s Disease study and 
Geriatric Assessment Tool databases. 
 
 
a. All patients (n=3020)    b. All patients with dementia (n=2,160) 
 
 
c. Dementia excluding    d. Alzheimer’s dementia (n=1,483) 
    depression (n=1,879)      
   
 
   e. Vascular dementia   f. Mixed dementia (n=400) 
      (n=130) 
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g. Alzheimer’s, vascular,    h. Frontotemporal dementia (n=41) 
    mixed dementia (n=2,013) 
 
 












This study compares the accuracy of the Qmci and the SMMSE in different dementia 
subtypes using a large sample of patients pooled from three different data sets. The 
SMMSE and Qmci are both accurate cognitive screens in those with dementia. Like 
the original validation data [O’Caoimh et al., 2013], this analysis confirms the Qmci 
is more accurate and LM its most accurate subtest in MCI. It also has high levels of 
accuracy for most dementia subtypes and patients with comorbid depression. The 
SMMSE again is less suitable in MCI [O’Caoimh et al., 2012], VaD and PDD [Bak et 
al., 2005], supporting previous studies in these conditions, where an alternative 
instrument like the Qmci may be used. The study suggests that comorbid depression 
affects the scores (total and subtests) and accuracy of instruments and their cognitive 
domains in patients with MCI. It suggests that comorbid depression likely made those 
with MCI perform less well on cognitive screening as suggested by the fact that both 
instruments were better able to detect patients with a history of comorbid depression 
than those without a history of depression.  
 The strength of this study is derived from its large sample size and careful 
pooling of data derived from similar data sets collected by the same principle 
investigator. This study also has limitations. As with the analysis of cut-off scores, 
pooling data from discreet, albeit related, data sets may create bias. Some data on 
gender were missing. The number of patients with atypical or less common dementia 
subypes was small and may be unrepresentative of the true performance of the 
instruments in that subtype, leading to bias. The data collection began in 1999 when 
the awareness of LBD was low. Likewise only patients with AD or those with 
AD,VaD and mixed dementia were included in the DARAD and Qmci validation 
databases respectively. Further, this study was a retrospective review of patients with 
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no detailed information available regarding the presence of active depressive 
symptoms. That said, those patients with normal cognition, with depression as the 
primary or only symptom, were excluded from the analysis. Similarly, it was not 
possible to assess MCI subtypes in this study, though the majority of patients in the 
GAT database reported amnestic type symptoms suggesting that most had aMCI.  
 In summary, this study confirms the accuracy of the Qmci in MCI. It also 
reaffirms that both the Qmci and SMMSE are useful in patients with dementia. It 
shows that different short screens have significantly different accuracy in different 
dementia subtypes, suggesting that pre-screen/pre-test suspicion of a possible 
diagnosis (MCI or specific dementia subtype) based upon history and examination 
should direct the choice of instrument. The results also suggest that a history of 
depression may effect the accuracy of cognitive screening, particularly in those with 
MCI. The effect of comorbid depression on cognitive screening scores merits further 
investigation. Further study as part of this PhD will investigate the accuracy of the 
Qmci and its subtests in an Irish setting against the SMMSE by way of comparison 




















Diagnostic utility of the Qmci:  
Comparison to the Montreal Cognitive Assessment (MoCA); 




As described in Chapter 2, memory loss is a spectrum from SMC but normal 
cognition on neuropsychological testing to MCI and dementia. Sensitivity and 
specificity are the most important psychometric properties of short cognitive screens, 
with high sensitivity preferable to exclude false negatives [Alberg et al., 2004]. The 
MoCA is highly sensitive at differentiating MCI from normal cognition and dementia 
[Nasreddine et al., 2005] and is widely validated against the most commonly used 
cognitive screen, the MMSE [Folstein et al., 1975],[Shulman et al., 2006],[Ismail et 
al., 2010], in multiple settings [Luis et al., 2008],[Olson et al., 2011],[Smith et al., 
2007], disorders [Hoops et al., 2009],[Videnovic et al., 2010][Godefroy et al., 2011], 
and languages [Thissen et al., 2010],[Selekler et al., 2011],[Lee et al., 2008],[Fujiwara 
et al., 2010]. Normative population data are also increasingly available [Rossetti et al., 
2011].  The MoCA overcomes the high ceiling effects and educational bias associated 
with the MMSE [Damian et al., 2011], has fewer practice effects and is available in 
multiple formats [Damian et al., 2011].  
  The MoCA has challenges; it is long, taking at least 10 minutes to complete 
[Nasreddine et al., 2005] and its specificity at its recommended cut-off (<26) is low 
[McLennan et al., 2011], considerably different from the 87% reported in the original 
validation cohort [Nasreddine et al., 2005]. Recently, different more specific cut-offs 
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have been published [Freitas et al., 2013]. In addition, the MoCA subtest scores are 
criticized for having low accuracy when predicting impairment in their respective 
cognitive domains [Moafmashhadi et al., 2013].  The 6CIT [Katzman et al., 1983], 
described and presented in Chapter 2, is another commonly used cognitive screening 
instrument. It identifies dementia with high accuracy though its accuracy in those with 
MCI is less established. A recent validation in a memory clinic population showed a 
sensitivity of only 66% [Abdel-Aziz & Larner 2015]. To date, no study has compared 
the effects to the MoCA and 6CIT. 
 Neither the MoCA nor Qmci are usually compared to short screens designed 
to detect MCI as well as dementia. Furthermore, little is known about the optimal cut-
off scores for either instrument in patients referred to clinic. Given this, the primary 
objective of this study was to externally validate the Qmci by comparing it to the 
widely used MoCA in a memory clinic population. The 6CIT is also scored in clinic 
but was not originally part of the data collection. Given that the 6CIT has only one 
recent validation in patients with MCI, the secondary objective was to compare it with 
the Qmci in the same population. As this was a secondary outcome, the results of this 
subanalysis are discussed separately at the end of this chapter. Further, the MoCA was 
also compared with the 6CIT. Inter-rater reliability of the clock drawing test was also 




Patients referred for investigation of memory loss were recruited from a university 
hospital memory clinic in Cork City, Ireland. Alzheimer’s type and vascular dementia 
was classified using the DSM-R (4th-edition) [APA 2000]. Severity was correlated 
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with the Reisberg FAST scale [Reisberg 1988]. Amnestic type MCI was diagnosed 
using Petersens’ criteria [Petersen et al., 1999] according to the National Institute on 
Aging-Alzheimer’s Association workgroup diagnostic guidelines [Albert et al., 2011]. 
FTD was diagnosed using the Lund-Manchester Criteria [Brun et al., 1994]. FTD 
MCI was diagnosed clinically with reference to proposed criteria [de Mendonça et al., 
2004]. PDD and MCI was defined by the Movement Disorder Society Task Force 
Guidelines [Emre et al., 2007],[Litvan et al., 2012], LBD and MCI using the third 
report of the LBD Consortium [McKeith et al., 2005]. SMC was defined as subjective 
non-progressive memory loss in patients without objective cognitive deficits or 
functional decline, scoring ‘poor’ or ‘fair’ on a five-point Likert scale in response to 
the question “how is your memory?" [Paradise et al., 2011]. Normal controls were 
recruited by convenience sampling from healthy participants, usually caregivers, 
without cognitive problems, accompanying the patients. Those with active depression 
(n=23) or delirium (n=2), aged <45 years (n=22), declining consent (n=3), with an 
unclear diagnosis (n=21) or unable to communicate in English (n=2) were excluded. 
Depression was excluded clinically and screened with the GDS short-form [Yesavage 
1988] using a cut-off  of ≥7 to optimize specificity [Marc et al., 2008]. Functional 
level was based upon clinical history and examination. To support the decision the 
Barthel Index [Collin et al., 1988] and Quick Activities of Daily Living (Qadl) scale 
were collected. Unless there was co-existing physical disability The Barthel Index 
measure basic ADL and is scored from functional independence 20/20 to full 
dependence 0/20 and is presented in Table 7.1. Even though this instrument is not 
validated in dementia, it is a well established instrument to measure ADL and is 
collected routinely in clinic. The Qadl is a shortened version of the Lawton-Brody 
ADL scale and includes both instrumental and basic ADL. It has 10 subtests, scored 
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by informants: medications, finances, telephone use, food preparation, grooming, 
bathing, walking, toileting (urine/feces), transfering and feeding themselves. Each 
subtest has two questions: what is the level of care required, and how much of a 
problem is this. Each subtest is scored from zero to four, with higher scores 
suggesting greater dependency. The Qadl has excellent inter-rater reliability 
[O’Caoimh, Trawley & Molloy, 2012] and is presented in Appendix 2.6. All patients 
diagnosed with SMC or MCI had a normal Barthel Index score of 20 or Qadl score of 
40. 
Table 7.1. The Barthel Index (BI) scoring sheet. 
Item Range Score 
Feeding 0 Unable 
1 Needs help cutting, spreading butter etc, or needs modified    
   diet 
2 Independent 
 
Bathing 0 Dependent 
1 Independent (or in shower) 
 
Grooming 0 Needs help with personal care 
1 Independent face/hair/teeth/shaving (implements provided) 
 
Dressing 0 Dependent 
1 Needs help but can do about half unaided 
2 Independent (including buttons, zips, laces, etc.) 
 
Bowels 0 Incontinent (or needs to be given enemas) 
1 Occasional accident 
2 Continent 
 
Bladder 0 Incontinent or catherized and unable to manage alone 
1 Occasional accident 
2 Continent 
 
Toilet Use 0 Dependent 
1 Needs some help but can do something alone 
2 Independent (on and off, dressing, wiping) 
 
Transfers (bed to chair and back) 0 Unable, no sitting balance 
1 Major help (one or two people, physical), can sit 
2 Minor help (verbal or physical) 
3 Independent 
 
Mobility (on level surface) 0 Immobile or < 50 metres 
1 Wheelchair independent, including corners, > 50 metres 
2 Walks with help of one person (verbal or physical) > 50 metres 
3 Independent (but may use any aid; for example, stick) 
 
Stairs 0 Unable 
1 Needs help (verbal, physical, carrying aid) 
2 Independent 
 




The optimal Qmci cut-off score for CI (MCI or dementia), based upon the cut-off 
analysis in Chapter 5, used was <60. For screening in primary care, where high 
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sensitivity is required, the established MoCA threshold of <26 is suggested 
[Nasreddine et al., 2005]. For testing in memory clinics, a lower threshold (<24) may 
have better predictive value [Damian et al., 2011].$A cut-off of ≥8/28 for dementia 




Consecutive referrals underwent a comprehensive work-up for memory loss including 
history, physical examination, laboratory testing and neuroimaging. A short 
neuropsychological battery (the SMMSE [Molloy et al., 1991],[Molloy et al 1997] 
and two informant-rated assessments (the AD8 questionnaire [Galvin et al., 
2005],[Razavi et al., 2014] and IQCODE Short Form [Jorm 1994]) were conducted by 
a consultant geriatrician to inform the diagnosis. Cognitive screening was performed 
in a random counterbalanced order, approximately one hour before consultant review, 
by two independent trained raters, blind to each other and the final diagnosis. 
Alternate validated versions of VF and LM were used for the Qmci to reduce learning 
effects [Cunje et al., 2007]. Normal controls underwent the same comprehensive 
review. The study adhered to the tenets of the Declaration of Helsinki. Ethics 
approval was obtained and subjects provided verbal consent. Assent was obtained 
from individuals who were felt to lack capacity.  
 
Analysis 
Data were analyzed using SPSS 20.0. The Shapiro–Wilk test was used to test 
normality and found that the majority of data were non-parametric. These were 
compared using the Mann–Whitney U test. Accuracy was assessed with ROC curves, 
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compared with the Hanley method [Hanley et al., 1983]. Sensitivity, specificity, PPV 
and NPV were calculated for all tests at different cut-off points and by age (≤75 and 
>75 to balance numbers between groups) and education (<12 and ≥12, mean 





In total, 551 participant assessments were included: 73 with SMC, 103 with MCI, 274 
with dementia and 101 normal controls. Recruitment is presented in Figure 7.1. The 
majority of participants were female (n=363, 66%).  The median age of participants 
was 76 years (interquartile range, IQR +/-12). Patients with dementia (median age of 
77 +/-10 years) were significantly older than those with SMC (72 +/-11, p <0.001), 
MCI (76+/-13, p =0.03) and normal controls (74 +/-14, p <0.001). The median time in 
education was 12 +/-4 years. Those with dementia had spent less time in education 
(11+/-3 years), compared to those with SMC (12+/-4, p =0.07), MCI (13+/-5, p 
<0.001), or controls (13+/-4, p <0.001). There was no significant difference in age (p 
=0.82) or education (p =0.16) between those with SMC and controls. The majority of 
patients with dementia were classified as early to mild stage (n=201, 73%). 
Participant characteristics, median test scores according to diagnosis and the 
prevalence of MCI and dementia subtypes are presented in Table 7.2. Median 
administration time for the Qmci was 4.5 (+/-1.3) minutes, compared to 9.5 (+/-2.8) 
for the MoCA.  IRR, measured using Pearson’s correlation coefficient for a small 
sample of patients (n=14), choosen at random, was strong (r =0.97). 
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-Depression, N=23  
-Age ≤45, N=22 
Diagnosis in transition, N=21  
Language barrier, N=2 
Delirium, N=2  
Refused consent , N=3  
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Table 7.2. Baseline characteristics including dementia and mild cognitive impairment subtypes and 
median Quick Mild Cognitive Impairment (Qmci) screen and Montreal Cognitive Assessment (MoCA) 
scores, with inter-quartile range (IQR) values, for normal controls and patients with subjective memory 
complaints (SMC), MCI and dementia. 
 
 
Accuracy of Qmci Versus MoCA 
Comparing the accuracy of the tests at differentiating normal controls from MCI 
showed that the Qmci had significantly greater accuracy, AUC of 0.90 (95% 
confidence interval: 0.86-0.94) than the MoCA, AUC of 0.80 (95% confidence 
interval: 0.74-0.86), p =0.009. In their ability to discriminate SMC from MCI, the 
Qmci had better (AUC 0.81) accuracy than the MoCA (AUC 0.73), p =0.09, albeit a 
non-significant difference. The Qmci and MoCA had similar excellent accuracy at 
differentiating MCI from dementia (p =0.2), normal controls from cognitive 
impairment (p =0.04) and patients with SMC from cognitive impairment, (p =0.23). 
Both tests were poor at discriminating normal controls from SMC, (p =0.28). ROC 



































































































































































































Dementia (%) 176 (64%) 40 (15%) 24 (9%) 8 (3%) 12 (4%) 3 (1%) 11 (4%) 
MCI (%) Amnestic type 72 (70%)  14 (13.5%) 8 (8%) 5 (5%) 3 (3%) 1 (0.5%) - 
SMC  - - - - - 1 - 
$ 131$
Figure 7.2. Receiver Operating Characteristic curves demonstrating the accuracy of the Quick Mild 
Cognitive Impairment (Qmci) screen, and Montreal Cognitive Assessment (MoCA) in differentiating 
(a) mild cognitive impairment (MCI) from normal controls, (b) MCI from subjective memory 
complaints (SMC), (c) MCI and dementia, (d) normal controls from cognitive impairment (MCI and 
dementia), (e) SMC from cognitive impairment and (f) SMC from normal controls. 
  
a.    b. 
 
c.    d.         
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Area Under the Curve 
(95% Confidence Intervals) 
























The ability of both instruments to separate normal controls from cognitive impairment 
(MCI and dementia) was then assessed using different cut-off scores. Patients with 
SMC were analysed separately. At their established cut-offs, <62 for the Qmci and 
<26 for the MoCA, the Qmci had a sensitivity of 90% and specificity of 87% (PPV of 
0.92, NPV 0.70) for cognitive impairment, compared to 96% sensitivity and 58% 
specificity (PPV of 0.89, NPV 0.80) for the MoCA. At these cut-offs, the MoCA had 
a false positive rate of 11% compared to 4% for the Qmci. The MoCA misclassified 
42/101 (42%) of controls as having cognitive impairment compared to 7/101 (7%) 
with the Qmci. Increasing the Qmci cut-off to <65 improved the sensitivity (94%) but 
reduced the specificity (80%). Reducing the MoCA cut-off for cognitive impairment 
to <24 yielded an optimum sensitivity and specificity for the test, 89% and 83% 
respectively, and reduced the false positive rate to 5%. Sensitivity, specificity, PPV 
and NPVs are presented in Table 7.3. Adjusting the Qmci cut-off scores for age and 
education showed that the Qmci using a cut-off of <62 had an optimal sensitivity and 
specificity for cognitive impairment in younger patients with less education (<12 
years), with a sensitivity of 99% and specificity of 85%. Lowering the cut-off to <60 
improved the specificity (88%) for older people (>75), giving an arguably better 
balance between sensitivity and specificity, suggesting that this maybe the optimal 
cut-off in a geriatric clinic or GP setting. Sensitivity was lowest for younger patients 
aged <75 with >12 years in formal education (74%). The MoCA had better sensitivity 
(99%) for older patients (>75) with less education (<12) but very low specificity 
(37.5%). The MoCA had greater sensitivity for those with more education. These 
values, adjusted for age and education, are presented in Table 7.4. Re-analysis of the 
data comparing the ability of the tests at their established cut-offs to differentiate 
SMC from MCI and dementia showed similar results, see Table 7.5. 
131$
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Table 7.3. Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative 
Predictive Value (NPV), with 95% confidence intervals (CI), for different Quick Mild 
Cognitive Impairment (Qmci) screen and Montreal Cognitive Assessment (MoCA) 
cut-off scores for cognitive impairment (mild cognitive impairment and dementia), 
without adjustment for age or education, compared with normal controls. 
$
† Cut-off for cognitive impairment selected from O’Caoimh et al., 2014  
* Cut-off for cognitive impairment selected from Nasreddine et al., 2005  
** Cut-off for cognitive impairment selected from Damian et al., 2012  
*** Cut-off for cognitive impairment selected from Luis et al., 2008  


















 Prevalence of cognitive impairment 
of 79% 
 

























































































































































































Table 7.4. Sensitivity, specificity, positive predicative value (PPV), negative 
predicative value (NPV), and false positive and negative values for the Quick Mild 
Cognitive Impairment (Qmci) screen (using two different cut-off points) and Montreal 
Cognitive Assessment (MoCA), based upon cut-off scores for cognitive impairment 
































































(15-50) 70 (75-63=12) 













(26-62) 78 (81-71=10) 













(24-50) 79 (84-75=9) 




































(8-44) 70 (75-63=12) 
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(11-56) 27 (29-25=4) 
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Table 7.5. Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative 
Predictive Value (NPV), with 95% confidence intervals (CI), for different Quick Mild 
Cognitive Impairment (Qmci) screen and Montreal Cognitive Assessment (MoCA) 
cut-off scores for cognitive impairment (mild cognitive impairment and dementia), 
without adjustment for age or education, compared with patients diagnosed with 
subjective memory complaints. 
 
$
† Cut-off for cognitive impairment selected from O’Caoimh et al 2014  
* Cut-off for cognitive impairment selected from Nasreddine et al 2005  
** Cut-off for cognitive impairment selected from Damian et al 2012  
*** Cut-off for cognitive impairment selected from Luis et al 2008  
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Inter-rater reliability of the clock drawing test 
IRR of the clock drawing test was determined by asking two trained and one 
untrained raters (given the administration and scoring guidelines, including the clock 
drawing scoring template prior to testing) to score a random sample of clocks, n=20.  
Pearsons correlation coefficient demonstrated a strong correlation, r =0.99, p <0.001, 
between trained raters. A strong correlation was also demonstrated between trained 
and untrained raters, r =0.96, p <0.001. Cohen's Kappa (K, Weighted) also showed 
strong to near perfect agreement between trained raters (Κ =0.8909, SE = 0.0297, 
95%CI = 0.8327 to 0.9490) and trained versus untrained raters (Κ =0.7925, SE 
=0.0494, 95%CI = 0.6957 to 0.8892). There was also an overall fair level of 
agreement between the three (trained and untrained) raters, (Fleiss’s Κ =0.3754, SE = 
0.0483, 95%CI = 0.2807 to 0.470). 
 
7.4 Discussion 
This study compares the ability of Qmci and MoCA to detect cognitive impairment 
and differentiate NC from MCI and dementia. Overall, the results suggest that the 
Qmci is the shorter, more accurate and useful screen for detecting cognitive 
impairment, producing the best balance between sensitivity and specificity at its 
established cut-off score. Comparing the ability of the two tests to differentiate NC 
from MCI, the Qmci demonstrated statistically significantly greater accuracy, an AUC 
of 0.82 compared to 0.74 for the MoCA. At the widely used cut-off of <26, the 
MoCA had 96% sensitivity but only 41% specificity for detecting cognitive 
impairment compared to 88% and 88% respectively for the Qmci at a cut-off of <60. 
The poor specificity of the MoCA at this cut-off is similar to results published 
elsewhere of between 35% [Luis et al., 2008] and 52% [Damian et al., 2011] for 
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detecting cognitive impairment. The specificity of the MoCA improved when the cut-
off was lowered and from this data, the optimal cut-off appears to be that suggested 
by Luis et al at <23 [Luis et al., 2008], which produced a sensitivity of 85% and 
specificity of 82% for cognitive impairment. Although reducing the cut-off threshold 
improved its specificity, this was at the cost of sensitivity, the main advantage of 
using the MoCA. The Qmci and MoCA had similar good  to excellent accuracy (non-
significantly different) in separating patients presenting with SMC but found to have 
normal cognition and those with cognitive impairment (MCI or dementia). This 
suggests that the instruments are both appropriate in this setting, but given the Qmci’s 
short administration time it may be the more useful particularly where time is short. 
The Qmci is more efficient because it takes half the time to complete compared to the 
MoCA.  In this study, the median length of time to score the Qmci was 4.5 minutes, 
half the time of the MoCA. 
 This study demonstrates several other advantages of the Qmci over the MoCA. 
The Qmci was associated with fewer false positive results for cognitive impairment, 
4% at <62, compared to 12% for the MoCA at <26. At this cut-off the majority of 
subjects with controls (54%) screened positive using the MoCA. While this questions 
the tests’ utility at this cut-off, it also questions the broader utility and ability of the 
test to differentiate normal controls from MCI, because the majority with normal age 
associated memory loss test positive for cognitive impairment necessitating more 
detailed assessment and negating the purpose of the test. The suboptimal specificity of 
the MoCA has been reported previously for cognitive impairment associated with PD 
[Hoops et al., 2009] and stroke [Godefroy et al., 2011]. To our knowledge, this is the 
first time this has been demonstrated among subjects, predominantly diagnosed with 
AD, in an outpatient memory clinic setting. The cut-off scores for the MoCA are less 
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clearly defined than those of the Qmci. Several studies have demonstrated that 
established cut-offs for the MoCA lack accuracy, particularly specificity, among older 
adults and those with less time in formal education [Rossetti et al., 2011].  This might 
be related to the fact that the MoCA and its established cut-off score of <26 were 
originally validated exclusively among subjects with AD. In contrast, the original 
Qmci validation sample included those with AD, vascular dementia and mixed AD-
vascular subtypes [O’Caoimh et al., 2012]. While the MoCA is validated in different 
conditions, the same cut-offs are often applied although recent evidence suggests that 
the original cut-off requires adjustment for both MCI and dementia [Freitas et al., 
2013] as well as for specific types of cognitive impairment [Hoops et al., 
2010],[Godefroy et al., 2011].  
 The Qmci is the more useful test in clinical practice with wider and more 
clinically significant percentage difference in median scores that can better 
discriminate MCI from normal controls and dementia. The MoCA, like the SMMSE 
is scored out of 30 points giving it a narrow scoring range and reducing its utility in 
clinical practice. In addition, with this limited scoring, much of the detail and richness 
of the assessment is lost. This is exemplified by the scoring of the Clock. Although 
requiring more interpretation, the scoring of the Qmci-Clock, provides more 
information and contributes more to the final score of the test, particularly in those 
with established cognitive impairment. The MoCA also had significant floor effects, 
with a median score of two points, making it particularly difficult for those with 
moderate to severe dementia to complete and therefore limiting its utility in severe 
dementia.  
 The Qmci incorporates fewer subtests that require normal vision than the 
MoCA. Visual impairment affects the performance of subjects on cognitive testing, 
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particularly in older adults [Killen et al., 2013]. Visual tasks account for 27% of the 
MoCA’s (Visuospatial/Executive and Naming) overall score compared to 15% for the 
Qmci (clock drawing). This said, both tests can be corrected to account for incomplete 
data and recently a modified version of the MoCA for the visually impaired has been 
validated [Wittich et al., 2010]. However, the elimination of subtests that require 
vision (naming, visuospatial and executive function) reduces the discriminating 
function of the ‘MoCA-BLIND’, particularly its ability to differentiate MCI from NC 
[Wittich et al., 2010]. Given that this is the principal advantage of the MoCA over 
other cognitive screens, this suggests that the MoCA is overly weighted towards tests 
that require normal vision, an especially important component when assessing older 
adults [Killen et al., 2013]. The Qmci on the other hand derives its accuracy for 
identifying MCI from its delayed recall, verbal fluency and logical memory subtests 
[O’Caoimh et al., 2013]. At present, no accepted population norms for age, culture or 
education have been published for the MoCA [Rossetti et al., 2011], although the 
ACE trial is currently planned to develop these specific cut-offs. Similarly, no cut-
offs, adjusted for age or education, exist for those presenting with memory loss. 
Finally, the Qmci is arguably easier to use than the MoCA, requiring less training, 
thereby increasing its generalizability. 
 The MoCA may however be more sensitive and specific for younger subjects 
with more education. In older adults the MoCA may perform with more accuracy 
using a lower cut-off than the established score. The MoCA is less weighted towards 
language, with 73% of the test requiring verbal skills versus 85% for the Qmci. That 
said, the MoCA subtests are subject to greater educational bias, than the Qmci. 
Although the Qmci is easier to score, its Clock subtest, scored out of 15 points, 
requires greater interpretation. That said, the Qmci-Clock scoring method is validated 
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against and is superior to other forms of Clock drawing [Kanji et al., 2006] and 
showed good IRR in this study, consistent with research showing excellent IRR for 
clock drawing for specialists in dementia [Nair et al., 2010].  
 The MoCA is validated widely, in different languages [Thissen et al., 
2010],[Fujiwara et al., 2010] and in different clinical settings. Validation of the Qmci 
in other countries, languages and cultures is now underway.  Future validation should 
also include comparison with the MoCA and other standardized neuropsychological 
tests in different clinical populations.  
 This study has a number of limitations. The diagnosis of MCI is contentious 
and the criteria used here are not a gold standard. In particular, no formal 
neuropsychological testing was routinely performed.  That said, at present no single 
screening instrument is recommended for MCI, no standardized criteria are accepted 
[Bischkopf et al., 2002] with definitions differing between studies [Stephan et al., 
2013]. The protocol was developed and data collection begun before the publication 
of DSM-5. For these reasons MCI was defined according to its fundamental 
characteristics: the presence of subjective and corroborated memory loss, in the 
absence of impairment in ADLs. Possible learning effects due to repetition of VF and 
LM may have been present although different versions were used in an attempt to 
minimize this. No specific screening test such as the MAC-Q was used for SMC 
[Crook et al., 1992]. This said, a short Likert scale in response to a single question has 
been used in previous studies assessing SMC [Paradise et al., 2011]. 
 This is the first study to compare a short cognitive screen, designed 
specifically to differentiate MCI from normal cognition and dementia with the 
MoCA. While the MoCA overcomes many of the difficulties associated with the 
MMSE, particularly in those with high levels of education, this study suggests that the 
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MoCA is too challenging and overly sensitive among older adults attending a memory 
clinic. This study also confirms the growing concern that the established MoCA cut-
off (<26), while sensitive to cognitive impairment, has poor specificity and produces 
an unacceptably high false positive rate. As older adults represent the majority of 
patients who have cognitive screening performed for symptoms of memory loss, the 
Qmci is likely to be a shorter and more accurate alternative. Further research is 
required to confirm these findings and compare the Qmci and MoCA in different 
clinical settings, particularly in primary care, where the brevity and usability of the 
Qmci is likely to be of most benefit. The MoCA may be better with a lower cut-off 
than the established score, particularly for older adults. The Qmci, with a cut-off of 
<60 for CI, has superior sensitivity and specificity and should be considered as a 
shorter alternative to the MoCA for use in everyday practice. 
 
7.5 Subanalysis: comparison of the Qmci to the 6-Item Cognitive 
Impairment Test (6CIT) and MoCA. 
 
Results  
As described in the introduction to Chapter 7, the 6CIT was scored in clinic in 
addition to the requirements of this study. The results of the 6CIT scoring were 
blinded to the attending consultant and they did not influence the diagnosis. In all, 
142 6CIT assessments were available (21 with SMC, 32 MCI and 89 with dementia). 
No normal controls were available. The median age of patients included was 76 years 
(interquartile range: 81-70= +/-11). In all, 68% were female. The median Qmci score 
was 44 (+/-33) compared to 10/28 (18-4= +/-14) for the 6CIT. The median Qmci 
score for SMC, MCI and dementia was 69 (73-63= +/-10), 57 (62-52 +/-10) and 
32.5/100 (42-20= +/-22) respectively compared to 2/28 (4-0= +/-4), 5/28 (9-2= +/-7) 
and 17/28 (21-10= +/-11) respectively for the 6CIT. Characteristics of patients 
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included in this subanalysis are presented in Table 7.6. The Qmci had excellent 
accuracy for identifying cognitive impairment (either MCI or dementia) with an AUC 
of 0.96 (95% CI: 0.94-0.99). It performed significantly better than the 6CIT, AUC 
0.88 (95% CI: 0.82-0.94), z=2.4, p =0.02, but not the MoCA in this data set 0.92 
(0.87-0.97), z=1, p= 0.32. The MoCA had similar accuracy to the 6CIT (z=-0.54, p 
=0.59). The Qmci had greater accuracy than the 6CIT in differentiating MCI from 
those with SMC, AUC of 0.91 versus 0.71,although this did not reach statistical 
significance, z=1.7, p =0.09. It did however, have significantly better accuracy in 
differentiating MCI from dementia, AUC of 0.97 versus 0.87, z=2.1, p =0.04. Median 
administration times were 4.38 minutes for the Qmci versus 2.05 for the 6CIT. ROC 
curves demonstrating the accuracy of the Qmci, MoCA and 6CIT in differentiating 
MCI from SMC and dementia are shown in Figure 7.3. 
Table 7.6. Characteristics of patients included in the subanalysis of 6-item Cognitive 
Impairment Test (6CIT) in patients with subjective memory complaints (normal), mild 
cognitive impairment (MCI) and dementia. 
!
 
Group Total SMC MCI Dementia 
Number of Assessments 142 21 32 89 
Gender (% female) 68% 43% 75% 72% 
Age  
(years) Median 76 71 77 77 
 Interquartile 
range (IQR) 
(81-70=11) (75-66=9) (80-71=9) (82-71=11) 
 range 49-91 54-89 61-91 49-91 
Education     
(years) Median 12 11 12 11 
 Interquartile 
range (IQR) 
(14-10=4) (13-10=3) (16-11=5) (13-10=3) 
 range 7-18 9-17 9-18 7-18 
Qmci 






























Figure 7.3. Receiver Operating Characteristic curves demonstrating the accuracy of the Qmci, MoCA 












This subanalysis presents the results of comparison between three short cognitive 
screens, the Qmci, MoCA and 6CIT, in a geriatric memory clinic. The results show 
that the Qmci was more accurate than the 6CIT, in identifying cognitive impairment. 
Although all three instruments had statistically similar accuracy in separating MCI 
from SMC, the Qmci had the larger AUC suggesting greater accuracy. All three 
instruments were equally able to identify dementia suggesting that the 6CIT with its 
shorter administration time, may be useful as a short screen when assessing patients 
with a high index of suspicion for dementia or monitoring progression of dementia 
over time. Designed for primary care, the 6CIT is more weighted towards verbal skills 
(100%) compared to the Qmci (85%) and lacks tests of higher cognitive function. In 
conclusion, though the sample size was small, this study suggests that the 6CIT is not 
useful in differentiating CI from SMC in clinic settings and may be more useful as a 
quick screen to confirm dementia particularly in settings such as hospitals.  
Screen Area Under the Curve Area Under the Curve 
Diagnosis a) SMC from MCI 
(95% confidence intervals) 
b) MCI from dementia 
(95% confidence intervals) 
Qmci 0.87 (0.77-0.96) 0.97 (0.95-1.00) 
6CIT 0.71 (0.57-0.85) 0.87 (0.81-0.94) 




Measuring cognitive change over time;  




A number of cognitive screening instruments are used in clinical care and research. 
To standardise assessments and allow comparison between settings, there is a need for 
valid and reliable cognitive assessment tools. No single cognitive screening 
instrument is ideal, and to date, none have become established as the standard 
[Gifford et al., 1999]. Several are limited by their inability to detect significant 
variations between patients with respect to age and or educational status [Crum et al 
1993]. Researchers and clinicians require short instruments that are reliable, valid and 
responsive to change across a wide range of cognitive function. They need multiple, 
standardised scoring formats that measure changes early (high ceiling) and in the later 
stages of dementia (low floor). The existing accepted standard for measuring 
cognitive function in clinical trials in dementia, is the ADAS-cog [Rosen et al., 
1984],[O'Halloran et al., 2011],[Weyer et al., 1997] and its standardised version, the 
SADAS-cog. The hypothesis tested in this study within the PhD is whether the short 
Qmci screen could be used in clinical trials instead of the longer SADAS-cog.  In 
order to test this we performed an analysis of data from the Doxycycline and 
Rifampicin for Alzheimer’s Disease (DARAD) trial comparing the Qmci with the 
SADAS-cog, to investigate the extent to which the two tests were correlated and to 






The DARAD trial investigated the use of two antibiotics, doxycycline and rifampicin, 
in 406 patients with mild to moderate Alzheimer’s dementia. Subjects were 
randomised into four arms: doxycycline 100 mg twice daily with rifampin 300 mg 
daily, or doxycycline 100 mg twice daily with placebo-rifampin daily, or rifampin 
300 mg daily with placebo-doxycycline twice daily or placebo-doxycycline twice 
daily, with placebo-rifampin daily [Loeb et al., 2004],[Molloy et al., 2012]. Patients, 
were recruited from 14 Canadian geriatric clinics, between 2006 and 2010. The 
DARAD database contains data for a range of variables at one, three, six, nine and 
twelve months.  Patient’s aged ≥50 years, meeting the NINCDS criteria for 
Alzheimer’s disease [McKhann et al., 1994], with SMMSE scores between 14 and 26, 
were included.  Patients were excluded if they were unable to communicate verbally 
in English.   
 
Measures 
The co-primary outcomes in the DARAD trial were the SADAS-cog and the Clinical 
Dementia Rating scale (CDR) using the Sum of the Boxes technique [Morris 1993],[$
Schafer et al., 2004]. Secondary outcomes included the Qmci and Lawton-Brody 
ADL scale [Lawton & Brody, 1969]. A trained rater administered the SADAS-cog, 






The Standardised Alzheimer`s Disease Assessment Scale-cognitive section 
 (SADAS-cog) 
The SADAS-cog is described in detail in Chapter one and is presented in Appendix 
2.5. 
The Clinical Dementia Rating scale (CDR) 
The CDR is a global assessment scale measuring cognitive impairment in six areas: 
memory, orientation, judgment and problem solving, community affairs, home and 
hobbies, and personal care [Morris 1993],[$Schafer et al., 2004]. The CDR is scored 
from zero to three and is presented in Table 8.1. 
 
 





Clinical Dementia Rating 
(CDR) Scale score 
Stage Description 
CDR-0 Normal - 
CDR-0.5 MCI Memory problems are slight but consistent; some 
difficulties with time and problem solving; daily life 
slightly impaired 
CDR-1 Mild Memory loss moderate, especially for recent events, 
and interferes with daily activities. Moderate difficulty 
with solving problems; cannot function independently 
at community affairs; difficulty with daily activities 
and hobbies, especially complex ones. 
CDR-2 Moderate More profound memory loss, only retaining highly 
learned material; disoriented with respect to time and 
place; lacking good judgment and difficulty handling 
problems; little or no independent function at home; 
can only do simple chores and has few interests. 
CDR-3 Severe Severe memory loss; not oriented with respect to time 
or place; no judgment or problem solving abilities; 
cannot participate in community affairs outside the 
home; requires help with all tasks of daily living and 
requires help with most personal care. Often 
incontinent. 
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Lawton-Brody Activities of Daily Living Scale 
The Lawton-Brody ADL scale is an established instrument for measuring 
instrumental and basic ADLs [Lawton & Brody, 1969]. It includes 14 subtests, scored 
from 14 to 65 points, with higher scores suggesting greater independence. Basic ADL 
include: the ability to toilet, feed themselves, dress, groom, bath and walk. 
Instrumental include the ability to shop, prepare food, perform housekeeping, laundry, 
arrange transportation, administer medication, use the telephone and manage 
finances). The scale can be self-reported or completed by an informant. It has high 
IRR (0.85) [Lawton & Brody, 1969]. 
 
Data Analysis 
Data from the DARAD database were analysed using SPSS, version 20.0 The 
Shapiro-Wilk test was used to test normality and found that most data were 
approximately symmetrical, having a small deviation from normality. The median and 
IQR were reported for skewed continuous data (age and SMMSE). This analysis 
included only those patients who had complete data. The correlations between the 
Qmci and the SADAS-cog, were calculated using the data collected at one, three, six, 
nine and twelve months. The original values were standardized, to remove within 
subject variations, and simple regression analyses were run to estimate correlation 
coefficients. To address the validity of the two instruments, the relationship between 
both the SADAS-cog and the Qmci and two other variables (Lawton-Brody ADL 
scale and CDR), were analysed using different analytic approaches.  Correlations 
were analysed at each time point, then for all time points together and finally for 
mean values across time.  Fishers Z test was used to determine differences in 
correlations between tests. To compare the responsiveness of the two instruments, at 
each time point, the standardized response mean (SRM), the mean score change 
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divided by the standard deviation of the score change using baseline as the initial 
score, were calculated for the SADAS-cog and Qmci. Paired-samples t-tests were 
performed to detect if a statistically significant difference existed in the SRM between 
the SADAS-cog and Qmci. 
 
8.3 Results 
Overall, 365 of the 406 patients who entered the DARAD study completed one year. 
Median age of the total population was 79 years, IQR 10. The median SMMSE score 
at baseline was 23, IQR 5. Over 90% were taking a cholinesterase inhibitor and 13%, 
the N-Methyl-D-Aspartate receptor antagonist, memantine.  In total, 360 patients had 
complete data for the Qmci and 363 for the SADAS-cog, 364 for the Lawton-Brody 
ADL scale and 360 for the CDR. 358 patients had complete data for the Qmci and 
SADAS-cog, at each time point, over the year. Correlation coefficients between the 
outcome measures along with their 95% CI, at each time point, at all time points and 
using mean values across time are reported in Table 8.1.The correlation coefficients 
demonstrated significant, strong correlation between the Qmci and the SADAS-cog, 
at each time point, r =-0.69 (95% CI, -0.62 to -0.78) p=<0.001, for the first month and 
-0.76, (95% CI, -0.70 to -0.83), p <0.001 for the last month. The data most closely 
correlated at nine months, r =-0.78, p <0.001. Each patient was included five times 
(corresponding to each time point) in the calculation, which would be expected to 
inflate the value of the correlation coefficient.  However, estimating correlations 
between measures overall, at all time points, pooled together, showed that the 
correlations between the SADAS-cog and Qmci remained strong and significant r = -
0.75 (95% CI, 0.72 to 0.78), p <0.001. Correlations increased to -0.8 using mean 
values across time.  
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Table 8.2.  Demonstrating correlation coefficients, with 95% Confidence Intervals 
(CI), between the Standardised Alzheimer`s Disease Assessment Scale-Cognitive 
section (SADAS-cog) and Quick Mild Cognitive Impairment (Qmci), Lawton-Brody 
Activities of Daily Living (ADL) scale and Clinical Dementia Rating scale (CDR) 
using different analysis methods. 
 
$
The relationship between the SADAS-cog and Qmci, and the other measures, Lawton-
Brody ADL scale and CDR, at each of the five time points, showed modest to strong, 
significant correlations. Correlations between the CDR and SADAS-cog (range from 
0.41 to 0.59) were stronger than between the Lawton-Brody ADL scale and SADAS-
cog (range from -0.31 to -0.49). Figure 8.1 provides the correlations between the 
SADAS-cog and Qmci, and between the Qmci and SADAS-cog and the other 
variables, Lawton-Brody ADL scale and CDR, at each time point.  Confidence 
intervals for correlations between the outcome measures at different time points 
overlap, indicating no difference between them. Fishers Z test confirmed that there 
was no statistically significant difference in correlations between the SADAS-cog and 
Qmci with either Lawton-Brody ADL scale, z=1.67, p =0.09 or CDR scores, z =-0.28, 
p= 0.78. Responsiveness of the SADAS-cog and Qmci, determined using the SRM, 
demonstrated that the mean change in SADAS-cog scores, between months one and 
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[95% CI]) 












Coefficient   
[95% CI]) 






at each time 
point 
1 -0.69  
[-0.62 to -0.76] 
-0.31 
[ -0.21 to -0.40] 
0.26  
[0.17 to 0.36] 
z = .66  
p = .51 
0.41  
[0.32 to 0.50] 
-0.38  
[-0.29 to -0.47] 
z = .44  
p = .66 
3 -0.75  
[-0.69 to -0.82] 
-0.41  
[-0.32 to -0.50] 
0.32  
[0.22 to 0.42] 
z = 1.39  
p = .17 
0.45  
[0.36 to 0.54] 
-0.48  
[-0.39 to -0.57] 
z = -.52  
p = .60 
6 -0.76  
[-0.69 to -0.83] 
-0.44  
[-0.34 to -0.53] 
0.34  
[0.24 to 0.44] 
z = 1.45  
p = .15 
0.56  
[0.48 to 0.65] 
-0.55  
[-0.46 to -0.64] 
z = .28  
p = .78 
9 -0.78  
[-0.71 to -0.85] 
-0.46  
[-0.36 to -0.56] 
0.39  
[0.29 to 0.49] 
z = 1.14  
p = .25 
0.59  
[0.50 to 0.68] 
-0.56  
[-0.46 to -0.65] 
z = .70  
p = .48 
12 -0.76  
[-0.70 to -0.83] 
-0.49  
[-0.40 to -0.58] 
0.45  
[0.36 to 0.55] 
z = .65  
p = .51 
0.57  
[0.49 to 0.66] 
-0.55  
[-0.46 to -0.64] 
z = .42  






 -0.75  
[-0.72 to -0.78] 
-0.42  
[-0.37 to -0.46] 
0.37  
[0.33 to 0.42] 
z = 1.67  
p = .09 
0.51  
[0.47 to 0.55] 
-0.52  
[-0.48 to -0.56] 
z = -.28  







[-0.74 to -0.86] 
-0.43  
[-0.34 to -0.52] 
0.38  
[0.29 to 0.47] 
z = .75  
p = .45 
0.54  
[0.46 to 0.62] 
-0.54  
[-0.46 to -0.62] 
z = -.02  
p = .98 
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deviation (SD) of 7.56.The estimated mean difference in scores, repeated for the 
Qmci, was 5.41 points, SD of 10.02 .Paired-samples t-test, showed there was no 
statistically significant difference in the SRMs for SADAS-cog and Qmci, t(357) =     
-0.32, p =0.75. This means that the change in Qmci scores are very similar to changes 
in SADAS-cog scores, between months one to twelve. There was a statistically 
significant increase in SADAS-cog scores, mean of 21.56, SD of 7.89 at month one, 
to a mean of 26.56, SD 12.01, at month twelve, t(362) = 12.60, p < 0.001. There was 
a statistically significant decrease in Qmci scores from month one, mean 38.58, SD = 
12.83, to month twelve, mean = 32.76, SD = 15.593, t(359) = -10.23, p <0.001. 
 
 
Figure 8.1.  Scatter plot depicting correlations between a) Standardised Alzheimer`s 
Disease Assessment Scale-Cognitive section (SADAS-cog) and Quick Mild 
Cognitive Impairment (Qmci), b) SADAS-cog and Lawton-Brody Activities of Daily 
Living (ADL) scale and c) SADAS-cog and Clinical Dementia Rating (CDR), at each 












Internal Consistency of the Qmci 
Internal consistency of the Qmci was assessed using Cronbach’s Alpha and by 
calculating the correlation between Qmci scores over time (five data points in the 
DARAD trial: Months 1,3,6,9 and 12). Internal consistency of the Qmci measure 
measured using Cronbach's Alpha for five data points was exceptionally strong α = 
0.95. Strong significant correlation was seen between the Qmci and itself over time, 
correlations ranging between r= 0.73 and 0.83. These are presented in Table 8.3. 
 
Table 8.3.  Correlation of a) the Standardised Alzheimer`s Disease Assessment Scale-
Cognitive section (SADAS-Cog) to itself and b) the Quick Mild Cognitive 
Impairment (Qmci) to itself, over each time point (1,3,6,9,12 months). 
 
a 
 (1) (2) (3) (4) 
(1) SADAS-cog at 1 month -    
(2) SADAS-cog at 3 months .86** -   
(3) SADAS-cog at 6 months .86** .89** -  
(4) SADAS-cog at 9 months .83** .88** .90** - 
(5) SADAS-cog at 12 months .79** .84** .87** .91** 
 
b 
 (1) (2) (3) (4) 
(1) Qmci at 1 month -    
(2) Qmci at 3 months 0.80** -   
(3) Qmci at 6 months 0.79** .83** -  
(4) Qmci at 9 months 0.77** 0.81** .83** - 
(5) Qmci at 12 months 0.73** 0.76** .78** .82** 
**. Correlation is significant at the 0.001 level 
 
8.4 Discussion 
This study compared the SADAS-cog to the Qmci, Lawton-Brody ADL scale and 
CDR, by comparing observations at multiple time points, from data collected in the 
DARAD trial, over one year. The SADAS-cog correlated closely with the Qmci, 
irrespective of the method of analysis.The SADAS-cog and ADL also correlated with 
both the Lawton-Brody ADL scale and CDR. The confidence intervals for correlation 
coefficient estimates for the Qmci and SADAS-cog and intervals for correlations 
between the SADAS-cog and ADL or CDR, did not overlap, indicating a significantly 
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stronger relationship between the Qmci and SADAS-cog than between the ADL or 
CDR and SADAS-cog and Qmci scores. In other words, the Qmci and SADAS-cog 
are better predictors of each other than of the other two measures (ADL and CDR). 
This is expected given that the SADAS-cog and Qmci are measures of cognitive 
function, although the SADAS-cog also correlated to functional status [Caro et al., 
2002]. Both the Qmci and the SADAS-cog are equally sensitive to change, and have 
similar responsiveness. Both had weak correlations with ADL, particularly at the 
outset. Correlation between the Qmci and the Lawton-Brody ADL scale was 
especially weak at month one (r=0.26) but improved towards moderate at one year. 
This weak correlation with ADLs at the entry point to the study was also found for the 
more detailed neuropsychological test, the ADAS-cog. This is not unexpected as ADL 
are a poor surrogate marker for cognitive scores and vice versa.  ADL strongly reflect 
the stage of cognitive impairment but can be confounded by medical conditions and 
physical disability. Cognitive screening instruments such as the Qmci, like more 
detailed neuropsychological testing, are often confounded by baseline IQ, age and 
education. The CDR, a global marker of dementia incorporating function and 
cognition, had weak correlation to the Qmci, which again became moderate as the 
study progressed. There was no statistically significant difference with the SADAS-
cog showing that the performance of both the longer neuropsychological battery and 
short screening instrument were similar. The reasons for the improvement in the 
correlation coefficients over time are unclear. It might reflect improved inter-rater or 
test-re-test reliability as the study progressed, a therapeutic effect or convergence as 
cognitive function and ADL function declined over time. It may also reflect the poor 
content validity of the Lawton-Brody ADL scale. The strength of this paper lies in its 
methodology. Correlation between the SADAS-cog and each of the measures was 
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demonstrated using different statistical methods. Each consistently confirmed strong 
correlation between the SADAS-cog and Qmci and moderate to strong correlation 
between the SADAS-cog and Qmci, Lawton-Brody ADL scale and CDR. The 
correlations demonstrated at each of the five time points, were similar to the pooled 
correlation coefficients. Another strength, is that this data, a post hoc analysis of the 
DARAD trial database, represents the “real life” performance of the Qmci, compared 
to the accepted standard, in a previously conducted, multi-centre, blinded, randomised 
control trial.  Given that a four-point change at six months in the ADAS or SADAS-
cog is widely recognised as a clinically significant difference [Matthews et al., 
2000],[Aisen et al., 2003], the similar responsiveness of the Qmci and SADAS-cog 
suggests that a comparable change in the Qmci is equivalent to a significant change in 
the SADAS-cog. Given that the Qmci is shorter and easier to score, this data supports 
the use of the Qmci as an alternative to the SADAS-cog in clinical trials. While a 
small change and only relevant if associated with clinical improvement, it is required 
by the Food and Drug Administration in the United States before a drug can be 
licensed in dementia. 
 This study has several limitations. Although a four-point change in the 
SADAS-cog is traditionally accepted as significant, it is not an ideal test. Comparing 
the Qmci to the SADAS-cog only suggests that the Qmci has similar sensitivity and 
responsiveness, not that it is a “gold standard”. Although useful, the Qmci is less 
comprehensive than the SADAS-cog and not all neuropsychological domains are 
accounted for. That said, in contrast to the SADAS-cog the Qmci is shorter and easier 
to apply, covering many relevant cognitive domains including orientation, working 
memory, visuospatial, executive function, semantic memory and episodic memory. In 
contrast, the SADAS-cog is overly long and heavily weighted towards language. The 
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SADAS-cog, because of ceiling effects, is less responsive to detecting MCI [Skinner 
et al., 2012], possibly limiting its usefulness. The Qmci, in contrast, is accurate at 
differentiating MCI from normal cognition and dementia [O’Caoimh et al., 2012] 
suggesting that where this is the outcome measure of interest the Qmci could be used 
in preference. The ADL measure used in this study, the Lawton-Brody ADL scale, 
has limitations. Although it is widely validated, it measures instrumental ADLs and 
like any measure of ADL is self-reported, potentially over or under-estimating 
functional impairment and is not a recognised standard for measuring ADLs. This 
said, no gold standard of measure of ADL is available. 
 In summary, the ADAS-cog and its standardised form the SADAS-cog, are 
valid, reliable and widely used cognitive measures in clinical trials [Rockwood et al., 
2006],[$Molloy et al., 2012],[Chen et al., 2011],[Sano et al., 2011]. They have been 
validated internationally from Iceland [Hannesdóttir et al., 2002] to Turkey [Mavioglu 
et al., 2006] and Hong-Kong [Chu et al., 2000] and despite flaws, remain the standard. 
This data demonstrates that the Qmci correlates strongly, significantly and 
correspondingly over time to the SADAS-cog and that both are equally sensitive with 
similar responsiveness to deterioration over time. Although the correlation with each 
other was stronger, the SADAS-cog and Qmci had moderate to strong correlations 
with both functional (Lawton-Brody ADL scale) and global assessments (CDR), 
confirming their utility in clinical practice as well as in drug trials. Although further 
external validation of the instrument in other clinical settings, trials and languages is 
required, this study provides a rationale for using the shorter Qmci, as a cognitive 
outcome measure in clinical drug trials, particularly where differentiating MCI from 





Clinical utility of the Qmci outside of a memory clinic; 




The prevalence of movement disorders is also increasing as society ages with the 
number of persons with PD worldwide expected to nearly double by 2030 [Tanner 
2013]. The most prevalent movement disorder worldwide is PD [Dorsey et al., 2007]. 
With this will come an increase in the prevalence of cognitive impairment associated 
with PD. Cognitive impairment is common in PD and is the most common non-motor 
symptom of PD [Sitek et al., 2014]. Prevalence rates approach 80% [Aarsland et al., 
2003], while the lifetime incidence of PDD lies between 40% and 100% [Aarsland et 
al., 2003]. Many patients with PD have CI from the time of diagnosis. PD with mild 
cognitive impairment (PD-MCI) is common [Litvan et al., 2011] and is associated 
with an increased chance of developing dementia, particularly when already present at 
diagnosis [Pederson et al., 2013].  
 Cognitive impairment impacts upon life expectancy [Marder et al., 1991], 
quality of life [Schrag et al., 2000], and ADL even among those without PDD 
[Aarsland et al., 2003]. Early diagnosis of cognitive decline is important to facilitate 
prompt treatment, identify reversible or compounding factors and plan for the future 
[Boise et al., 1999]. Monitoring change over time is important and screening with 
short cognitive instruments and repeated neuropsychological testing [Pederson et al., 
2013] is recommended to increase prognostic accuracy, particularly conversion from 
PD-MCI to PDD. PD-MCI in particular is challenging to diagnose. It differs from 
MCI associated with Alzheimers disease [Caviness et al., 2007] and typically presents 
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with exaggerated attention and executive function deficits [Petrova et al., 2010]. 
Other movement disorders such as LBD [Molano et al., 2010],[Ferman et al., 2013] 
and vascular PD [APA 2013] are also associated with a MCI phase, that differs from 
those seen in other neuro-degenerative disorders. 
 
The MMSE [Folstein et al., 1975] and its standardised form, the SMMSE [Molloy et 
al., 1997], is widely used in the detection of cognitive impairment associated with PD 
[Lyness et al., 2014]. The MoCA [Nasreddine et al., 2005] has been recommended, by 
the Movement Disorder Society, as the cognitive screen of choice in PD [Emre et al., 
2007],[Barton et al., 2012].  The MoCA is more sensitive than the MMSE for 
detecting mild cognitive deficits in PD [Gill et al., 2008] and has several advantages 
over the MMSE. The MoCA lacks a ceiling effect [Zadikoff et al., 2008] making it 
more useful in younger and more educated subjects and it is weighted more towards 
attention, visospatial and executive functioning and less towards orientation and 
language, which are relatively well preserved in PD [Petrova et al., 2010],[Caviness et 
al., 2007]. Despite these advantages some challenges remain with using the MoCA in 
routine clinical practice as described above in Chapter 7. In particular, it takes time 
(10-12 mins), it is has low specifcity [McLennan et al., 2011] and a high false positive 
rate in older adults at its recommended cut-off score (≥26 for normal cognition). 
Given this we sought to investigate if the Qmci screen, designed to detect MCI and 
validated in patients without PD, could be used to detect cognitive impairment in a 
movement disorder clinic and how it compared to two of the most widely used 






Patients, referred to a university hospital movement disorder clinic were classified as 
having normal cognition, MCI or dementia by a consultant physician, specialised in 
the diagnosis and management of cognitive impairment associated with movement 
disorders. A diagnosis of PD-MCI was made by a consultant geriatrician using level I 
diagnostic criteria according to the Movement Disorder Society Task Force 
Guidelines [Litvan et al., 2012], defined as recent, subjective but corroborated 
memory loss without obvious loss of social or occupational function, with evidence of 
deficits on a global cognitive scale: the Unified Parkinson's Disease Rating Scale 
(UPDRS) part I, in those with established PD. A diagnosis of LBD-MCI was made 
using the third report of the LBD Consortium [McKeith et al., 2005]. Subjects were 
excluded if they were under 55 years of age, unable to communicate verbally in 
English, if they had active depression, diagnosed clinically and supported by the 
GDS-Short Form, using a cut-off greater than seven to increase specificity [Marc et 
al., 2008], or if a reliable collateral was not available. The GDS Short Form, scored 
out of 15 points, is validated in older adults with PD [Weintraub et al., 2006] and has 
been used in other movement disorders including LBD [Kao et al., 2009]. Patients 
presenting with essential tremor (n=3) were also excluded. 
 
Data Collection 
Patients attending a movement disorder clinic in Cork City, Ireland, between July 
2013 and July 2014 underwent comprehensive clinical assessment and were screened 
for cognitive impairment. An attempt was made to screen patients consecutively but 
because of time restraints and practical reasons sampling was by convenience. The 
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Qmci and MoCA were scored in random order, by two trained raters, prior to the 
clinic and blind to the diagnosis, one of whom was a trained Parkinson’s nurse 
specialist. The SMMSE is collected routinely by clinic nursing staff. The presence 
and severity of any extrapyramidal symptoms were graded using the motor 
component of the UPDRS. All patients provided verbal consent; assent was obtained 
from individuals who were felt to lack capacity. Diagnosis was made by the attending 
consultant Geriatrician, Dr Suzanne Timmons using clinical history and examination, 
supported by the UPDRS. 
 
Measures 
The MoCA and Qmci were compared in this study. The Qmci was used with an initial 
cut-off score of <62 as described above in Chapter 5. A score of <26 was used as the 
MoCA cut-off for cognitive impairment [Nasreddine et al., 2005]. The severity of PD 
was determined using the UPDRS [Fahn et al., 1987]. The UPDRS total score 
consists of the sum of parts I (mentation, behaviour and mood), II (ADL) and III 
(motor examination), with scores ranging from 0 (not affected) to 176 (most severey 
affected). A score of one or more on item one (intellectual impairment) of part I was 
taken as suggestive of cognitive impairment. Type of medications including the use of 




Accuracy was determined from analysis of the AUC generated by receiver ROC 
curves. Sensitivity, specificity, PPV and NPV were also determined. The majority of 
the data were non-parametric. The Mann –Whitney U test compared two variables; 




In total, 84 paired assessments (from 66 individual patients) were available. The 
majority of patients had PD (n=57); nine had LBD. The characteristics of patients 
including their time since diagnosis, UPDRS scores and cognitive screen scores are 
presented in Table 9.1. The median age of patients was 75 years and there were no 
significant differences in ages profile between those with normal cognition, MCI or 
dementia, z =5.1, p =0.08. Patients with normal cognition reported having spent more 
time in education than those with MCI or dementia. Where available, median time 
since diagnosis of a movement disorder (predominantly PD) was 7.5 years +/-8. 
Patients with MCI and dementia had similar disease duration, (median 9.5 years, z =-
0.2, p = 0.86). As would be expected patients with dementia had greater median 
UPDRS total scores though no difference in scores were found for those with MCI or 
normal cognition (median 36). The median Qmci score for those with normal 
cognition was 70 +/-8 compared with a median of 55 +/-7 for those with MCI and a 
median of 36 +/-17 for patients diagnosed with dementia. There was only a small 
difference in median MoCA scores between normals and those with MCI, 23 versus 
22 respectively, although this was statistically significantly different, z =-3.1, p 
=0.002. A statistically significant difference was also found for the Qmci, z =-4.7, p 
<0.001.  Twelve patients were receiving an anti-cholinergic and only 11/29 





Table 9.1. Characteristics of patients with normal cognition, mild cognitive impairment (MCI) and dementia, recruited from the movement 
disorder clinic including demographics, Unified Parkinson’s Disease Rating Scale (UPDRS), Standardised Mini-Mental State Examination 






















































































































































































































ROC curves showing the accuracy of the Qmci and MoCA are presented in Figure 
9.1. The Qmci had similar accuracy to the MoCA in differentiating MCI from SMC 
and dementia, with no statistically significant differences between either screen found 
in this sample. Examining the sensitivity and specificity of both instruments suggests 
that the best balance for the Qmci was produced at a cut-off score less than 60 (i.e. 
<61). At this cut-off its sensitivity was 94% and specificity 95%. At the cut-off 
presented in chapter 5, <62, the sensitivity was 94% and specificity 90%. The 
established MoCA cut-off score for cognitive impairment (<26) produced high 
sensitivity (97%) but markedly low specificity (30%). A cut-off of <23 provided the 
optimal balance for the MoCA (sensitivity of 88%, specificity of 70%). Sensitivities 
and specificities for a range of MoCA and Qmci cut-offs are presented in Table 9.2. 
The median administration time for the Qmci was 5.17 mins compared to 9.24 mins 


























Figure 9.1. Receiver Operating Characteristic curves demonstrating the accuracy of 
the Quick Mild Cognitive Impairment (Qmci) screen and Montreal Cognitive 
Assessment (MoCA) in differentiating patients with movement disorders (Parkinson’s 
disease and Lewy Body Dementia) with (a) mild cognitive impairment (MCI) from 
normal cognition, (b) MCI and dementia, (c) normal from cognitive impairment (MCI 
and dementia), (d) Dementia from everything else. 
 
 
a.     b. 
 














Figure MoCA Qmci Comparison 
Area Under the Curve 
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Table 9.2. Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative 
Predictive Value (NPV), with 95% confidence intervals (CI), for different Quick Mild 
Cognitive Impairment (Qmci) screen and Montreal Cognitive Assessment (MoCA) 
cut-off scores for cognitive impairment (mild cognitive impairment and dementia) 
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Figure 9.2 presents ROC curves for the Qmci subtests; Figure 9.3 presents the curves 
for the MoCA subtests. The results suggest that the most accurate Qmci subtest for 
differentiating MCI from normal cognition is LM (AUC 0.90), while the most 
accurate MoCA subtest were the visuospatial tasks (AUC 0.79). The DR (five word 
recall) subtests were both poor in separating those with MCI form normal cognition 
was poor ( AUC 0.62 for the Qmci and 0.56 for the MoCA). Orientation was the best 
subtest for both instrument for differentiating MCI from dementia (AUC 0.82 for the 
Qmci and 0.84 for the MoCA). LM was less able to separate MCI from dementia in 
this population (AUC 0.66). Good to excellent accuracy for both instruments subtests 
were found for the ability to distinguish cognitive impairment (MCI and dementia) 
from normal and dementia from normal and MCI. ROC curves for patients with PD, 






















Figure 9.2. Receiver Operating Characteristic curves demonstrating the accuracy of 
the Quick Mild Cognitive Impairment (Qmci) screen subtests in differentiating 
patients with movement disorders (Parkinson’s disease and Lewy Body Dementia) 
with (a) mild cognitive impairment (MCI) from normal cognition, (b) MCI and 
dementia, (c) normal from cognitive impairment (MCI and dementia), (d) Dementia 
from everything else. 
 
 
a.       b. 
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Figure 9.3. Receiver Operating Characteristic curves demonstrating the accuracy of 
the Montreal Cognitive Assessment (MoCA) subtests in differentiating patients with 
movement disorders (Parkinson’s disease and Lewy Body Dementia) with (a) mild 
cognitive impairment (MCI) from normal cognition, (b) MCI and dementia, (c) 
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Figure 9.4. Receiver Operating Characteristic curves demonstrating the accuracy of 
the Quick Mild Cognitive Impairment (Qmci) screen and Montreal Cognitive 
Assessment (MoCA) in differentiating patients with Parkinson’s disease only with (a) 
mild cognitive impairment (MCI) from normal cognition, (b) MCI and dementia, (c) 
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9.4 Discussion  
This study compares two short cognitive screening instruments, the Qmci and the 
MoCA, in their ability to differentiate normal cognition from MCI and dementia in a 
sample of patients attending a movement disorder clinic. It shows that the Qmci had 
greater accuracy than the MoCA in differentiating normal cognition from MCI, 
although this did not reach statistical significance. Both instruments had similar 
accuracy in detecting dementia. The study also explores the accuracy of both 
instruments’ subtests and shows that visiospatial tasks and LM were the most useful 
in separating those with normal cognition from MCI. It also shows that orientation is 
the most accurate for identifying dementia.  
 A cut-off score of <61 for the presence of cognitive impairment for the Qmci 
provided the balance between sensitivity (94%) and specificity (95%). This cut-off is 
similar to that seen in the pooled Canadian database, presented in Chapter 5 and the 
external validation of the Qmci against the MoCA in Chapter 7. This study also 
reaffirms that the traditional MoCA cut-off of <26 is unsuitable in older adults 
including those attending a movement disorder clinic. At this widely used cut-off the 
MoCA had excellent sensitivity (97%) but a very poor specificity of 30%. Again, a 
lower cut-off, in this case <23, produced a better balance (sensitivity of 88% and 
specificity of 70%) though the specificity remained relatively low. This MoCA cut-
off is the same as that seen in patients attending the memory clinic presented in 
Chapter 7. Further, the established cut-off produced a very high level of false positive 
results (18%), which reduced to 10% with a cut-off of <23, suggesting that the MoCA 
would be less useful in screening patients with movement disorders in general 
practice.  
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This study also shows that a relatively high proportion of this sample were currently 
receiving anti-cholingeric medications and few with dementia were treated with 
cholinesterase inhibitors. Though this study was not designed to examine the reasons 
for this, it suggests that poor recognition of cognitive status may lead to inappropriate 
prescribing. Given that even short term exposure to mild anti-cholinergics is 
associated with an increased incidence of MCI [Cai et al., 2012], this raises concern 
that inadequate screening and submaximal identification of those with cognitive 
impairment could result in an occult deterioration in cognition. Given that the 
presence of PD-MCI at diagnosis is highly predictive of early dementia [Pederson et 
al., 2013], patients with early cognitive impairment, including those with SMC but 
normal cognition should be monitored closely and re-screened at a suitable interval. 
As the median time since diagnosis of movement disorder for the total in this study 
was 7.5 years (IQR +/-8) and that the mean time from PD onset to PDD (the main 
movement disorder subtype in this study) is approximately 10 years [Aarsland et al., 
2007], this may explain the high prevelance of cognitive impairment found in this 
sample. However, this study was not a prevalence study and although attempts to 
sample patients consecutively were made, no inference on prevalence can be drawn. 
The study also showed that the prevalence of cholinesterase inhibitor prescription in 
those with dementia was low. 
 The SMMSE, although not used as an outcome measure in this study, was less 
accurate than both the MoCA & Qmci in differentiating both normal cognition & 
dementia from MCI. The SMMSE, because of its low ceiling effect and selected 
cognitive domains, misses cognitive deficits in these patients. Given the high 
prevalence of cognitive impairment in patients with movement disorders a balance 
between sensitivity and specificity is required where specificity is also important. A 
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strength of this study is that patients with normal cognition, MCI and dementia were 
well matched.  
 
Limitations  
This study has a number of limitations. The diagnosis of PD-MCI remains 
contentious. In this study the diagnosis was made clinically in conjunction with the 
cognitive component of the UPDRS-cog, which while not a gold standard, is widely 
used to register cognitive impairment in patients with movement disorders. Despite 
this, it is not possible to confirm duration of movement disorders and this information 
was not available for all patients creating potential bias. Furthermore, the diagnosis of 
PD-MCI was sometimes based on a single cognitive assessment score which may 
have reduced accuracy. That said, it is argued that where clinical findings are 
consistent with screening scores, multiple repeated and or neuropsychological 
assessment may not be required [Sitek et al., 2014]. Likewise, the diagnosis of LBD 
including LBD-MCI is also poorly defined [Huang & Halliday, 2013]. That said, the 
study uses recognised criteria advocated by the Movement Disorder Society. Another 
limitation of this study is that there was again a high prevalence (76%) of cognitive 
impairment in the sample, in keeping with a sample of predominantly older adults 
with complex needs attending a movement disorder clinic under the care of a 
consultant geriatrician. Thus, the main benefit of using a short cognitive screen such 
as the Qmci, with its brief administration time (almost half that of the MoCA) may be 
in its ability to flag up subtle changes in cognition in high risk patietns like those with 
a known movement disorder. Finally, the sample size was again small, limiting the 
ability to say that one instrument was definitely more accurate than another in 
differentiating MCI from normal cognition. Likewise, not all patients were re-
reviewed in this study. However, this study was not a longitudinal follow-up study 
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and patients that had a clear diagnosis of dementia at first assessment or who were 
under follow-up with an already established diagnosis of dementia, were only 
assessed and included once. Future studies, comparing the Qmci and MoCA in this 
subgroup of patients, require larger numbers to confirm superiority. 
 In summary, cognitive impairment is common among patients attending the 
movement disorder clinic and may be overlooked using commonly used but less 
accurate instruments like the MMSE and SMMSE. Failure to recognise cognitive 
impairment in a movement disorder clinic may result in failed opportunities to initiate 
early appropriate treatment and discontinue inappropriate medications like anti-
cholinergics. As clinic is busy and cognitive impairment is not the sole focus of these 
appointments, unlike memory clinics, there is a need for brief and accurate screening 
instruments for use in this subpopulation of older patients. The results show that the 
Qmci had a better balance between sensitivity and specificity at their optimal cut-off 
scores (<61 for the Qmci and <23 for the MoCA) although no statistically significant 
difference in accuracy as determined by ROC curve analysis was found. This study 
suggests that the Qmci may be the more useful test particularly given its shorter 
administration time though further research is required to confirm this. The study also 
demonstrates that different cognitive domains are useful where there is suspicion for 
MCI or dementia confirming that a battery of subtests are required to allow 








Reliability and validity of the Qmci in General Practice  
 
10.1 Introduction 
Establishing the presence of cognitive impairment in general practice is challenging 
and there is evidence that it often goes unrecognized [Brodaty et al., 1998], [Valcour 
et al., 2000],[ Boustani et al., 2005], with more than half of patients diagnosed outside 
of GP surgeries [Knopman 2006]. The diagnosis of MCI, because it represents a 
heterogeneous group of memory disorders [Petersen et al., 2004] with subtle, 
cognitive changes and variable progression rates [Mitchell et al., 2009], is particularly 
difficult to diagnose in general practice [Kaduszkiewicz et al., 2010]. Distinguishing 
MCI is important as treatment choices and prognosis differ [Peterson 2005],[Tricco et 
al., 2013]. Specific barriers to GPs include poor recognition and response to 
symptoms of MCI and dementia [O’Connor 1996], perceived lack of benefit [Boise et 
al., 1999], patient and caregiver stigma [lliffe et al., 2003],[lliffe et al., 2005], and 
limited time, financial, and human resources [Boustani et al., 2003]. Compounding 
this, although patients and their caregivers are often open to early diagnosis [Luck et 
al., 2012], they frequently do not recognise or report cognitive difficulties [Watson et 
al., 2005]. As cognitive screening takes approximately 20 minutes per patient 
[Boustani et al., 2003], time in particular, constrains the use of formal 
neuropsychological testing, necessitating the use of short cognitive screens or 
informant questionnaires.  
 At present community screening for cognitive impairment is not 
recommended [Lin et al., 2013] and few screening programmes have been trialed in 
general practice [Boustani et al., 2005]. A major reason for this is the lack of suitable 
screening instruments [Winblad et al., 2004], [Boustani et al., 2005]. Features of 
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acceptable cognitive screens, for use in GP surgeries include brevity, ease of 
administration and sufficient sensitivity and specificity to differentiate between 
normal cognition, MCI and dementia. Sensitivity is particularly important in primary 
care to avoid false negatives. Although several cognitive screens are available, 
including those designed specifically for GPs, the most commonly used tests remain 
the abreviated mental test score and the MMSE [Ismail et al., 2010]. The GPCOG 
[Brodaty et al., 2002], Mini-cog [Borson et al., 2000], and Memory Impairment 
Screen are all recommended for use in primary care to screen for dementia [Brodaty 
et al., 2006]. While the MoCA is gaining acceptance as a cognitive screen of choice in 
multiple settings [Nasreddine et al., 2005], it does not appear to be validated in 
general practice. The GPCOG, described in Chapter 2 and presented in Appendix 2.3 
is designed specifically for use by GPs, is short (5-6 mins) and acceptible to patients 
and physicians alike [Brodaty et al., 2002]. The GPCOG, which has a sensitivity of 
85%, specificity of 86%, a misclassification rate of 14%, and a PPV of 71.4% 
[Brodaty et al 2006] has not been validated in MCI. It is also critised for having age 
and educational bias [Cullen et al., 2007],[Brodaty et al., 2004]. Given the brevity, 
accuracy and ease of use so far demonstrated in this PhD, the utility of the Qmci 
screen, including IRR and concurrent validity against the MoCA and GPCOG, was 




Consecutive patients attending two large GP surgeries in Co Cork: Mallow Primary 
Healthcare Centre (MPHC) and Elmwood Medical Centre, Douglas, Cork City, were 
invited to participate in cognitive screening. Subjects were included if they 
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complained of symptomatic memory loss, were aged > 55 and were fluent in English. 
Subjects with active depression, screened using the 15-point GDS Short Form 
[Yesavage 1988] (score of seven or more), were excluded.  
 
Data Collection 
All subjects underwent a comprehensive clinical assessment including evaluation of 
baseline demographics (age, gender, number of years in education) and 
cardiovascular risk factors. Where a collateral history was possible, informant 
screening was performed using both the IQCODE-SF [Jorm 1994] and AD8 [Galvin 
et al., 2005], in person or by telephone. Each subject had the Qmci, MoCA and 
GPCOG administered sequentially, but randomly by two trained raters, who were 
blind to the eventual diagnosis. All subjects were subsequently reviewed by a 
consultant physician, specialised in the diagnosis of cognitive impairment, and 
diagnosed with either MCI, dementia or SMC but normal cognition. An “outreach” 
memory clinic was created in MPHC for the purposes of this study. A diagnosis of 
MCI was based upon a history of subjective and corroborated memory loss, without 
loss of social or occupational function using the results of an SMMSE and the 
informant reports to form the diagnosis. Dementia was diagnosed using DSM-IV-R 
criteria [APA 2000]. Persons with SMC but normal cognition were also included. 
These underwent the same work-up. Ethical approval was obtained and all subjects 
provided informed verbal consent. Assent was obtained from individuals with 





Qmci inter-rater reliability in general practice 
GPs were trained prior to the study on how to score the Qmci. Training involved a 
lecture on the Qmci. In addition, the Qmci has been filmed by the Health Service 
Executive for training and teaching purposes and was made available to all GP raters. 
Qmci IRR, between the GP and Memory clinic trained raters, was shown by 
comparing the results of the Qmci scored by the GP with the repeat in the memory 
clinic (n =57). Six were reviewed in clinic more than one month after the initial 
scoring by the GP and were therefore not included in the IRR analysis. 
 
Analysis 
Analyses were conducted using SPSS 20.0. The Shapiro–Wilk test was used to test 
normality and found most of the data were non-parametric. Simple descriptive 
statistics were performed. Data were also analysed using ROC curves.  
 
10.3 Results 
In all, 63 patients (31 normals with SMC, 16 with MCI and 16 with dementia) were 
screened. Only 57% (n=36) of patients were accompanied by a caregiver or provided 
contact details for a collateral history, reducing the number of AD8 or IQCODE-SF 
scores that could be completed. Characteristics of patients included in this study are 
presented in Table 10.1. Pearson’s correlation coefficient showed good IRR between 
the trained GPs and the clinic assessment, r =0.89, for the 57 subjects included in the 
IRR analysis. The median age of all patients was 73 years, (IQR +/-17). Patients with 
SMC were significantly younger than those with MCI or dementia, p <0.001. Median 
Qmci, MoCA and GPCOG scores were 60/100 (+/-24), 22/30 (+/-8) and 8/9 (+/-5) 
respectively. Figure 10.1 presents ROC curves comparing the Qmci, MoCA and 
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GPCOG in their ability (accuracy) to distinguish SMC from MCI and dementia. The 
Qmci was more accurate than the MoCA or GPCOG in differentiating MCI from 
those with SMC but normal cognition, AUC of 0.91 versus 0.85 and 0.65 
respectively. There was no statistically significant difference in the accuracy of the 
Qmci and MoCA (p=0.46) in differentiating MCI from SMC. The Qmci (p=0.01) but 
not the MoCA (p=0.06) was significantly more accurate than the GPCOG. All had 
similar accuracy in differentiating those with SMC from those with cognitive 
impairment, AUC of 0.95 versus 0.92 and 0.80. The GPCOG classified 34% of 
patients as having cognitive impairment (including 93% of those with dementia) with 
only 3.6% of patients with SMC but normal cognition misclassified.  
 Median administration time was 4.4 (5-4= +/-1) minutes for the Qmci 



























Figure 10.1. Receiver Operating Characteristic curves demonstrating the accuracy of 
the Quick Mild Cognitive Impairment (Qmci) screen and Montreal Cognitive 
Assessment (MoCA) and the General Practitioner Assessment of Cognition (GPCOG) 
in differentiating patients attending general practice with (a) mild cognitive 
impairment (MCI) from subjective memory complaints (SMC) but normal cognition, 
(b) MCI and dementia, (c) SMC from cognitive impairment (MCI and dementia), (d) 
Dementia from everything else. 
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Table 10.1. Characteristics of patients reviewed in General Practice including AD8, 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), 
Standardised Mini-Mental State Examination (SMMSE), Quick Mild Cognitive 
Impairment (Qmci) screen, Montreal Cognitive Assessment (MoCA) and General 








This study presents a comparison between the commonly used SMMSE, the primary 
care specific GPCOG and the Qmci. It shows that the Qmci was statistically 
significantly more accurate in differentiating patients presenting to general practice 
with SMC from those with MCI. The GPCOG had poor accuracy (AUC 0.65) in MCI 
and was significantly less able to distinguish MCI from SMC compared with the 
Qmci and MoCA. The study also shows that that all three instruments had statistically 
similar accuracy in identifying cognitive impairment (either MCI or dementia) and 
dementia (from MCI or SMC). All three instruments had a median administration 
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time less than 10 minutes with the GPCOG and Qmci having median times less than 5 
minutes. The Qmci had excellent IRR. This study provides further evidence that the 
Qmci is an accurate instrument in identifying impairment across the cognitive 
spectrum (O’Caoimh et al., 2012) and confirms that it has comparable accuracy but is 
shorter than the MoCA (O’Caoimh et al., 2013). To our knowledge this is the first 
study validating the MoCA in general practice. Again, this study shows that while 
accurate, its administration time is longer than other short screens potentially limiting 
its use in busy general practice clinics.    
 The strengths of the study include the detailed assessment and work-up for 
cognitive impairment. Limitations include the small number of participants, 
underpowering the study to show superiority of one instrument over another and 
limiting this study to a non-inferiority study.                                                         
 Although evidence for  routine screening for cognitive impairment is lacking, 
there is increasing opinion that early recognition of symptomatic individuals benefits 
patients, relatives and services alike [Iliffe et al., 2003],[Clionsky 2014]. Due to time 
and other constraints, short accurate screening instruments, that are easy to interpret 
and administer, are required in general practice. The brevity of the Qmci compared 
with the MoCA and its higher accuracy in MCI over the GPCOG suggest that it may 
represent the ideal brief screen in general practice, able to screen across the cognitive 














Cognitive impairment is frequently under-diagnosed among patients in rehabilitation 
units [Ruchinskas & Curyto, 2003]. The Irish National Audit of Dementia (INAD) 
2013 [http://www.ucc.ie/en/inad/], [ de Siún et al 2014] investigated the management 
of dementia in acute hospital settings in Ireland and found that only 43% of patients 
with dementia had a standardised cognitive test recorded and only 14% of patients 
with dementia had their level of cognitive impairment summarised and recorded at 
discharge [de Siún et al 2014]. The INAD found that the average length of stay for a 
person with dementia admitted from and discharged to their home was 22 days with 
this figure increasing to 59 days for discharge to nursing home care [de Siún et al 
2014]. Cognitive impairment adversely affects the quality of rehabilitation, 
lengthening the rehabilitation stay [Wang et al., 2002] and increasing risk of adverse 
outcomes, mortality and institutionalisation [Poynter et al., 2011]. The MoCA is more 
sensitive and specific than the MMSE in a geriatric rehabilitation setting [Sweet et al., 
2011]. 
 Given that few studies have investigated the utility of different short cognitive 
screening instruments in this population of older adults, this study compared the 
SMMSE, MoCA and Qmci screen in their ability to differentiate cognitive 
impairment from normal cognition in a general older adult rehabilitation unit in St 
Finbarrs Hospital, Cork City. 
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11.2 Methods  
Consecutive stable inpatients, newly admitted to a university hospital rehabilitation 
unit, were screened for cognitive impairment. The unit comprises a male and female 
general rehabilitation and a mixed 15 bed stroke rehabilitation unit. A diagnosis of 
cognitive impairment (MCI or dementia) was determined independently by multi-
disciplinary team assessment. The team was asked to confirm whether patients were 
cognitively impaired or not based on usual practice (using the SMMSE and MoCA as 
screens and the Rowland Universal Dementia Assessment Scale to confirm the 
diagnosis). This diagnosis was made independently of the trained raters who scored 
three short cognitive screens (SMMSE, Qmci and MoCA), blinded to the decision and 
to the patients’ medical notes. Patients who were medically unstable, screened 
positive for depression using the GDS Short Form, or who were unable to 
communicate verbally due to dysphasia were excluded. This was confirmed after 
discussion with the Clinical Nurse Manager for the unit and the multi-disciplinary 
team. Descriptive statistics were performed and accuracy was determined from the 
AUC of ROC curves. IRR was measured using Pearson’s correlation coefficient. 
Additional data were collected as part of a medical students (Brian Daly) final year 
project and these results are currently in preparation for publication but are not 
included in this PhD.  
 
11.3 Results 
In total, 32 patients were assessed, of which 30 were included: 13 with NC and 17 
with cognitive impairment. In all, 9/30 (30%) were post stroke. Two patients were 
excluded because of dysphasia. IRR was tested a median of four days following the 
initial assessment for a small sample (n=13), r =0.77. Characteristics of inpatients 
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included in this analysis are presented in Table 11.1. The median age of patients was 
81.5 (IQR ±9.75) years; 18 (60 %) were female. The median SMMSE score for those 
with normal cognition was 27 (±4), compared to 22 (±7.5) for the MoCA and 61 for 
the Qmci. Median scores for cognitive impairment for the SMMSE, MoCA and Qmci 
were 19 (±7), 12 (±4.75) and 35 (±18) respectively. ROC curves demonstrating the 
accuracy of the Qmci, MoCA & SMMSE and the Qmci subtests, in differentiating 
cognitive impairment from normal cognition, are presented in Figure 11.1.  
  The Qmci and MoCA had similar accuracy in differentiating cognition 
impairment from normal (AUC of 0.93, 95% CI:!0.84-1.00 for the Qmci and 0.92, 
95% CI:!0.83-1.00 for the MoCA). Both were greater than the SMMSE (AUC of 0.88, 
95% CI:! 0.75-1.00) although this was not a statistically significant difference for 
either (p >0.05). The most accurate Qmci subtest was DR (AUC 0.95) followed by 
VF (AUC 0.87) and LM (AUC 0.83). All subtest CI overlapped suggesting that there 
is no statistically significant difference between them. Median administration times 
for the SMMSE, MoCA and Qmci were 5 min, 11 s (±1 min, 35s), 8min, 37s (±1 min, 
27s) and 4 min, 25s (± 50 seconds) respectively. 
 
Table 11.1. Characteristics of rehabilitation inpatients including their median and 
interquartile (IQR) Quick Mild Cognitive Impairment (Qmci) screen, Montreal 
Cognitive Assessment (MoCA) and Standardised Mini-Mental State Examination 





Figure 11.1 Receiver Operating Characteristic curves demonstrating the accuracy as 
measured by the area under the curve (AUC) of the Quick Mild Cognitive Impairment 
(Qmci) and Standardised Mini-Mental State Examination (SMMSE) a) total scores 




























Orientation 0.82 0.66-0.98 
Registration 0.70 0.51-0.89 
Clock  0.77 0.60-0.95 
Recall 0.95 0.87-1.00 
Verbal Fluency 0.87 0.74-1.00 
Logical Memory 0.83 0.68-0.93 
! 184!
11.4 Discussion 
This small pilot study shows the accuracy of the Qmci in a stable inpatient 
rehabilitation population compared to two commonly used instruments in geriatric 
rehabilitation units, the MoCA and SMMSE. The results suggest that all three 
instruments are useful (accurate) but that the Qmci has a shorter administration time. 
As shown in other studies in this PhD, the median score for normal cognition for the 
MoCA was below its established cut-off for cognitive impairment (<26), suggesting 
that it is less useful in clinical practice. The study showed that the most accurate Qmci 
subtest was DR, which is different to both the memory clinic and movement disorder 
clinic studies described above, where LM was the most accurate subtest. This likely 
reflects the different sampling strategies employed and the particularly small sample 
included in this initial pilot, presented at the Irish Gerontological Society meeting 
[O’Caoimh et al., 2013, abstract] and part of an ongoing study. Although most 
patients were general medical or orthopaedic patients, a proportion were stroke 
patients. The MoCA is a well established valid cognitive screen in stroke [Godefroy 
et al., 2011] and this study suggests that the Qmci may also be of use, albeit in stable 
inpatients in a rehabilitation unit. However, given the very small sample of these 
patients it is difficult to generalise on the utility of the Qmci in this population. 
! In summary, all three of the cognitive screens were accurate, at differentiating 
cognitive impairment from normal cognition. The Qmci was the most accurate 
although this did not reach statistical significance. Delayed recall was the most 
accurate Qmci subtest. This study reaffirms the accuracy and short administration 
time of the Qmci, in this case quicker than both the SMMSE and MoCA. Futher study 
is required with much larger sample sizes to confirm these findings, in particular, 








Utility of the Qmci in predicting disease progression: 




There is growing interest in developing interventions to prevent cognitive impairment 
[Kivipelto et al., 2013] or prevent conversion from MCI to dementia [Gates et al., 
2011]. The Study of Mental and Resistance Training trial [Fiatarone et al., 2014] 
compared two interventions: progressive resistance training and cognitive training, 
either in isolation or combination, in patients with MCI showing that resistence 
training alone improved global cognitive function. While combining treatment 
modalities is not new, multi-modal approaches are now increasingly being trialed in 
MCI and dementia. Tailored intervention strategies incorporating combinations of 
diet, exercise, stress reduction and cognitive stimulation have shown potential in 
patients with aMCI [Bredesen 2014] but the evidence for the efficacy of single or 
combined interventions remains limited.  
 This study investigated the effects of a “memory-gym” suite of lifestyle 
interventions and education strategies delivered in group therapy in a subgroup of 
patients with MCI attending the memory clinic in St Finbarrs Hospital. The 
hypothesis was that the “memory-gym” would slow or prevent conversion to 





The study was designed as a case-control trial comparing a six week “memory-gym” 
group-therapy programme with one three-month booster session to usual care, among 
consecutive patients recently diagnosed with MCI attending a university hospital 
memory clinic. MCI was diagnosed as described in Chapter 7. The “memory-gym” 
suite of stratgies included weekly cognitive training exercises (using three 
commercially-available apps, on tablet computers, according to an established 
protocol [Scanlon et al., 2014]), for one hour per week with an additional hour of 
either compensatory techniques, dietary advice, exercise instructions, stress 
management, mindfulness techniques or art therapy. Patients were included if 
baseline and end-point (standardised at six months apart) SMMSE, Qmci and 
Caregiver Burden scores were available. The Caregiver Burden score is a shortened 
version of the Zarit burden score. It is composed of six questions and describes the 
degree to which caring affects the caregiver from 0 (none of the time) to 6 (all of the 
time). Completed by the caregiver, scores <15/30 suggest no significant burden, 
scores suggest severe burden or burnout, see Appendix 2.7.  The Caregiver Burden 
score is routinely self-administered by caregivers attending the memory clinic in St 
Finbarr’s Hospital. In this study, it was collected by a retrospective chart review. 
 
12.3 Results 
In all, 13 participants completed the intervention in two groups, median age 72 years 
(interquartile +/-6) compared to 76 (+/-11) for controls, (n=17). The median follow-
up was 18 months versus 18.5 months respectively, p=0.72. No significant differences 
in baseline age, gender, education, SMMSE, Qmci or caregiver scores were found 
(see Table 12.1). There was a significant difference in median six month rate of 
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change in Qmci scores for those with MCI, +0.4/100 points versus -3.5/100 points, p= 
0.024. No significant differences in SMMSE (-0.66/30 versus -0.39/30, p=0.58), or 
Caregiver Burden (0 versus 0, p=0.55) scores were shown (see Figure 12.1). Only 
15% (2/13) of participants with MCI converted to dementia compared to 47% (8/17) 
of controls, p =0.12. 
 
Table 12.1.! Baseline characteristics, median and interquartile range (IQR), of 
participants (cases) and non-participants (controls) including median six-month rates 
of decline in Standardised Mini-Mental State Examination (SMMSE) and Quick Mild 








Number 13 17 - 
Follow-up in months  











Gender (% female) 71% 70% 1.0 
Education in years  










































Δ Qmci scores (MCI only) 0.4 




Δ Caregiver Burden Scores 













Figure 12.1. Comparison of median six-month rates of decline in Standardised Mini-
Mental State Examination (SMMSE) and Quick Mild Cognitive Impairment screen 
(Qmci) scores in those with mild cognitive impairment, between participants (cases) 





12.4 Discussion  
This study shows that there was a significant difference in the median 6-month rate of 
decline in Qmci scores between cases and controls and although it did not reach 
significance, almost half (47%) of controls converting from MCI to dementia 
compared to only 15% of participants. There were large differences in the six-month 
rate of change of Qmci scores between cases and controls (>3/100 points per six 
months, p =0.057) that reached statistical significance (again >3/100 points per six 
months, p =0.024) when patients with early dementia were excluded to leave only 
those with a diagnosis of MCI. No such difference was seen for the SMMSE, which 
may suggest it is less sensitive at detecting these small but significant differences. No 
differences in caregiver burden (as measured by the Caregiver Burden score) were 



















zero), as would be expected for carers managing the care of patients with mild 
cognitive deficits and who are more or less functionally independent (MCI). 
These results suggest that a multi-modality intervention using educational strategies, 
delivered in the form a “memory-gym”, by trained therapists aligned to a memory 
clinic, may slow progression in MCI. Although changes associated with the 
“memory-gym” were small and of uncertain clinical significance, if sustained over 
years, the compounding effects may have significant clinical benefits. A strength of 
this case control study is that both cases and controls were well matched with no 
significant differences in baseline demographics. Limitations include the small 
sample size, short training duration, short period of follow-up, lack of randomization 
or blinding and the inability to isolate individual components of the “gym”. 
Furthermore, no recognized global assessment such as the ADAS-cog or SADAS-cog 
was used. However, this study shows the potential of the Qmci to measure progession 
of MCI, supporting the results presented in Chapter 8 where the Qmci was shown to 
correlate with the SADAS-cog, CDR and the Lawton-Brody ADL scale in a clinical 
trial. The patients included in this case control trial remain under follow-up but 
without booster sessions any beneficial effects of the “gym” are unlikely to be 
sustained. To confirm the preliminary findings and the ability of the Qmci to predict 
those who will convert from MCI to dementia a larger same size, followed for longer, 
is required. A randomised controlled trial is planned to investigate the potential 





Shortening the Qmci to develop a caregiver administered 
cognitive screen; The Quick Memory Check (QMC) 
 
13.1 Introduction 
Traditionally, cognitive screens can be divided into directly administered 
performance-based instruments scored by trained raters in a clinical setting or 
informant-based observer rated scales. Interest in self-diagnosis including home-
administered screening is increasing and is widely reported in the media [Adelman & 
Karlawish, 2013], particularly social media [Robillard & Johnson 2013]. 
Computerised neuropsychological batteries have potential to replace traditional 
“paper-based” assessments [Scanlon et al., 2014]. A wide variety of performance-
based instruments are available [Lonie et al., 2009],[Cullen et al., 2007] though it is 
suggested that none will fit all situations [Cullen et al., 2007]. Informant-based scales, 
administered in conjunction with family or caregivers, provide a collateral, 
documenting symptoms suggestive of cognitive impairment. Although widely 
validated, they are long and not useful in detecting decline in cognition over time 
[Eramudugolla et al., 2012]. Informant-based scales may not be objective and 
collateral histories can be unreliable [Nieuwenhuis-Mark et al., 2009].  
 Another method of testing cognition is with home assessment. This has 
several potential advantages. Psychosocial stress is known to impair memory retrival 
[Kulmann et al., 2005] and there is evidence [Cockburn & Smith 1994], albeit 
conflicting [Hoffman & alAbsi, 2004], that anxiety affects performance on 
neuropsychological testing. While white coat effects are well established in 
hypertension, white coat effects related to the administration of cognitive screening 
testing are less well established and little is known about their effect on patients with 
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cognitive impairment. Home administration in a familiar setting could potentially 
reduce the anxiety associated with assessment in busy clinics. As time is limited in 
clinical practice, assessment prior to clinic may reduce waiting times. Home-
administration may identify variation in patient scoring, allowing more frequent 
assessments at different time intervals, capturing variability that may suggest the 
presence of subtle cognitive impairment [Kaye et al., 2014]. With the growing use 
and availability of the internet, particularly on mobile devices, there has been an 
increase in the propagation of internet-based, self-administered tests for dementia 
[Robillard 2013, abstract]. Most however, have poor reliability and validity, with 
ethical concerns raised over data collection, privacy and follow-up [Robillard 2013, 
abstract]. To date, only a few self-administered cognitive screens have been validated 
in clinical practice and of those that are most still require supervision. Their potential 
was first demonstrated by the Test Your Memory (TYM) instrument [Brown et al., 
2009], the most widely studied self-administered cognitive screen though it requires 
supervision. Other validated self-administered tests include the Computerized Self 
Test (CST) [Dougherty et al., 2010] and the Self-Administered Gerocognitive 
Examination (SAGE) [Scharre et al., 2010]. 
 While increasingly used and validated, these tests are limited by the need for 
supervision by trained staff (TYM), lack of comparison with established short 
cognitive screens (SAGE and CST), particularly accurate tests identifying MCI and 
early dementia. A potential solution to this is to utilise caregivers or those close to 
patients. Although there is evidence that caregivers actively wish to engage with the 
diagnosis [Beauchamp et al., 2005], little information is available on the ability of 
caregivers to administer cognitive screens. As yet, no cognitive screens scored by 
caregivers of persons with symptomatic memory loss have been validated. Given the 
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increasing use of  “home administered” cognitive screens, we sought to shorten the 
Qmci in order to develop and validate a new caregiver-administered cognitve 
screening test, which was christened the Quick Memory Check (QMC), to be used in 




Development of the Quick Memory Check 
The QMC is based upon the Qmci screen [O’Caoimh et al., 2012],[O’Caoimh et al., 
2013]. Previous analyses of the Qmci subtests revealed that verbal fluency VF and 
LM best differentiated MCI from normal cognition, while orientation best 
differentiated MCI from dementia [O’Caoimh 2013]. Based upon this analysis, the 
Qmci was shortened and reweighted to produce the QMC, see Table 13.1. Orientation 
was increased to 15 points (from 10 points), VF (for animals as initial piloting found 
that animals were the easiest to score) from 20 to 40 points and LM from 30 to 45 
points. The QMC was designed to be completed in three minutes, 30 seconds for the 
caregiver report and two and half minutes for the caregiver assessment (one minute 
for the orientation and VF subtests each and 30 seconds for LM). The QMC along 













Table 13.1. Comparison of the Quick Mild Cognitive Impairment (Qmci) Screen and 






Orientation 10 Orientation 15 
Registration 5 Verbal fluency 40 
Clock drawing 15 Logical Memory 45 
Delayed recall 20   
Verbal fluency 20   
Logical Memory 30   




Consecutive patients attending a university hospital memory clinic were screened and 
assessed for cognitive impairment. All patients had a complete assessment including 
history, physical examination and work-up for causes of cognitive impairment 
including a brain CT, an electrocardiogram and blood tests where appropriate. 
Patients were classified as having NC (age associated memory loss), MCI or 
dementia. Dementia was diagnosed using DSM-R, (4th edition revised) criteria [APA 
2000]. Dementia severity was correlated with the Reisberg FAST scale [Reisberg 
1988]. MCI was diagnosed clinically based upon the presence of collaborated and 
progressive memory loss, without obvious loss of functional impairment using 
Petersens criteria [Petersen et al., 1999]. Patients were excluded if they were aged 
under 45 years, if they were depressed or if they were unable to provide a caregiver 
(spouse, child, friend or other person known to the person including a healthcare 
professional) . Depression was diagnosed clinically and screened using the GDS Short 
Form [Yesevage 1988], using a cut-off of ≥7, to optimize specificity [Marc et al., 
2008]. After assessment those with LBD or PD were also excluded and analysed 
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separately as these often present atypically with a different MCI syndrome [Caviness 
et al., 2007]. Test-retest reliability was calculated by comparing the test completed at 
home and a repeat performed by a different caregiver in clinic. Inter-rater reliability 
(IRR) was determined by comparing the home-administered result to a repeat 
performed by a clinic nurse on arrival, for a sample of patients chosen by simple 
randomisation, n = 30. 
 
Data Collection 
The QMC with scoring instructions was posted with the appointment letter prior to 
clinic. Data were collected between 2013 and 2014. The scoring instructions, posted 
in advance with the QMC, stipulated that the test be dated (including time of day) and 
completed just before attending clinic. Caregivers were asked to provide their 
personal details including age, gender, occupation, educational level and time spent 
with the patient (days per week). In clinic, each patient had demographic data 
collected including age, gender and number of years of education. Each patient had 
the Qmci screen and MoCA administered sequentially but randomly by two trained 
raters, blind to the final diagnosis as part of the same data collection described in 
Chapter 7. Alternative forms of the Qmci were used to reduce learning effects and 
bias [Cunje et al., 2007]. Caregiver satisfaction was measured using anonymous self-
completed questionnaires, developed by the researchers. Caregivers were asked ten 
questions (using a five-point Likert scale from strongly agree to strongly disagree) 






Data were entered into SPSS version 20.0. Subjects were subdivided according to age, 
> or <75 years and educational level, > or <12 years, the mean number of years in 
formal education in North America. The Shapiro–Wilk test was used to test normality 
and found that the majority of data were non-parametric. The accuracy of the 
individual screening tests was determined from the AUC using ROC curves. 
Youden’s Index was used to calculate cut-off scores for the QMC [Youden 1950]. 
Sensitivity, specificity, PPV and NPV were calculated for each of the cognitive 





In total, 340 assessments, were available for analysis. Of these, 309 assessments were 
included. An additional 34 normal controls, recruited from bridge clubs in Cork City, 
were also included. Normal controls were scored by untrained raters (with normal 
cognition), who also attend the clubs, to demonstrate the ability of older untrained 
raters to score the instrument. This normative data is part of a medical students final 
year project and although their demographic details are included for comparison their 
data is not included in this analysis. Thirty one were excluded because of missing data 
(n=2), refusal to consent (n=2), unclear diagnosis (n=2), active depression (n=14), 
LBD/PD (n=9) and age <45 years (n=2). Overall, 58 had NC (22%), 68 MCI (20%) 
and 183 had dementia (58%). Of those with dementia, 134 were classed as early-mild 
dementia, 39 as moderate and 10 as severe. Patient selection is presented graphically 
in Figure 13.1. The median age at assessment of those included was 76, interquartile 
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range (IQR) 11 years. Of those included 81 (34%) were male. Patients with dementia 
were  similar in age to those with MCI (median age of 77 verus 75 years, p=0.1), but 




Figure 13.1. Flow chart of participants included in the validation of the Quick 
Memory Check, including number of assessments, excluding those with Parkinson’s 






























Missing data n=2 
-Unclear diagnosis n=2 
-Declined consent n=2 
-PD/LBD, N=9 
-Aged <45, N=2 
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Caregiver characteristics  
The median age of caregivers at the time of assessment was 52 years (IQR =68-43= 
+/- 25), and the majority (70%) were female. In all, 9% of assessments were scored 
by caregivers that had completed primary education only, 44% secondary and 47% 
third level. Most caregivers scoring the QMC were the child of the patient (50%) 
followed by their spouse (38%) and other relationship (12%). The caregiver was 
currently in employment in 50% of cases, retired in 21% and not working outside the 
home in 29% of QMC assessments. Older caregivers, ≥65 years, were also 
predominantly female (58%), mainly retired (60%) and the majority (89%) were 
spouses. In keeping with this 94% saw the patient seven days a week. 
 
Performance of the QMC 
The median time between home testing and attending clinic was one month. Test-
retest reliability was 0.95. IRR was 0.82. Median administration time for a sample of 
30 patients, timed in clinic, was 2.5 minutes. The median QMC score for those with 
SMC was 64 points (IQR 19) compared to 52 (19) for MCI and 31 (21) for dementia. 
Normal controls had a median QMC score of 73 (16). Median and IQR scores of  
each of the outcome measues are presented in Table 13.2. Of the four tests, the Qmci 
most accurately identified patients with cognitive impairment, AUC of 0.95 (95% 
confidence interval: 0.93–0.98). The QMC however, compared favourably with the 
other tests with an AUC of 0.89 (95% confidence interval: 0.85–0.93), for 
differentiating cognitive impairment from SMC (see Table 13.3). Each of the 
cognitive assessments also accurately differentiated MCI from NC, although again the 
Qmci was most accurate, with an AUC of 0.84 (95% confidence interval: 0.76–0.91).  
The QMC was the next best performing test, AUC 0.75 (95% confidence interval: 
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0.66–0.84), compared with 0.71 (95% confidence interval: 0.61–0.80) for both the 
SMMSE and MoCA. The QMC also had excellent accuracy in its ability to 
differentiate MCI from dementia, AUC of 0.82 (95% confidence interval: 0.75–0.86). 
ROC curves comparing the accuracy of the instruments are presented in Figure 13.2. 
 
Table 13.2. Characteristics of the total sample, controls, those with subjective 
memory complaints (SMC), mild cognitive impairment (MCI), dementia and 
combined cognitive impairment (CI) groups, including median Quick Memory Check 
(QMC), Quick Mild Cognitive Impairment screen (Qmci), Standardised MMSE and 
Montreal Cognitive Assessment (MoCA) scores with inter-quartile range (IQR), (Q1–













Group Total Controls SMC MCI Dementia CI 
Number of patients n=239 n=34 n=52 n=49 n=138 n=187 
Number of assessments n=309 n=34 n=58 n=68 n=183 n=251 
Age (years) 
 Median 76 71 72 75 77 77 
IQR (81-70=11) (76-65=10) (81-65=16) (80-70=10) (81-71=10) (81-71=10) 
Range 46-92 58-84 46-89 59-91 48-92 48-92 
Education (years) 
 Median 11 14 12 12 11 11 
IQR (14-10=4) (16-12 =4) (14-9.5=4.5) (14-10=4) (13-10=3) (13-10=3) 
Range 7-18 8-18 8-18 8-18 7-18 7-18 
QMC 
























































Table 13.3. Comparison of area under the curve (AUC) values with 95% confidence 
intervals for the QMC, Qmci, SMMSE and MoCA in their ability to differentiate 
cognitive impairment (CI) from those with subjective memory complaints (SMC), 
mild cognitive impairment (MCI) from SMC, MCI from dementia and dementia from 
MCI and SMC. 
 
Diagnosis Test AUC 95% Confidence Interval 
CI from SMC QMC 0.89 0.85-0.93 
Qmci 0.95 0.93-0.98 
SMMSE 0.89 0.85-0.94 
MoCA 0.89 0.85-0.93 
MCI from SMC QMC 0.75 0.66-0.84 
Qmci 0.84 0.76-0.91 
SMMSE 0.71 0.61-0.80 
MoCA 0.71 0.61-0.80 
MCI from Dementia QMC 0.82 0.75-0.86 
Qmci 0.95 0.92-0.98 
SMMSE 0.90 0.86-0.95 
MoCA 0.90 0.86-0.95 
Dementia 
(from MCI & SMC) 
QMC 0.88 0.84-0.92 
Qmci 0.97 0.95-0.99 
SMMSE 0.93 0.90-0.96 



























Figure 13.2. ROC curve demonstrating the accuracy of the Qmci, MoCA, SMMSE 
and QMC in differentiating (a). Mild cognitive impairment (MCI) from subjective 
memory complaints (SMC), (b). MCI from dementia, (c). Cognitive impairment from 
































Developing cut-off scores for the QMC 
Using Youden’s Index [Youden 1950] the estimated QMC cut-off score for cognitive 
impairment was ≤50. At this cut-off the QMC had a sensitivity of 85%, specificity of 
80%, PPV of 96% and NPV of 50%. The optimal cut-off that differentiated MCI from 
SMC was ≤53, yielding a sensitivity of 79% and specificity of 55%. The cut-off that 
best differentiated dementia was ≤48 with a sensitivity of 72% and specificity of 91%. 
These results are presented in Table 13.4. 
 
Acceptibility of the QMC 
In total 50 caregivers returned the questionnaire, a response rate of 67%. The results 
of the questionnaire suggest that the majority of caregivers were happy with screening 
and would be willing to do it again. These results are presented in Figure 13.3. 
 
13.4 Discussion 
This paper presents the results of a caregiver “home” administered cognitive screen, 
administered by caregivers to patients with symptomatic memory loss, prior to 
attending a memory clinic, in comparison to a selection of short cognitive screens 
including the progenitor of the QMC, the Qmci. Caregivers, scoring the QMC, were 
predominantly middle-aged, female, children with a median age of 52 years. Half 
were in employment. This reflects the profile of other caregivers of patients with 
dementia [Sink et al., 2006]. Older caregivers (≥65) had similar profile except they 
were more often spouses living with the patient. The results demonstrate that the 
QMC accurately (AUC 0.89) differentiated those with SMC from cognitive 
impairment and compared well with formal cognitive screening using validated 
instruments including the SMMSE, MoCA and Qmci screen. The accuracy of the 
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QMC, in differentiating established cognitive impairment from SMC but normal 
cognition, also compares well with the results of other home-administered instruments 
such as the TYM, AUC of 0.94 [Hancock & Larner 2011] and the SAGE, AUC of 
0.92 [Scharre et al., 2010]. In this sample a QMC cut-off score of <50 appears 
appropriate for differentiating cognitive impairment (either MCI or dementia) from 
SMC. At this score, calculated using Youden’s Index, the QMC had 85% sensitivity 
and 80% specificity. A slightly higher cut-off of <53 produced the optimal cut-off for 
MCI and slightly lower (<48) the optimal cut-off for dementia. The cut-off for MCI 
however, had poor sensitivity (55%). It was instead more sensitive at its optimal cut-
off for dementia suggesting that while useful in separating cognitive impairment of 
any type from SMC but normal cognition than specifically identifying MCI. 
 The advantage of home-administered instruments are that they allow subjects 
to complete cognitive screening, a key part of any memory assessment, at home, away 
from the busy atmosphere of clinic. In this way, the QMC potentially reduces the 
“white-coat” effect associated with cognitive testing in clinical environments and 
allows raters more time to compare the reliability of more detailed cognitive testing 
performed in clinic. There are several disadvantages. Physicians cannot see and assess 
the conditions under which the test was administered. Tests may create unnecessary 
anxiety for patients or their caregivers in advance of attending clinic. However, the 
results of the user questionnaires, administered to caregivers, suggest that these 
effects are minimal. The QMC itself is simple and quick to administer with 
considerably shorter administration times (median 2.5 minutes) compared to similar 
home-administered tests [Brown et al 2009],[ Scharre et al 2010]. This is at the 
expense of the inclusion of fewer cognitive domains potentially reducing its accuracy 
in early cognitive impairment. That said, the QMC includes three key domains: 
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orientation, semantic memory (VF) and episodic memory (LM). LM even as a single 
subtest, is highly sensitive and specific for MCI [O’Caoimh et al., 2013].It should also 
be remembered that the QMC, as with all short cognitive screens, is not designed to 
provide a diagnosis but instead to be used as part of a screening and assessment 
pathway, either prior to clinic, as in this case, or in conjunction with other short 
cognitive screens administered by trained healthcare professionals. Given that the 
QMCs construct is similar to the Qmci, it would seem reasonable to compare the 
results of these two instruments in clinic as a form of ‘white coat effect’ screening.  
Instruments such as the TYM have shown the potential of home-administered screens 
to reduce indiscriminate assessment of asymptomatic patients, reducing the numbers 
of false positives. Until further validation in the community is available and better 
treatments provide justification for unselected community screening [Lin et al., 2013], 
its use outside of a memory clinic cannot be advised. 
 
Strengths and limitations 
The strengths of this study are that it validates a home-administered cognitive screen 
against standardised instruments that are widely used and validated in clinical 
practice, including the SMMSE, Qmci and MoCA. The use of standardised scoring 
instructions may have reduced variability in scoring, as witnessed by the high test-
retest reliability. In addition, this is the first study to provide age and educational cut-
off scores for a home-administered instrument. It also includes large numbers of 
patients, particularly those with MCI, compared with other studies of home-
administered tests [Brown et al., 2009],[Scharre et al., 2010]. There are a number of 
limitations. The QMC was not compared to any other home-administered cognitive 
screens and none of the short instruments it was compared against can be considered a 
! 204!
gold standard.  That said, no gold standard has been established [Lin et al., 2013] and 
the MMSE and MoCA are widely validated in patients with SMC. A relatively low 
IRR (caregiver versus trained rater) compared with high test-retest reliability 
(caregiver versus caregiver) may suggest that instructions provided to caregivers, 
posted with the QMC in advance of the clinic, were insufficient. Further, the median 
administration time obtained in clinic may not reflect the time taken by caregivers. 
More study is now required to clarify this, although only 4% of respondents strongly 
agreed that the test was too time consuming, suggesting that home-administration 
times were similarly brief. The use of caregivers rather than patients or trained raters 
may also have created bias. Although it is unknown whether caregiver administration 
affects subject performance, evidence from informant-based observer-rated 
instruments suggests that results may be biased [Nieuwenhuis-Mark et al., 2009], 
particularly as caregiver stress may affect caregiver cognition [MacKenzie et al., 
2007]. That said, bias may also occur through self-administration/reporting of any 
test.  Also, as this study was conducted with older adults (median age 76 years) 
attending a memory clinic with symptomatic memory loss, the sample was heavily 
weighted towards those with CI, prevalence of  78% (187/239 patients). This may 
also affect the accuracy of the proposed cut-off scores. That said, unlike other studies 
of home-administered tests [Brown et al., 2009], [Scharre et al., 2010], this study 
included relatively large numbers of symptomatic older adults with normal cognition 
(SMC) rather than including a random sample of older adults that were presumed 
normal. One limitation is that only a small sample of controls were available. 
However, the QMC was designed for patients referred for assessment of memory loss 
in a memory clinic and not for use by asymptomatic older adults in the community. 
Further study would be required to confirm utility of the test in this population but 
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evidence/guidelines recommend against/suggest that asymptomatic adults should not 
be routinely screened [Lin et al., 2013]. Finally, that it was conducted in a single 
centre may also reduce the generalisability of the results.  
 The QMC now requires external validation with larger numbers and in 
different clinical settings e.g. general practice, where the test could arguably be best 
suited. Future research should focus on refining its different domains and cut-off 
scores and investigating if the QMC is also valid as a self-administered screen by 
comparing it with instruments such as the TYM [Brown et al., 2009] and the SAGE 
[Scharre et al., 2010]. In summary, the QMC is a home-administered cognitive screen 
validated for use by caregivers. It is short (median 2.5 mins), acceptable, easy to use 
and can be administered in an informal setting without direct clinical supervision. 
Based upon these results, the authors recommend that low scores (cut-off <50) on the 
QMC should prompt the need for further assessment. The QMC suggests that 
caregiver-administered cognitive screening tests may have a role in the assessment 
pathway for cognitive impairment, potentially reducing testing time and patient stress 
(white coat effects). It may also be useful as a pre-screen for MCI and early dementia 
in community settings, supporting the utility of shortening and refining the Qmci 
further such that an additional reduction in administration time is not off-set by a 
large reduction in accuracy. It may also be useful when combined with short a self or 
caregiver rated questionnaire evaluating symptoms of cognitive impairment such as 
the AD8. These could be supervised by GPs in the community, particularly where 
patients or caregivers approach with concerns. Patients screening positive could then 
be assessed formally in primary care and prompt referral arranged if required. Further 
research is now required to confirm these findings and elucidate the benefits if any of 
these community-based referral pathways. 
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Table 13.4. Comparison of cut-off scores for the QMC, Qmci, SMMSE and MoCA to differentiate cognitive impairment from those with 
subjective memory complaints (SMC), mild cognitive impairment (MCI) from SMC, MCI from dementia and dementia from MCI and NC, 
including sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), including 95% confidence intervals at 
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External Validation of the Qmci in English (Australia) and 
non-English (Dutch) speaking populations 
 
14.1 Introduction 
Few short cognitive screening instruments such as the Qmci are available to identify 
MCI. As the Qmci has not been externally validated outside of this PhD project, the 
objective of this chapter is to confirm the accuracy of the Qmci in different 
populations and languages. This aim of thus study is to compare the accuracy of the 
Qmci screen with the SMMSE in differentiating MCI from normal cognition and 
dementia in an Australian outpatient and community setting. In addition, given that, 
few short screening tools, able to discriminate properly between MCI and normal 
cognition or dementia, are available in the Dutch language, we chose to adapt the 
Qmci for use in Dutch-language countries and to validate the Dutch version of the 
Qmci (Qmci-D), against the Dutch translation of the SMMSE (SMMSE-D). 
 
14.2 Methods 
To date, in Australia 224 subjects (156 with dementia, 43 with MCI, and 25 normal 
controls) have been recruited. Each were reviewed in geriatric outpatients or in the 
community by the Aged Care Assessment Team in Perth, Western Australia. Trained 
raters independently scored the SMMSE and Qmci. In the Netherlands (Groningen) 
the Qmci was translated to Dutch with a combined qualitative and quantitative 
approach. In all, 90 subjects were recruited from a hospital geriatric clinic (25 with 
dementia, 30 with MCI, 35 controls). The Qmci-D and SMMSE-D were administered 
by a trained rater and results were compared. Accuracy was determined from AUC 
from ROC curves. 
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14.3 Results 
In Australia the Qmci is, like in Ireland and Canada, proving to be more accurate than 
the SMMSE in differentiating MCI from normal cognition, AUC of 0.81 (95% 
confidence interval (CI) of 0.69-0.93), compared with 0.69 (95% CI:0.54-0.85). 
Comparing the two instruments showed the Qmci to be significantly better than the 
SMMSE (z=-0.168, p=0.046). Similar results were obtained after correction for age 
and education. Both the Qmci and SMMSE had similar accuracy in identifying 
dementia, AUC of 0.87 (95% CI:0.81-0.93) versus 0.92 (95% CI:0.88-0.96) 
respectively, (z=1.32, p= 0.19). In the Netherlands the Qmci-D was more sensitive 
than the SMMSE-D in discriminating MCI from dementia with a significant 
difference in the AUC (0.73 compared to 0.60 respectively, p= 0.024), and in 
discriminating dementia from controls with an AUC of 0.95 compared to 0.89 (p= 
0.006). Both screening instruments discriminated MCI from NC with an AUC of 0.86 
(Qmci-D) and 0.84 (SMMSE-D). 
 
14.4 Discussion 
Preliminary results from Australia, the first external validation of the Qmci outside of 
this PhD, reaffirm that the English language version of the Qmci is more accurate in 
differentiating MCI from normal cognition than the still widely used SMMSE. In the 
Netherlands, the Qmci-D is more sensitive and specific than the widely used 
SMMSE-D in differentiating MCI from dementia and dementia from controls. Given 
its diagnostic accuracy, brevity and ease of administration, the Qmci-D seems a useful 
cognitive screen in a Dutch population. Validation is ongoing in both countries and in 









5.1 Overview of results 
Population ageing has resulted in an increased prevalence of cognitive impairment, 
including MCI [Plassman et al., 2008],[Nie et al., 2011]. Unlike dementia, MCI is not 
associated with functional decline and there is increasing interest in management 
strategies targeted at prevention of conversion to dementia [Fiatarone et al., 
2014],[O’Caoimh et al., 2015]. Although screening large numbers of asymptomatic 
older adults is not recommended at present [Lin et al., 2013], targeted screening may 
be beneficial, particularly as new treatments and better preventative measures emerge. 
Studies are therefore required that investigate the benefits of early intervention i.e. 
therapies targeted to individuals with asymptomatic or occult disease. A key step in 
realising the potential benefits of cognitive screening is the development of short, 
easy to use and highly sensitive and specific instruments. This PhD presents and 
explores the development and the results of the validation of the Quick Mild 
Cognitive Impairment screen or Qmci, a new, short cognitive screen for 
differentiating MCI from SMC and early-mild dementia, using data gathered by Prof 
William Molloy in Canada. Building on the published evidence for a previous version 
of the instrument, the ABCS 135 [Molloy et al., 2005],[Standish et al., 2007], the 
initial validation showed that the Qmci has greater accuracy over the commonly used 
standardised MMSE [O’Caoimh et al., 2012]. It also shows comparable accuracy with 
its predecessor. Examination of the Qmci’s subtests showed that the new subtest, 
logical memory, added to transform the ABCS 135 into the Qmci, is the most accurate 
! 211!
at differentiating MCI from normal controls [O’Caoimh et al., 2013]. Median 
administration time was just over four minutes and it has excellent test-retest 
reliability [O’Caoimh et al., 2013]. The ABCS 135 had previously been used in 
another outpatient database and a RCT called the DARAD trial, both conducted in 
Canada. This data were pooled with the original Qmci data set providing a large 
sample of patients and normal controls from which to develop cut-off scores. The 
results of this analysis suggest that a cut-off score of <60 produces the optimal 
balance between sensitivity and specificity for the presence of cognitive impairment. 
This combined dataset provided cut-off scores adjusted for age and education 
confirming the requirement to adjust scores, particularly for those aged over 75 years. 
Analysis of this combined data set also showed that the Qmci has superior accuracy to 
the SMMSE across different dementia subtypes. It likewise confirmed the utility of its 
LM subtest in a large sample of patients. Data from the DARAD trial was also used to 
assess internal consistency and the responsiveness of the Qmci to change over time 
[O’Caoimh et al., 2014]. It showed that the Qmci had high internal validity, was 
responsive to change over time and correlated with a detailed neuropsychological 
battery (Standardised ADAS-cog), a global assessment of cognition (CDR) and an 
ADL scale (Lawton-Brody scale), suggesting that the Qmci could be substituted for a 
more detailed neuropsychological instrument in clinical trials [O’Caoimh et al., 
2014]. 
 As the Qmci had not yet been externally validated, data collection in an Irish 
memory clinic was conducted. This study included detailed independent 
neuropsychological and informant testing not included in the original validation. It 
showed that the Qmci had a shorter administration time, excellent accuracy, 
comparable sensitivity and greater specificity than the MoCA at their established cut-
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off scores. This is the first validation of the MoCA against an instrument designed 
specifically to screen for MCI. Even though the study was likely underpowered to 
show superiority, given the brevity and arguably easier scoring instructions of the 
Qmci relative to the MoCA, it suggests that the Qmci may be the better instrument to 
use as a screen. This is particularly true in busy general practice.  
 This project demonstrated that GPs, after a brief education session had 
excellent IRR compared to trained raters working in a memory clinic. The Qmci 
compared well with a selection of instruments in primary care including the GPCOG 
and the MoCA, though again the study was underpowered to show superiority to the 
MoCA. Despite this, the brevity and ease of administration (no requirement for an 
informant unlike the GPCOG) suggest that it is useful in this setting. Other studies 
conducted during this PhD showed that the Qmci has good to excellent accuracy in 
patients with cognitive impairment (MCI and or dementia) attending a movement 
disorder clinic [O’Caoimh et al., 2012 abstract] and among inpatients in a university 
hospital rehabilitation unit [O’Caoimh et al. 2013, abstract]. Additional concurrent 
validity was confirmed against another commonly used short cognitive screen, scored 
periodically in the Memory clinic during the period of data collection, the 6CIT 
[O’Caoimh et al. 2014, abstract]. 
 Another important component of the PhD was an attempt to shorten the Qmci 
further without compromising its ability to detect either MCI or dementia. This 
shortening was based on the results of the subtest analysis and led to the development 
of another screening instrument called the Quick Memory Check or QMC [Coughlan 
et al., 2013 abstract]. Analysis suggested that LM and VF were two highly accurate 
subtests for the detection of MCI and that orientation was most accurate in dementia. 
This test was trialed as a new “home” caregiver-administered instrument [Coughlan et 
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al., 2013 abstract] and ongoing data collection, the results of which are presented in 
Chapter 13, show that it has good to excellent accuracy in detecting MCI and 
dementia, comparing favourably to a battery of established cognitive screening 
instruments administered by trained raters. The Qmci was also used as an outcome 
measure in a case-control study investigating the effects of a suite of lifestyle 
interventions on the progression of MCI [O’Caoimh et al., 2015], suggesting its 
predictive validity. Finally, the Qmci has been translated into multiple languages and 
has been externally validated in Dutch and Australian populations. Validation is 
ongoing in Italy and Portugal. 
 
5.2 Limitations of this research 
This project has several limitations. The sample size of the external validation of the 
Qmci against the MoCA was small and likely underpowered the study to show 
superiority.  Based upon previous analysis, conducted as part of this research, the 
overall sensitivity and specificity of the Qmci for detecting cognitive impairment was 
approximately 85% and 80% respectively, compared to a sensitivity of 90% and 
specificity of 75% for the MoCA, The effect size was deemed to be small to medium. 
To detect a 5-10% difference in sensitivity and specificity between the two tests at a 
significance level of 0.01, a total sample size of 300 paired analyses was required to 
give a power of 80%. Thus, this post-hoc analysis (power calculation) suggests that 
approximately 300 paired (MCI-SMC) observations would be required to demonstrate 
superiority of the Qmci over the MoCA. Given that the prevalence of cognitive 
impairment in this study was high (>70%) and that this was predominantly patients 
with dementia, data collection would have taken more time than was possible within 
the limits of this PhD. The issue of small sample size and high prevalence of 
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cognitive impairment was common to the studies conducted in this PhD and given 
that consecutive patients were sampled over periods when the principle investigator 
was in clinic, this likely reflects the nature of those attending hospital clinics (memory 
or movement disorder), general practice surgeries with symptomatic memory loss, 
and inpatients in a rehabilitation unit. 
 Another limitation is that the cut-off scores were derived from pooled data 
sets, potentially creating bias in that the baseline characteristics of participants may 
have been different. Age and education cut-offs were also derived from this data. This 
said, comparisons of the databases showed only marginal, albeit statistically 
significant, differences in their demographic details and all three data sets were 
coordinated by the same principle investigator Prof William Molloy. All three 
databases were collected in a Canadian population. Appling these cut-off scores 
outside of Canada may have created bias. However, that Canada is a large multi-
cultural country suggests that findings can be extrapolated and used in similar 
populations. 
 
5.3 Future research 
This PhD and each of the studies within it suggest the need for and direction of 
further studies. The optimal extent, type and benefits of cognitive screening remain 
uncertain [Lin et al., 2013] with opposing views on the best way forward [Clionsky & 
Clionsky, 2014],[McCartan 2013],[Boustani 2013]. Undoubtedly there is a place for 
cognitive screening, especially in busy non-specialised outpatient clinics and in 
general practice. It is clear that what is required now to facilitate this is a short, easy 
to administer, sensitive and specific cognitive screening instrument. To date, most 
studies have assessed the accuracy of screens in highly selected samples, usually 
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patients attending memory clinics where the prevalence of cognitive impairment is 
generally high. High prevalence rates, like in this project, affect the sensitivity and 
specificity of instruments [Altman & Bland, 1994],[ Larner AJ, Springer International 
Publishing, 2015]. Few instruments have been compared in general practice where the 
prevalence is low [Connolly et al., 2011] and the utility of and need for these 
instruments is arguably at its greatest. Further training of GPs and improved resources 
are also required to improve detection rates [Cahill et al., 2008] and studies to 
investigate the effects on patients with cognitive impairment are now required. In 
addition, the Qmci is as yet unvalidated in an acute hospital setting where the 
prevalence of cognitive impairment is high [Sampson et al., 2009],[Ryan et al., 2013]. 
 Given the challenges associated with traditional rater-administered screening, 
there may also be a place for other forms of administration including self-adminstered 
screening [Brown et al., 2009],[Scharre et al., 2010] and, as shown in this project, a 
caregiver administered instrument delivered before clinic. These screening 
techniques, while still in their infancy, show potential, though further rigourous 
external validation is still required including demonstration of their concurrent 
validity against detailed neuropsychological batteries, other short screens and new 
diagnostic algorithms that take neuroimaging, blood and cerebrospinal fluid results 
into account [Pankratz et al., 2015]. 
 Although the IRR of the Qmci was acceptable in this project, apart from the 
sample of GPs who scored the test, the Qmci was only administered by trained raters 
and all results were double checked to ensure the quality of scoring. The Qmci 
requires standardisation of its scoring instructions to improve IRR, a technique that 
has improved the scoring of the MMSE [Molloy et al., 1991] and ADAS-cog 
[Standish et al., 1996]. While the Qmci correlated with the SADAS-cog in the 
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DARAD, further validation against neuropsychological batteries is also required. 
Likewise although this project showed some evidence that the Qmci was responsive 
to change over time and useful in measuring conversion (in a memory gym-clinic 
sample)[O’Caoimh et al., 2015], it remains to be seen if the Qmci is useful in 
measuring and predicting progression from SMC to MCI and dementia. A 
computerised application for smart phones and tablets has been developed 
(www.doctot.ie). Comparing the paper-based Qmci to the application is ongoing to 
confirm convergent validity. This project sets out cut-off data for the Qmci including 
adjustments for age and education. Further adjustments for cultural background and 
pre-morbid intelligence quota (IQ) scores are also required [Alves et al., 2013]. 
Results show that premorbid IQ influences instruments like the MMSE and MoCA, 
predicting variance from 8.4% to 33.2% [Alves et al., 2013]. Obtaining IQ scores in 
particular represents a significant logistic challenge but the increasing use of these 
should allow their inclusion in future studies. Normative data is also required to place 
screening scores in context of normal ageing [O’Connor 1990]. Longitudinal studies 
of ageing offer the best opportunity and attempts to include the Qmci in the third 
wave of The Irish Longitudinal Study of Ageing [Kenny et al., 2013] should be made. 
 External validation of the Qmci is also ongoing in other countries and settings. 
As presented above, colleagues in Perth Australia are presently completing externally 
validation of the Qmci in another English speaking country. The Dutch version has 
been validated and is under review. Both Dutch and Italian versions are being used in 
the FP-7 funded PERsonalised ICT Supported Service for Independent Living and 
Active Ageing (PERSSILAA, see http://www.perssilaa.eu; project number 610359) 
[O’Caoimh, Van Velsen et al., 2014]. PERSSILAA is an integrated ICT model for the 
detection, assessment and management of pre-frailty in community-dwelling older 
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adults. As partners in the trial Prof Molloy and I have been allowed to externally 
validate the Qmci in the two study sites: one in Enschede the Netherlands, the other in 
the Campania region of Italy. Results are expected in 2016. This project is also 
determining whether the Qmci can be self-administered as the goal of PERSSILAA is 
to enable older adults to self-screen and participate actively in their health 
management. 
 
15.4 Conclusion and context 
This PhD represents an exploration of a new short screening instrument and suggests 
that the Qmci is brief, reliable, sensitive, specific and accurate in differentiating MCI 
from patients presenting with SMC and early to mild dementia. It compares 
favourably with the results of previously published systematic reviews investigating 
the utility of short cognitive screens in MCI [Lonie et al., 2009] and dementia [Cullen 
et al., 2007],[Woodford 2007]. Short cognitive screens need to be easy to administer, 
available in multiple formats, with high sensitivity but also specificity. Though at 
present there is still a paucity of evidence to support community screening for 
cognitive impairment [Lin et al., 2013], including in primary care, this may in a large 
part be due to a lack of suitable instruments. The Qmci may be close to the ideal of a 
short cognitive screen though further research is ongoing to confirm this. 
 In summary, this PhD thesis confirms the concurrent validity of the Qmci 
against a large selection of widely used and validated instruments. It also confirms its 
construct validity against global cognitive and functional scales and the gold-standard 
assessment used in clinical trials, the ADAS-cog. This exploration of a new and 
arguably much needed short but highly sensitive and specific cognitive screen shows 
that it is suitable for use where it is likely to be of most benefit, in busy outpatient 
! 218!
clinics and in general practice.  It also demonstrates the potential of shortening the 
instrument to allow caregivers score patients at home in an attempt to reduce 
performance anxiety and reduce waiting times in busy clinics, though this requires 
further validation. This project suggests that the Qmci could be substituted for more 
detailed and longer instruments in a wide variety of settings as a rapid screening test 
for cognitive impairment, particularly where the suspicion is for MCI. Further 
research will focus on increasing the sample size to confirm superiority over highly 
sensitive instruments such as the MoCA, target validation is clinical settings with a 
lower prevalence of cognitive impairment, attempt to develop of normative data and 
externally validate the Qmci in other cultures and languages. Measuring its predictive 
validity against more detailed neuropsychological testing such as the ADAS-cog or 
CANTAB is also required and an important next step towards building recognition of 
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1. Qmci and QMC scoring templates and 
administration and scoring guidelines 
 
Appendix 1.1. The Quick Mild Cognitive Impairment (Qmci) screen: double sided 
score sheet. 
 
                                        © O’Caoimh R, Molloy D. W 2011. 
 
     Quick Mild Cognitive Impairment screen (Qmci) 
Name:                             DOB:                 Gender:                 Years in Education:                Date:                Time: 
1. Orientation 
To begin ask 5 questions.  
! One minute. 
!  Give 2 points for correct answer, 1 if 
attempted but incorrect, 0 if no attempt. 
What country is it?                                                                             ___  / 2 
What year is it?                                                                                   ___  / 2 
What month is it?                                                                               ___  / 2 
What is todays date?                                                                          ___  / 2 




__/ 10  
2. Word Registration 
To begin say… 
“I am going to say 5 words.  
After I have said these 5 words, 
repeat them back to me.  Are 
you ready?”  
! 30 seconds. 
!  Give 1 point per word repeated, in any 
order, no hints. 
 
Dog   Rain    Butter      Love       Door 
     
Alternate word groups include… 
Cat Dark Pepper Fear Bed 









3. Clock Drawing  
“Use the circle provided over 
page to draw a clock face, set the 
time to ‘ten past eleven’.” 
! One minute approximately.  
!  Give 1 mark for each number, 1 for each 
hand & 1 for the pivot correctly placed or close 
to their ideal location. Loose 1 mark for each 
number duplicated or greater than 12, e.g, 15 or 
45, i.e. errors.  
 
 
Score:                Numbers  Correct + ______/ 12 
  Errors - ______ 
                           Hands  + ______/ 2 
                           Pivot                          + ______/ 1 








4. Delayed Recall  
 “A few minutes ago I named 
five words.  Name as many of 
those words as you can 
remember.”  
! 30 seconds. 
!  Recall in any order, within 30 seconds, 
giving 4 points per word, no hints. 
 
Dog   Rain    Butter      Love        Door 
     
Alternate word groups include… 
Cat Dark Pepper Fear Bed 









5. Verbal Fluency  
“Name as many animals as you 
can in one minute.  Ready? Go.” 
! One minute. 
!  Give half a point per animal named; to a 
maximum of 40. Accept all ‘creatures’ 
including birds, fish, insects etc. Do NOT count 
suffixes twice, e.g. mouse/mice but allow points 
for similar names calf, cow, bull.  
Alternative forms include: fruit & veg or towns & cities. 
Score 0.5 x number of animals =  










6. Logical Memory  
“I am going to read you ONE 
short story. After I have finished 
reading it completely, I want you 
to tell me as much of the story as 
you can. OK?”   
! 30 seconds. 
Give 2 points per highlighted word, recalled 
exactly, immediately within 30 seconds, in any 
order, no hints. Two alternatives are provided. 








The red It was a hot The brown It was a cold The white It was a warm 
fox May dog October hen September 
ran across 
the 
morning. ran across day. walked 
across 
afternoon. 
ploughed Fragrant  the metal Ripe the concrete  Dry 













a brown the bushes. a white the trees. a black the wind. 
dog.  Rabbit.  cat.   
Qmci Total score                                                                                                                            *___/ 100  
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Quick Mild Cognitive Impairment screen (Qmci) 
Administration and Scoring Guidelines 
1.   Orientation  
!    Scoring 
2 points for the correct answer, 1 point for wrong answers, and 0 points for no answer or 
a conceptually unrelated answer (see details below). 
! Timing 
 Maximum of 10 seconds for each answer.  
Instructions and Scoring Guide 
Year If the person gives the correct year score 2 points, the incorrect year score 1 
point, and 0 points if no year is given. 
Country Score 2 points for correct country, 1 point for incorrect country, and 0 if no 
country is named. 
Month Score 2 points for the correct month or for the previous or following month if 
within two days of the change of the month (for example, if the date is 
September 30th, score the full 2 points if person answers October. Similarly, 
if the date is October 2nd, score 2 points if person says September). Score 1 
point if the month is incorrect and 0 if no month is named. 
Date Score 2 points for exact date or ± one day, 1 point for any other date, 0 if no 
date is named. 
Day of 
week 
2 points for correct day, 1 point for incorrect day, 0 if no day named. 
To begin say...  
“I’d like to ask you some questions and give you some problems to solve.  Would that be 
OK?”  
What country is this? __________ 
What year is this?  __________ 
What month is this? __________ 
What is today’s date?  __________ 
What day of the week is this? __________ 
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2. Word Registration  
Instructions and Scoring Guide 
!    Scoring 
Score 1 point for each word recalled after the first reading. If subject recalls all five, 
repeat the five items once and then go on to clock drawing.  If subject does not repeat all 
5, repeat the 5 items and ask the subject to repeat them.  Do this until the subject 
correctly recalls all 5 items or for a maximum of 3 trials. Do not score for trials 2 and 3.  
These trials are to help the person learn in preparation for the delayed recall task.   
" Timing 
 Say the words very deliberately, one per second.  Allow 10 seconds for the recall. 
To begin say… 
“I am going to say 5 words.  After I have said these 5 words, repeat them back to me.  Are 
you ready?”  
Dog  rain butter love door 
 
Score __________ / 5  
When finished, say…  “Remember these words because I’ll ask you to recall them later.” 
Alternate word groups include… 
cat dark pepper fear bed 
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3. Clock Drawing  
Instructions and Scoring Guide 
!    Scoring 
Place the circle of the transparent scoring template over the circle of the patient’s 
completed clock.  Rotate the template circle so that the “12” s align.  Score 1 point each if 
the 1, 2, 4, 5, 7, 8, 10, and 11 are in the correct quadrants.  Score 1 point each if the 12, 
3, 6, and 9 touch their quadrant lines.  Subtract one point for each number repeated or for 
numbers above 12.  (Should the patient not have drawn a “12” align the template with the 
3, 6, or 9.) 
Score the placement of hands according to the tips and pivot.  Give 1 point for each hand 
between the dashed lines.  Score 1 point for hands connecting at the pivot. 
! Timing 
 One minute.  
To begin… 
Give the sheet of paper with the pre-drawn circle and a pencil to the patient. Say “Now put in the 
numbers like the face of a clock.”  Then say “Set the hands to show ten past eleven.”  
Place the numbers and hands as carefully as you can.” 
You may prompt at each stage…”put in the numbers…. put the time as ten past eleven”.  
Score:  Numbers  Correct + ______/ 12 
  Errors - ______ 
 Hands  + ______/ 2 
 Pivot  + ______/ 1 
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4. Delayed Recall 
Instructions and Scoring Guide 
!    Scoring  
  Score 4 points for each word recalled. Subjects may recall words in any order.   
! Timing 
 10 seconds. 
To begin say…  
A few minutes ago I named five words.  Name as many of those words as you can 
remember.  
dog  rain butter love door 
Score __________ / 20  
Alternate word groups include… 
cat dark pepper fear bed 
rat heat bread round chair 
 
5. Verbal Fluency 
Instructions and Scoring Guide 
!    Scoring.  
Give ½ point for each correct word recalled to a maximum of 40 words.  Round up the 
final score.  Do not count words with different suffixes twice (e.g. fish / fishes, mouse / 
mice, etc.).  Accept alternate species (e.g. blue jay, robin, sparrow, duck, etc.). Alternate 
forms include fruits and vegetables, cities and towns.   
! Timing. 
60 seconds. Write down each word the patient says.  (You may need to develop some 
kind of “shorthand” for the speedier patients, such as writing the first 3 letters of each 
word and then completing them later.) 
To begin say…  
“Name as many animals as you can in one minute.  Ready? Go.” 
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6. Logical Memory 
Instructions and Scoring Guide 
!    Scoring.  
Give 2 points for each correct word item recalled verbatim.   All bolded words within each 
section must be recalled for score 2 points.  Otherwise score 0.  Recall may be in any 
order.   
! Timing. 
30 seconds. Check off each word unit recalled.   
To begin say…  
“I am going to read you a short story. After I have finished reading I want you to tell me as 
much of the story as you can.  OK?”  [patient signifies agreement, then begin reading the 
paragraph at about 1 second for each word unit]  “The red… fox… ran across........… the 
bushes.”  
6. Logical Memory       
The red The brown The white 2 / 0 
fox dog hen 2 / 0 
ran across ran across walked across 2 / 0 
the ploughed the metal the concrete  2 / 0 
field. bridge. road. 2 / 0 
It was chased by It was hunting It was followed by 2 / 0 
a brown a white a black 2 / 0 
dog. rabbit. cat. 2 / 0 
It was a hot It was a cold It was a warm 2 / 0 
May October September 2 / 0 
morning. day. afternoon. 2 / 0 
Fragrant  Ripe Dry 2 / 0 
blossoms apples leaves 2 / 0 
were forming on were hanging on were blowing in  2 / 0 
the bushes. the trees. the wind. 2 / 0 
 
Score __________ / 30  
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The Clock Transparency Scoring Template 
Scoring 
Place this scoring template over the completed clock with the template’s “12 o’clock” line placed 
over the subject’s 12.  Adjust the template to maximize the score for the numbers and hands. The 
total score is 15. Record scores on the score sheet as follows: 
 
Numbers 
• For the numbers 12, 3, 6, and 9 score one (1) point if they touch their respective lines, 
zero (0) point if missed, and zero (0) if the number is omitted.  
• For the numbers 1, 2, 4, 5, 7, 8, 10, and 11 score one (1) point for each number in the 
correct quadrant, zero (0) point if the number is outside the quadrant, and zero (0) if the 
number is omitted. 
• Subtract one point for each number repeated or more than 12. 
 
Hands 
• Score the placement of the entire hand. If the hands are drawn within range, score one 
(1) point for each hand; if the hands are drawn outside the hatched line or are omitted 
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The Quick Memory Check 
 
Instructions. 
1. Make sure you have the full attention of the person being tested. 
2. Get their permission to carry out the test. 
3. Make sure the person being tested can hear you and that there is no background noise or 
distractions. Get their glasses or hearing aid.  
4. Make sure you have a clock/watch to accurately time the test, be strict with time! 
5. Try to avoid clues or feedback regarding their performance. Don’t nod or smile when they 




Tell us about yourself first. 
 
What relation are you to the person? Spouse  Child   Friend  
Other:  Please state______ 
How many days each week, on average, do you see this person?__________ 
What is your occupation? __________Your age?_____Male  Female  
Level of education you’ve completed: Did not complete Primary  
Completed:  Primary   Secondary   Third level  
 
Caregiver Report 
What age is the person being assessed?_____ 
Describe the person over the last few years. 
 
Circle the appropriate answer  
Q1 Is there memory loss? (Is the person forgetting names, 
appointments, birthdays, conversations? repeating questions, 
losing objects frequently? etc) 
Y N 
Q2 Is it getting worse recently? (Has the memory loss been more 
obvious in recent months?) 
Y N 
Q3 Is the person unable to do anything now that he/she could 
do before the memory loss began?""
(e.g. managing finances, medications, cooking, shopping, 





Q4 Does the person seem more confused in the last few months? 
(e.g. getting lost, disorientated, not aware of the time, place or 
people around, difficulty with new tasks, unsure what to do in 
an emergency?) 
Y N 
Q5 Has there been a recent change to the quality of speech and 
conversation? (e.g. word finding difficulties, mixing up names, 













Caregiver Assessment  
To begin say “I’d like to ask you some questions and give you some problems to solve”. 
!
Date""""""/""""""/"""""""""""""""""""""Time"of"day:"
  Correct Score 
Q1 Orientation Test 
Ask the person...  
What country is this? 
Score 3 points for correct country, 
accept exact country only. 
Y N /3 
What year is this? 
Score 3 points for correct year, 
accept exact year only. 
Y N /3 
What month is this? 
Score 3 points for the correct month 
or on the first day of the new month 
or last day of the previous, either. 
Y N /3 
What day of the week is this? 
Score 3 points for correct day, 
accept exact day only. 
Y N /3 
What is the date? 
Score 3 points for exact date or ± 
one day. 
Y N /3 
Q2 Naming Test 
Ask them to name as many 
“animals” they can think of 
in one minute. Give 1 point 
for each, to a maximum 40. 
 
Accept all ‘creatures’, 
including animals, birds, fish 
or insects. 
 
Do not count repeated names 
or different suffixes twice e.g. 
mouse/mice but allow points 
for similar names e.g. calf, 
cow, bull. 
List 
Write down each word the patient 










Q3 Repeating a Short 
Story: Read ONCE only!
“Once I have FULLY read 
this short story to you, repeat 
it for me, word for word”. 
Give 3 points for each correct word 
recalled verbatim. Otherwise score 0.  
Recall may be in any order. Read 
once & count underlined words only.  




















2. Other Assessment Instruments  







Now we want you to remember what your friend or relative was like 10 years ago and 
to compare it with what he/she is like now. 10 years ago was in 19__. Below are 
situations where this person has to use his/her memory or intelligence and we want 
you to indicate whether this has improved, stayed the same or got worse in that 
situation over the past 10 years. Note the importance of comparing his/her present 
performance with 10 years ago. So if 10 years ago this person always forgot where 
he/she had left things, and he/she still does, then this would be considered "Hasn't 
changed much". Please indicate the changes you have observed by circling the 
appropriate answer. 
 
Compared with 10 years ago how is this person at: 
 
   1 
 
  2     3   4   5 
1. Remembering things about 














2. Remembering things that 












3. Recalling conversations a 












4. Remembering his/her 












5. Remembering what day and 












6. Remembering where things 












7. Remembering where to find 
things which have been put in 












8. Knowing how to work 





















9. Learning to use a new 


























11. Following a story in a book 






































14. Handling financial matters 













15. Handling other everyday 
arithmetic problems e.g. 
knowing how much food to 
buy, knowing how long 













16. Using his/her intelligence 
to understand what's going on 




















     
 
$''HPHQWLD6FUHHQLQJ,QWHUYLHZ                       Patient ID#:__________    
                                                                                                        CS ID#:___________ 




































































Appendix 2.3. General Practitioner Assessment of Cognition (a) patient examination, 





Patient name:__________________________ Date: _____________ 
 
 
GPCOG Screening Test 
 
Step 1: Patient Examination 
Unless specified, each question should only be asked once 
 
Name and Address for subsequent recall test 
 
1. “I am going to give you a name and address.  After I have said it, I want you to repeat 
it.  Remember this name and address because I am going to ask you to tell it to me 
again in a few minutes: John Brown, 42 West Street, Kensington.”  (Allow a maximum 
of 4 attempts). 
 
Time Orientation Correct Incorrect 
2. What is the date?  (exact only) 
 
 
Clock Drawing – use blank page 
3. Please mark in all the numbers to indicate  
the hours of a clock (correct spacing required) 
4. Please mark in hands to show 10 minutes past 




5. Can you tell me something that happened in the news recently? 
(Recently = in the last week.  If a general answer is given, 








 West (St) 
 Kensington 
 
(To get a total score, add the number of items answered correctly 
Total correct (score out of 9) 
 
If patient scores 9, no significant cognitive impairment and further testing not necessary. 
If patient scores 5-8, more information required.  Proceed with Step 2, informant section. 
If patient scores 0-4, cognitive impairment is indicated.  Conduct standard investigations. 
© University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care; 
Brodaty et al, JAGS 2002; 50:530-534 












Informant Interview  
 
 Date:  ____________  
 
 
Informant’s name: ___________________________________   
Informant’s relationship to patient, i.e. informant is the patient’s:   _____________  
 
 
These six questions ask how the patient is compared to when s/he 
was well, say 5 – 10 years ago 






 Yes No Know N/A 
 
 Does the patient have more trouble remembering things 
 that have happened recently than s/he used to? 
 
 
 Does he or she have more trouble recalling conversations 
a few days later? 
 
 
 When speaking, does the patient have more difficulty in 




 Is the patient less able to manage money and financial 
affairs (e.g. paying bills, budgeting)? 
 
 




 Does the patient need more assistance with transport 
(either private or public)?  
(If the patient has difficulties due only to physical problems, e.g bad leg, tick ‘no’) 
 
 
(To get a total score, add the number of items answered ‘no’, ‘don’t know’ or ‘N/A’) 
 Total score (out of 6) 
If patient scores 0-3, cognitive impairment is indicated.  Conduct standard investigations. 
© University of New South Wales as represented by the Dementia Collaborative Research Centre – Assessment and Better Care; 
Brodaty et al, JAGS 2002; 50:530-534 
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WHITE-  ADCS COPY                        YELLOW-  INVESTIGATOR'S COPY                        PINK- CLINICAL MONITOR'S COPY
    Center Name               Patient Number              Patient Initials   Examiner Initials       Examination Date
Month     Day        Year
 P   R
   2.  NAMING OBJECTS AND FINGERS: Check each object/finger
  named correctly or check "NONE.”
             NONE
           Flower                 Rattle                            Wallet
           Bed                 Mask                    Harmonica
           Whistle                 Scissors                    Stethoscope
           Pencil                 Comb                            Tongs
None.
Very Mild: 1 or 2 instances, not clinically significant.
Mild: noticeable circumlocution or synonym substitution.
Moderate: loss of words without compensation on
   occasion.
Moderately Severe: frequent loss of words without
   compensation.
Severe: nearly total loss of content words; speech
   sounds empty; 1– to 2-word utterances.
None.
Very Mild: forgets once.
Mild: must be reminded 2 times.
Moderate: must be reminded 3–4 times.
Moderately Severe: must be reminded 5–6 times
Severe: must be reminded 7 or more times.
   11.  REMEMBERING TEST INSTRUCTIONS: Check level of




Year Time of day
   5.  IDEATlONAL PRAXIS: Check each step completed
       correctly or check “NONE”              NONE
None: attempted but drew no forms correctly.






Point to the ceilinq, then to the floor.
Put the pencil on top of the card, then put it back.
Put the watch on the other side of the pencil and turn over
   the card.
Tap each shoulder twice with two fingers keeping your eyes
   shut.
None: patient understands.
Very Mild:  one instance of misunderstanding.
Mild: 3–5 instances of misunderstanding.
Moderate: requires several repetitions and rephrasing.
Moderately Severe: patient only occasionally responds
   correctly; i.e., yes – no questions.
Severe: patient rarely responds to questions
   appropriately; not due to poverty of speech.
   1.  WORD RECALL TASK: Indicate the total number of
correct responses for each trial
     7.  WORD RECOGNITION TASK: Scoring will be done by the
  A.D.C.S. Data Coordinating Center.
Trial 1 Trial 2 Trial 3 Trial 1 Trial 2 Trial 3
   8.  LANGUAGE: Check level of impairment.
None: patient speaks clearly and/or is understandable.
Very Mild: one instance of lack of understandability.
Mild: patient has difficulty < 25% of the time.
Moderate: patient has difficulty 25–50% of the time.
Moderately Severe: patient has difficulty more than
   50% of the time.
Severe: one- or two-word utterances; fluent, but empty
   speech; mute.
   9.  COMPREHENSION OF SPOKEN LANGUAGE: Check level
     of  impairment
   3.  COMMANDS: Check each command performed
     correctly or check “NONE.”              NONE
   4.  CONSTRUCTIONAL PRAXIS: Check each figure
  drawn correctly.
   10. WORD FINDING DIFFICULTY: Check one response.
Fold a letter.
Put letter in envelope.
Seal envelope.
Address envelope.
Indicate where stamp goes.
   6.  ORIENTATION: Check each item answered
      correctly or check “NONE.”              NONE
   Thumb         Index            Ring
   Pinky         Middle
Alzheimer's Disease Cooperative Study
ADAS – Cognitive Behavior














WHITE-  ADCS COPY                        YELLOW-  INVESTIGATOR'S COPY                        PINK- CLINICAL MONITOR'S COPY
    Center Name               Patient Number              Patient Initials   Examiner Initials       Examination Date
Month     Day        Year
 P   R
Check EACH word correctly recalled.
Indicate total number of words correctly recalled for EACH trial on the ADAS Cognitive Behavior Form.
Present Word List #2.
    BOTTLE
    POTATO
    GIRL
    TEMPLE
    STAR
    ANIMAL
    FOREST
    LAKE
    CLOCK
























TOTAL                                      TOTAL                                     TOTAL
Alzheimer's Disease Cooperative Study
ADAS – Word Recall
SAMPLE FORM – Page 2 of 4
12.  Executive Function (Maze):
a. number of errors
b. time at completion or second error
(total seconds)
13.  Number Cancellation:
a. number of targets hit
(Range: 0 - 40)
b. number of errors
c. number of times to remind of task
If any item(s) 1-13 are incomplete or not
done, please specify reason:
Subject too cognitively impaired to
complete
Subject was unable to complete for
physical reasons
Subject refused




















WHITE-  ADCS COPY                        YELLOW-  INVESTIGATOR'S COPY                        PINK- CLINICAL MONITOR'S COPY
    Center Name               Patient Number              Patient Initials   Examiner Initials       Examination Date
Month     Day        Year
 P   R
    BOTTLE
    POTATO
    GIRL
    TEMPLE
    STAR
    ANIMAL
    FOREST
    LAKE
    CLOCK
    OFFICE
TOTAL
check EACH word correctly recalled.
Instructions:  Say to the patient, “NOW I WANT YOU TO TRY TO REMEMBER THE
WORDS THAT I SHOWED YOU EARLIER ON PRINTED CARDS.  CAN YOU TELL ME
ANY OF THOSE WORDS?”
Allow a maximum of two minutes for recall.
Alzheimer's Disease Cooperative Study
ADAS – Delayed Recall






































    Center Name               Patient Number              Patient Initials   Examiner Initials       Examination Date
Alzheimer's Disease Cooperative Study
WHITE-  ADCS COPY                        YELLOW-  INVESTIGATOR'S COPY                        PINK- CLINICAL MONITOR'S COPY
ADAS – Word Recognition
SAMPLE FORM – Page 4 of 4
Month     Day        Year
 P   R
*see procedures manual for further clarification
Check subject's response for each word.  Subject should respond "yes" to original words
which are bolded.  INCORRECT responses are shaded.  Three trials of reading and
recognition are given.

















































Yes No Yes No Yes No
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Q Activities of Daily Living Score 
Tell us how the patient manages his / her “activities of daily living”.  How does he / she function every 
day?  Circle the number that best applies in the past week.  If the person does not do this activity, e.g. 
another person does shopping, circle “N/A” for not applicable.  
 
Type of activity 
What is the level of care 
required? 
How much of a 
problem is this? 
 
 
In the past week how well was he/she able to…  
 
na Not applicable-never did this  
0 Performs spontaneously and 
 independently 
1 Needs prompting (verbal) 
2 Needs set-up (physical)  
3 Needs supervision (stand by) 
4 Needs assistance (physical) 
5 Complete care required  




4   Extreme 
manage their own medications na 0 1 2 3 4 5 0 1 2 3 4 
handle money (pay bills, shop, etc.) na 0 1 2 3 4 5 0 1 2 3 4 
use the telephone na 0 1 2 3 4 5 0 1 2 3 4 
prepare food na 0 1 2 3 4 5 0 1 2 3 4 
groom (hair, shaving, nails, etc.) na 0 1 2 3 4 5 0 1 2 3 4 
bath (bath, shower) na 0 1 2 3 4 5 0 1 2 3 4 
walk na 0 1 2 3 4 5 0 1 2 3 4 
toilet (urine / feces) na 0 1 2 3 4 5 0 1 2 3 4 
transfer (e.g. bed to chair) na 0 1 2 3 4 5 0 1 2 3 4 
feed themselves (eat and drink) na 0 1 2 3 4 5 0 1 2 3 4 
Is this person mainly limited or impaired by physical problems?   
Check off if any of the following reduced the person’s ability to care for him / her self. 
!  Blindness   !  Hearing   !  Weakness   !  Arthritis   !  Memory and thinking 
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3. Permissions and Ethical Approval 
 
Appendix 3.1. Permission to use the Montreal Cognitive Assessment (obtained by 








































Appendix 3.3. Ethical approval form for the extension of the external validation of the 















Appendix 3.4. Ethical approval form for the validation of the Quick Memory Check 









Appendix 3.5. Ethical approval form for the extension of the validation of the Quick 







4. Translations of the Qmci 
 
Appendix 4.1. Turkish Translation of the Qmci with scoring instructions 
Hızlı%Hafif%Kognitif%Bozukluk%Taraması%(hHKB)%
















kedi! karanlık! biber! korku! yatak!
sıçan! ısı! ekmek! yuvarlak! sandalye!
 
3. Saat Çizme  
Skor:%% Sayılar!! Doğru! ! +!______/!12!
! ! Hatalar! ! J!______!
! Saatin!kolları!(akrep,!yelkovan)! +!______/!2!
! Merkez!noktası! ! +!______/!1!












köpek%% yağmur% tereyağı% sevgi% kapı%
Skor%__________%/%20!!












6.%Mantıksal%Hafıza%% % % % % %
Kırmızı% Kahverengi%% Beyaz%% 2!/!0!
tilki% köpek%% tavuk% 2!/!0%
sürülmüş% metal% beton%% 2!/!0%
tarladan% köprüden!! yoldan!! 2!/!0!
koşarak%geçti.! koşarak%geçti.! yürüyerek%geçti.%! 2!/!0!
Kahverengi% Beyaz!! Siyah!! 2!/!0%






Sıcak!bir! Soğuk!bir! Ilık!bir!! 2!/!0!




Güzel%kokulu%% Olgun%% Kuru% 2!/!0!
çiçekler% elmalar% yapraklar% 2!/!0!












Hızlı Hafif Kognitif Bozukluk Taraması (hHKB) 
Uygulama ve Puanlama Kılavuzu 
1.   Yönelim  
!    Puanlama 
Doğru cevap için 2 puan, yanlış cevaplar için 1 puan, hiç cevap yok veya kavramsal 
olarak ilişkisiz cevap için 0 puan (aşağıdaki detaylara bakınız). 
! Zamanlama 
Her cevap için en fazla 10 saniye.  
Yönergeler ve Puanlama Kılavuzu 
Yıl Doğru yılı söylerse 2 puan, yanlış yılı söylerse 1 puan, yıl söylemezse 0 
puan verilir.  
Ülke Doğru ülke için 2 puan, yanlış ülke için 1 puan, ülke söylenmezse 0 puan 
verilir.  
Ay Doğru ay için veya ay değişiminin iki günü içerisinde iken önceki veya 
sonraki ay için 2 puan verilir (örneğin, tarih 30 Eylül ise, kişi Ekim cevabı 
verirse 2 puan verilir. Benzer şekilde tarih 2 Ekim ise, kişi Eylül derse 2 
puan verilir). Ay yanlışsa 1 puan, ay söylenmezse 0 puan.  
Tarih Doğru tarih veya ± bir gün için 2 puan, herhangi başka bir tarih için 1 
puan, tarih söylenmezse 0 puan verilir. 
Haftanın 
günü 
Doğru gün için 2 puan, yanlış gün için 1 puan, gün söylenmezse 0 puan 
verilir. 
Başlamak için şöyle söyleyin:  
“Size bazı sorular sormak ve çözmeniz bazı problemler vermek istiyorum. Sizin için 
uygun mu?”  
Hangi ülkedeyiz? __________ 
Hangi yıldayız?  __________ 
Hangi aydayız? __________ 
Bugünün tarihi nedir?  __________ 
Bugün haftanın hangi günü? __________ 
 
Skor __________ / 10  
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2. Kelime Kayıt Etme   
Uygulama ve Puanlama Kılavuzu 
!    Puanlama 
İlk okuma ardından hatırlanan her kelime için 1 puan verin. Kişi beşini birden 
hatırlarsa beş maddeyi bir seferde tekrarlayın ve saat çizme testine geçin. Kişi beşini 
birden hatırlayamazsa 5 maddeyi tekrarlayın ve hastanın tekrarlamasını isteyin. Bunu 
kişi doğru bir şekilde 5 maddeyi birden hatırlayana kadar ya da en fazla 3 deneme 
olacak şekilde tekrarlayın. İkinci ve üçüncü denemeler için puan vermeyin. Bu 
denemeler kişinin gecikmiş hatırlama testine hazırlanması için öğrenmesine yardım 
etmek içindir.    
" Zamanlama 
 Kelimeleri çok dikkatlice saniyede bir tane olacak şekilde söyleyin. Hatırlama için 10 
saniye zaman tanıyın.  
Başlamak için şöyle söyleyin: 
 “Size 5 kelime söyleyeceğim. Ben bu 5 kelimeyi söyledikten sonra bana onları tekrar 
edin. Hazır mısınız?”  
Köpek  yağmur tereyağı sevgi Kapı 
 
Skor __________ / 5  
Bitince şöyle söyleyin: “Bu kelimeleri hatırlayın çünkü daha sonra sizden onları 
hatırlamanızı isteyeceğim.” 
Alternatif kelime grupları şunları içerir:  
kedi karanlık biber korku yatak 
sıçan ısı ekmek yuvarlak sandalye 
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3. Saat Çizme  
Uygulama ve Puanlama Kılavuzu 
!    Puanlama 
Transparan puanlama şablonunu hastanın tamamlanmış saatinin dairesinin üzerine 
koyun. “12” yi hizalamak için şablon dairesini döndürün. 1, 2, 4, 5, 7, 8, 10 ve 11 
doğru kadranlardaysa her birine 1’er puan verin. 12, 3, 6 ve 9 kadran çizgilerine 
değiyorsa her birine 1’er puan verin. Tekrarlayan her sayı için veya 12’nin üzerinde 
her sayı için 1 puan çıkarın. (Hasta “12” yazmadıysa şablonu 3, 6, veya 9 ile 
hizalayın.) 
Saatin kollarının yerleşimini uçlarına ve merkez noktasına göre puanlayın. Kesikli 
çizgiler arasındaki her kol için 1’er puan verin. Merkez noktasında birleşen kollar için 
1 puan verin.  
! Zamanlama 
 Bir dakika.   
Başlamak için: 
Hastaya üzerinde önceden çizilmiş daire olan kağıdı ve kalemi verin. Şöyle söyleyin: “Şimdi 
saat oluşturacak şekilde sayıları yerleştirin.”. Sonra şöyle söyleyin: “Saatin kollarını on 
biri on geçiyor olacak şekilde yerleştirin.”  Sayıları ve kolları yapabildiğiniz kadar 
dikkatli yerleştirin.” 
Her evrede hatırlatma yapabilirsiniz… “sayıları yerleştirin. … saati on biri on geçiyor 
olacak şekilde yapın”.  
Skor:  Sayılar  Doğru  + ______/ 12 
  Hatalar  - ______ 
 Saatin kolları (akrep, yelkovan)  + ______/ 2 
 Merkez noktası    + ______/ 1 





4. Gecikmiş Geri Çağırma 
Uygulama ve Puanlama Kılavuzu 
!    Puanlama 
  Hatırlanan her kelime için 4’er puan verin. Kişiler kelimeleri herhangi bir sırayla 
hatırlayabilirler.    
! Zamanlama 
 10 saniye.  
Başlamak için şöyle söyleyin: 
Birkaç dakika önce beş kelime söyledim. O kelimelerden hatırlayabildiğiniz kadar çok 
kelimeyi sayın.   
köpek  yağmur tereyağı sevgi kapı 
Skor __________ / 20  
Alternatif kelime grupları şunları içerir:  
kedi karanlık biber korku yatak 
sıçan ısı ekmek yuvarlak sandalye 
 
5. Sözel Akıcılık  
Uygulama ve Puanlama Kılavuzu 
!    Puanlama  
En fazla 40 kelimeye kadar doğru hatırlanan her kelime için ½’ şer puan verin. Son 
skoru yukarıya yuvarlayın. Farklı soneklere sahip kelimeleri iki kere puanlamayın 
(örn. balık/balıklar, fare/fareler gibi). Aynı grubun farklı türlerini kabul edin (örn. karga, 
bülbül, serçe, ördek gibi.).  
Alternatif formlarında meyve ve sebzeler, şehirler ve kasabalar sorulabilir.   
! Zamanlama 
60 saniye. Hastanın söylediği her kelimeyi yazın. (Daha hızlı hastalar için bir çeşit 
“kısayol” geliştirmeniz gerekebilir. Örneğin, her kelimenin ilk 3 harfini yazıp sonradan 
tamamlamak gibi.) 
Başlamak için şöyle söyleyin: 
“Bir dakika içinde sayabildiğiniz kadar çok hayvan ismi sayın. Hazır mısınız? 
Başlayın.” 
Skor __________ / 20  
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6. Mantıksal Bellek 
Uygulama ve Puanlama Kılavuzu 
!    Puanlama  
Harfi harfine hatırlanmış her doğru kelime için 2’şer puan verin. 2 puan için her 
bölümdeki koyu belirtilmiş her kelimenin hatırlanması gerekir. Aksi takdirde 0 puan 
verin. Hatırlama herhangi bir sırayla olabilir.    
! Zamanlama 
30 saniye. Hatırlanan her kelime ünitesine çek atın.     
Başlamak için şöyle söyleyin:  
“Size kısa bir hikaye okuyacağım. Okumayı bitirdikten sonra bana hikayenin 
anlatabildiğiniz kadar çok kısmını anlatmanızı istiyorum. Tamam mı?”  [hasta kabul 
ettiğini belirttikten sonra her kelime bölümünü yaklaşık 1 saniyede olmak üzere paragrafı 
okumaya başlayın]  “Kırmızı… tilki… sürülmüş........… üzerinde oluşmaktaydı.”  
 
6. Mantıksal Hafıza       
Kırmızı Kahverengi  Beyaz  2 / 0 
tilki köpek  tavuk 2 / 0 
sürülmüş metal beton  2 / 0 
tarladan köprüden  yoldan  2 / 0 
koşarak geçti. koşarak geçti. yürüyerek geçti.  2 / 0 
Kahverengi Beyaz  Siyah  2 / 0 





2 / 0 
Sıcak bir Soğuk bir Ilık bir  2 / 0 
Mayıs Ekim Eylül 2 / 0 
sabahıydı. günüydü. öğleden sonrasıydı.  2 / 0 
Güzel kokulu  Olgun  Kuru 2 / 0 
çiçekler elmalar yapraklar 2 / 0 
çalıların  ağaçların  rüzgarda   2 / 0 
üzerinde 
oluşmaktaydı.  
üzerinden sarkıyordu.  savruluyordu.  2 / 0 
 
 
Skor __________ / 30  
 
hHKB Toplam Skor ____________ / 100 
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Saat Çizme Transparan Puanlama Şablonu 
Puanlama 
Transparan puanlama şablonunu hastanın tamamlanmış saatinin dairesinin üzerine şablonun 
“12”si hastanın “12”sinin üzerine gelecek şekilde koyun. Şablonu sayı ve kolların puanlarının 
en yüksek olacağı şekilde ayarlayın. Toplam skor 15’dir. Skor sayfasına skorları aşağıdaki 
gibi kaydedin.  
Sayılar 
• 12, 3, 6 ve 9 için ilgili çizgilere değiyorsa her birine bir (1) puan verin, değmiyorsa sıfır 
(0) puan verin ve sayı ihmal edilmişse sıfır (0) puan verin.   
• 1, 2, 4, 5, 7, 8, 10 ve 11 için doğru kadrandaki her sayı için bir (1) puan verin, sayı 
kadranın dışındaysa sıfır (0) puan verin ve sayı ihmal edilmişse sıfır (0) puan verin.  
• Tekrar eden her sayı için veya 12’nin üzerindeki her sayı için bir puan çıkarın.  
 
Saatin kolları (akrep, yelkovan) 
Kolun bütününün yerleştirilmesine puan verin. Kollar aralık içerisine çizildiyse her kol için bir 
(1) puan verin; kollar hazırlanmış çizgilerin dışında çizildiyse veya çizilmediyse sıfır (0) puan 













































































kat! donker! peper! angst! bed!
rat! hitte! brood! rond! stoel!
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Score:%% Cijfers!! Correct! +!______/!12!
! ! Fouten! J!______!
! Wijzers! ! +!______/!2!
! Middelpunt! ! +!______/!1!
% % % Totaal% % +%______/%15%
!
! 284!










hond% % regen% boter% liefde% deur%
Score%__________%/%20!!
Woordgroepen!ter!afwisseling!zijn…!
kat! donker! peper! angst! bed!










































6.%Logisch%Geheugen% % % % % % %
De%rode! De!bruine! De!witte! 2!/!0!
vos% hond% kip% 2!/!0%
rende%over% rende%over% liep%over% 2!/!0%
het!omgeploegde! de!metalen! de!geasfalteerde! 2!/!0!






een!bruine! een!wit! een!zwarte! 2!/!0%




morgen% dag% middag% 2!/!0%
in%mei.! in%oktober.! in%september.! 2!/!0%
Geurige% Rijpe% Droge% 2!/!0!
bloesems% appels% bladeren% 2!/!0!













Plaats dit scoresjabloon over de getekende klok met de “12 uur”- lijn van het sjabloon 
geplaatst op de 12 van de patiënt. Verschuif het sjabloon  om de score voor cijfers en wijzers 





























































































Katze! Dunkel! Pfeffer! Angst! Bett!
Ratte! Hitze! Brot! rund! Stuhl!
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Punktanzahl:%% Zahlen! Korrekt! +!______/!12!
! ! Falsch! J!______!
! Zeiger! ! +!______/!2!
! Mittelpunkt! ! +!______/!1!
% % % Total% % % % +%______/%15%
!
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Katze! dunkel! Pfeffer! Angst! Bett!












































6.%Logisches%Denken% % % % % %
Der%rote! Der!braune! Das!weiße! 2!/!0!
Fuchs% Hund% Hühnchen% 2!/!0%
lief%durch%%% lief%über% sprang%über% 2!/!0%
das!umgepflügte! die!metallene! die!asphaltierte! 2!/!0!






einem!braunen! einen!weißen! einer!schwarzen! 2!/!0%




Morgen% Tag% Nachmittag% 2!/!0%
im%März.! im%Oktober.! im%September.! 2!/!0%
Wohlriechende% Reife% Trockene% 2!/!0!
Blüten% Äpfel% Blätter% 2!/!0!
blühten% hingen% bewegten% 2!/!0%








Transparente Schablonen für die Uhrenaufgabe 
 
Punktanzahl 
Lege diese Schablone über die gezeichnete Uhr, wobei die 12-Uhr Linie der Schablone auf  
der 12 Uhr Linie von der gezeichneten Uhr vom Patienten liegt. Verschiebe die Schablone um 
die Punkte zu maximieren. Die maximale Punktzahl ist 15. Notiere die Punkte wie 





































©  O’Caoimh  R,  Molloy  D.  W  2011. 
QMCI- Quick Mild Cognitive Impairment screen 
(Test cognitivo Caoimh-Molloy) 
                                                    Test da allegare alla scheda generale dati partecipante n……. 
ANNO DI NASCITA                 SESSO   M    F             Istruzione:                            Data: 
 
1. Orientamento (un minuto) 
  
(Dare 2 punti per risposta corretta, 1 se ha tentato e se non è corretta, 0 se nessun tentativo) 
Che Paese è questo? __________ 
In che anno siamo?  __________ 
In che mese siamo? __________ 
Quante ne abbiamo oggi?  __________ 
Che giorno delle settimana è oggi? __________ 
 
Punteggio __________ / 10  
 
 
2.  Parole ricordate (30 secondi) 
Per cominciare diciamo ...  
“Sto per dire 5 parole. Dopo che le ho pronunciate, ripetile.  Sei pronto?” 
(Dare 1 punto per ogni parola ricordata, in qualsiasi ordineany order) 
 
Cane  pioggia burro amore porta 
 
 
Punteggio __________ / 5  
 
 
Gruppi  di  parole  alternative  includono  … 
gatto buio pepe paura letto 
ratto calore pane turno sedia 
 
 
3. Disegno  dell’orologio  (un minuto) 
 
“Utilizzare il cerchio fornito per disegnare un orologio, impostare il tempo di 
'11:10'.” 
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Sottrarre 1 punto per ogni numero duplicato o maggiore di 12, ad esempio, 15 o 45). 
 
Punteggio:  Numeri  Corretti + ______/ 12 
  Errati - ______ 
 Mani  + ______/ 2 
 Perno  + ______/ 1 
   Totale    + ______/ 15 
 
 
4. Ricordiamo (30 secondi) 
 
Per cominciare diciamo ...  
“Pochi minuti fa ho elencato cinque parole. Potresti ripetermele”   
(Ricordate in qualsiasi ordine, entro 30 secondi, dare 4 punti per parola)  
 
Cane  pioggia burro amore Porta 
 
 
Punteggio __________ / 20  
 
5. Fluidità verbale (un minuto) 
 “Dimmi, in un minuto, il maggior numero di nomi di animali che ti vengono in 
mente. Pronto? Cominciamo.” 
(Dare ½ punto per ogni parola corretta ricordata fino ad un massimo di 40 parole. Arrotondare il 
punteggio finale. Non contare le parole con suffissi diversi per due volte (es. pesce / pesci, topo / 
topi, ecc.) Accettare specie alternative (ad esempio pettirosso, passero, anatra, ecc.) Forme 
alternative includono frutta e verdura, città e paesi). 
 
Punteggio __________ / 20  
 






6. Memoria logica (30 secondi) 
 
 “Ho intenzione di leggere una breve storia. Dopo che ho finito di leggere voglio che 
tu mi ripeta gran parte della storia, OK? "[Se  il  paziente  è  d’accordo,  iniziare la 
lettura del paragrafo]" La  rossa  volpe………… attraversava ........... i cespugli.”   
(Dare 2 punti per parola evidenziata, che ha ricordato esattamente, subito entro 30 secondi, in 
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6. Logical Memory       
La volpe Il cane La gallina 2 / 0 
rossa marrone bianca 2 / 0 
corse attraverso corse attraverso attraversò 2 / 0 
il campo il ponte la strada  2 / 0 
arato metallico di cemento 2 / 0 
e fu  inseguita  Stava dando la caccia Era inseguita da 2 / 0 
da un cane a un coniglio un gatto 2 / 0 
marrone. bianco nero 2 / 0 
Era un caldo Era un freddo Era un tiepido 2 / 0 
giorno  giorno pomeriggio 2 / 0 
di Maggio. di Ottobre. di Settembre. 2 / 0 
Fiori  Mele Le foglie 2 / 0 
profumati mature secche 2 / 0 
stavano sbocciando 
tra 
pendevano erano soffiate via  2 / 0 
i cespugli. dagli alberi. dal vento. 2 / 0 
 
 
Punteggio __________ / 30  
 
 




                                               
                   Test eseguito da _____________________________                    Data    /    / 
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The Clock Transparency Scoring Template 
Punteggio 
Mettere questo modello sopra l'orologio disegnato dal paziente sovapponendo le "12:00" Regolare il 
modello massimizzando il punteggio per i numeri e le mani. Il punteggio totale è 15.  
Numeri 
•  Per  i  numeri  12,  3,  6  e 9, il punteggio 1 punto se toccano le rispettive linee, 0 punti  se non 
toccano le rispettive linee, 0 se il numero viene omesso. 
•  Per  i  numeri  1,  2,  4,  5,  7,  8,  10,  e  11  punteggio  1  punto  per  ogni  numero  nel  quadrante  corretto,  
0 punti se il numero è fuori dal quadrante, 0 se viene omesso il numero. 
•  Sottrarre  1  punto  per  ogni  numero  ripetuto  o  superiore  a  12. 
Mani  
Il punteggio per il posizionamento delle mani. Se le mani sono disegnate all'interno del 
campo, segnare 1 punto per ogni mano, se le mani sono disegnate al di fuori della linea 
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Gato! Escuro! Pimenta! Medo! Cama!
Rato! Calor! Pão! Redondo! Cadeira%!
 
! 299!






















Pontuação:%% Números!! Correto! +!______/!12!
! ! Errôneo! J!______!
! Agulhas! ! +!______/!2!
! Ponto!central!! +!______/!1!
% % % Total% % % % +%______/%15%
!
! 300!










Cão% % Chuva% Manteiga% Amor% Porta%%
Pontuação%__________%/%20!!
Os!grupos!de!palavras!alternativas!incluem!…!
Gato% Escuro% Pimenta% Medo% Cama%
Rato% Calor% Pão% Redondo% Cadeira%%
 







































6.%Memória%Lógica% % % % % % %
A!raposa% O!cão% A!galinha% 2!/!0%
Vermelha! Castanho% Branca% 2!/!0!
Corria%através% Corria%através% Caminhava%por% 2!/!0%
De!um%campo.! De!uma%ponte.! Uma%estrada.! 2!/!0!






Um%cão.! Um%coelho.! Um%gato.! 2!/!0!
castanho% branco! preto% 2!/!0%
Era!uma!manhã.! Era!um!dia.! Era!uma!tarde.! 2!/!0%
!quente% frio% calorosa% 2!/!0!
De%Maio% De%Outubro% De%Setembro% 2!/!0%
As%flores% As%maçãs% As%folhas% 2!/!0!
Perfumadas%% maduras% Secas% 2!/!0!
Floresciam% Penduravam%% Voavam!!! 2!/!0%








































Appendix 4.6. Chinese (Mandarin) Translation of the Qmci 
Quick%Mild0Cognitive0Impairment%screen%(Qmci)%
.]"¯*ÀÚ±fÓ' %àQmciá %














2. 即刻 (30秒) 
`H*…!




¢ % % Û % Ý % h % : %








¤ ! Þ ! ¿ ! Ng ! [ !










%!yJGÕAâl¼D 12àG 15l 45áân%!
!
d%:%% yJ!! °! +!______/!12!
! ! 8)! J!______!
! q6! ! +!______/!2!
! -e! ! +!______/!1!











¢ % % Û % Ý % h % : %






























6.%5/# %% % % % % %
1Á­ ! 1ÊÁ­ ! 1¬Á­ ! 2!/!0!
¡£ % ¢ % A % 2!/!0%
Í0 % Í0 % ¶0 % 2!/!0%
½³7­! ^×U !  !! 2!/!0!
¦Ö! ! >Ï! 2!/!0!
KÉ1ÊÁ
­ !
K?t ! K­7ÜÎÙ®! 2!/!0%
¢ ! 1¬Á­ ! 1ÞÁ­ ! 2!/!0%
ÑÌ®! I! ¤! 2!/!0!
2	­ ! 2	Q!­ ! 2	­ ! 2!/!0!
­% ,­ % ­ % 2!/!0%
| .! E! -! 2!/!0%
ÂÄ­ % Ò­ % X­ % 2!/!0!

















































































              வ ைர   மனநல   ைறபா  ேக வ தா   
 
ெபய :                                      ப ற த ேததி: 
பாலின :                                   ப : 
ேததி:                                       ேநர : 
1. ேநா நிைல: (_____/10)                         (ஒ  நிமிட ) 
நா  ேக  ேக வ க  வைரவாக பதி  ெசா ல ய சி 
ெச க . 
 
 இ  எ த நா  (___/2)      
 இ  எ த ஆ  (___/2)  
 இ  எ த மாத  (___/2) 
 இ ைறய ேததி எ ன (___/2) 
 இ  எ த கிழைம (___/2) 
2. ெசா  பதி : (_____/5)                          (30 வனா க ) 
நா  உ களட  ஐ  ெசா க  ேவ  அைத ந க  தி ப 
ற ேவ . 
 நா , மைழ, ெவ ைண, அ , கத . 
     மா  ெசா க : 
 ைன, இ , மிள , பய , ெம ைத. 
 எலி, ெவ ப , ெரா , வ ட , நா காலி. 
 
3. க கார  வைரத : (____/15)                         (ஒ  நிமிட ) 
உ க  ெகா க ப ட வ ட தி  க கார  வைர  
பதிெனா  ப  மணைய றி க . 
 எ : (____/12) 
 : (___/2) 










4. நிைன த : (___/20)                           (30 வனா க ) 
சிறி  ேநர   றிய ஐ  ெசா கைள ம ப  
ெசா ல .  
 நா , மைழ, ெவ ைண, அ , கத . 
     மா  ெசா க : 
 ைன, இ , மிள , பய , ெம ைத. 
 எலி, ெவ ப , ெரா , வ ட , நா காலி. 
 
5. வா ெமாழி சரள: (____/20)                      (ஒ  நிமிட ) 
உ க  ெதறி த வல  ெபய கைள வ ைசயாக ற . 
 0.5 * வல கி  எ ண ைக : _______________ 
 
  6. த க நிைன திற : (_____/30)                 (30 வனா க ) 
     நா  உ க  ஒ  கைத ெசா ேவ . அைத ந க  த            
வைர என  ம ப  ற ேவ . 
 
ஒ  சிவ  ந  உ த நில தி  ஓ ய  அைத வர ய த  ஒ  
ப  நா . 
 
அ  ஒ  டான ேம மாத  காைல, மண  வ  க   ெச கள  
 ெகா தத . 
 
மா  கைத: 
அ  ஒ  ள ரான அ ேடாப  தின ,  ஆ ப  கனக   மர தி  கா  
ெதா கி  ெகா தன. 
 
ஒ  ப  நா  பால தி  ஓ ய , அ  ஒ  ெவ ைள யைல 
ேவ ைடயா ய . 
 
 
ெமா த மதி ெப : _____________/100. 
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Όνοµα:                           Ηµ γενν:                 Φύλο:                 Έτη εκπαίδευσης:                









































%Βροχή% %%%Βούτυρο% %%%%%Αγάπη% %%%%%%Πόρτα%
% % % % %
Εναλλακτικές!λέξεις!περιλαμβάνουν…!
Γάτα% Σκοτάδι% Πιπέρι% Φόβος% Κρεβάτι%
































! ! Λάθοι! !J!______!
!!!!!!!!!!!!!!!!!!!!!!!!!!!Δείκτες! ! !!!!!!!!!!!!!!!!!!!!!!!!!!!!+!______/!2!
!!!!!!!!!!!!!!!!!!!!!!!!!!!Άξονας!περιστροφής! !!!!!!!!!!!!!!!!!!!!!!!!!!!!+!______/!1!
















%Βροχή% %%%Βούτυρο% %%%%%Αγάπη% %%%%%%Πόρτα%

















Γάτα% Σκοτάδι% Πιπέρι% Φόβος% Κρεβάτι%











































































αλεπού% του%Μαΐου! σκύλος% του%
Οκτώβρη!
κότα! απόγευμα!











χωράφι.! σχηματίζονταν% γέφυρα.! από!τα! δρόμο.! φύλλα!
Την!
κυνηγούσε!
στους!θάμνους%! Κυνηγούσε% δένδρα% Την!
ακολούθησε!
ανέμιζαν!!
ο'καφέ))
σκύλος)
)
) ένα'άσπρο)
κουνέλι')
)
η'μαύρη)
γάτα)
)
στον)αέρα.)
) ) %
Qmci0Συνολική%Βαθμολογία%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
*___/%100%*Να%προσαρμοστεί%η%βαθμολογία%για%την%ηλικία%και%εκπαιδευτικό%επίπεδο%(βλέπε!
παρακάτω).!!!!!!!!!!!!!!!!!!!!!!Χορηγήθηκε%από:____________________%%
 
 
 
